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Cancer develops through the acquisition of genomic alterations, i.e. changes in the DNA
sequence and chromosomal numerical content of a cell, such as point mutations, insertions,
deletions, amplications, and translocations. Such alterations may alter protein expres-
sion and/or function of oncogenesgenes promoting cancerand tumor suppressors
genes protecting from cancer. Other factors, caused by mechanisms which do not change
the underlying DNA sequence (e.g. DNA methylation and histone modication), may
also alter the expression of genes, and may thereby play a role in cancer as well. As
dierent biological processes, the so-called hallmarks of cancer (1, 2), need to be deregu-
lated before a cancer can develop, a combination of events is needed to change a normal
cell into a cancerous cell. Cancer is thought to arise through the stepwise acquisition of
such events (3), although it has become clear that dierent alterations may be caused
by a single event (4, 5), and particularly oncogene-activating translocations seem to be
sucient for oncogenesis in some types of leukemias, lymphomas, and sarcomas (6).
In cancer genomics, germline and somatic aberrations, i.e. aberrations present in the
germline of the patient and acquired aberrations, are studied in order to identify genes and
biological processes which are important in the development and progression of cancer.
Determining aberrations that are crucial for a cancer cell to survive, identifying defective
tumor suppressors, and identifying biological processes which facilitate tumor progression
is tremendously important for diagnostics and prognostics, and for the identication of
targeted treatments. In the late 1990s, high-throughput methods have been developed
which can be utilized in studying cancer genomicsso-called microarrays. In this thesis,
we have used these high-throughput techniques in order to study high-grade osteosarcoma
genomics, aiming to learn more on osteosarcoma biology, and to identify possible targets
for treatment.
High-grade osteosarcoma
High-grade osteosarcoma is a primary malignant tumor consisting of mesenchymal tumor
cells producing osteoid. The tumor is rare, with an approximate incidence of 56 patients
in a population of one million per year. The incidence is higher in adolescents and young
adults, and shows a second peak at middle age (7). Osteosarcoma developing later in adult
life is thought to be partially secondary, and may be caused by previous treatment with
radiation or by an underlying Paget's disease of bone. Males are more often aected by
osteosarcoma than females (with a ratio of 3:2). High-grade osteosarcoma most frequently
develops in the long bones of patients, with the metaphysis as the most frequent (91%),
and the diaphysis as the second most frequent site (< 9%). Most often, the tumor
develops in the region around the knee (distal femur and proximal tibia), followed by the
proximal humerus (8). Osteosarcoma is rarely seen in the axial bones of the patient. The
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incidence pattern of osteosarcoma suggests a link between the development of the disease
and growth (9) (this will be further discussed in Chapter 5).
High-grade osteosarcoma is a very aggressive tumor. Patients are usually treated
with several series of neoadjuvant chemotherapy consisting of a combination of dier-
ent chemotherapeutic drugs, especially cisplatin, doxorubicin, and high-dose methotrex-
ate (8). The tumor is then removed by limb-salvage surgery, although sometimes ampu-
tation is needed. Afterwards, a second series of adjuvant therapy is given to the patient.
Despite this intensive treatment schedule, a signicant number of patients die due to
the development of distant metastases, which are most often pulmonary. The tumor
metastasizes in approximately 45% of all patients (10). Overall survival of patients with
resectable metastatic disease is roughly 20% (11). Neoadjuvant treatment was introduced
in the 1970s, and improved overall survival from 1020% to approximately 60%. However,
except for macrophage-activating and recruiting agents, such as L-MTP-PE (discussed in
Chapter 4 of this thesis), no new treatment options have been developed that can raise
survival signicantly. The many caveats and challenges hampering osteosarcoma research,
which might explain why osteosarcoma patients still have no other treatment options, are
discussed in Chapter 2.
Known genes involved in osteosarcomagenesis have essential roles in cell cycle progres-
sion (12). The tumor suppressor TP53, which can induce cell cycle arrest or apoptosis
in response to cellular stress, such as DNA damage, is mutated in approximately 20% of
high-grade osteosarcomas and also often present in regions of copy number loss. MDM2,
which targets the p53 protein for degradation, is amplied in 615% of the tumors. TP53
and MDM2 aberrations have been described to be mutually exclusive (13), although in
our dataset, one sample (the osteosarcoma cell line HAL) had copy number loss of TP53
and gain of MDM2. Inactivating somatic mutations of RB1, a negative regulator of the
cell cycle, are also often found in osteosarcoma, and this gene is present in regions of copy
number loss in over 60% of osteosarcomas (14, 15). Other players of the Rb pathway have
been described in osteosarcoma as well, for instance CDKN2A deletions, which present
homozygously and occur in approximately 25% of all patients (16). TP53 and RB1 mu-
tations are not always somatica small percentage of osteosarcoma is hereditary, with
mutations present in the germline of patients. The associated hereditary syndromes, Li-
Fraumeni and Retinoblastoma for mutations in TP53 and RB1, respectively, give a strong
predisposition to develop osteosarcoma. A third hereditary syndrome that is thought to
predispose to osteosarcoma is Rothmund-Thomson syndrome, where REQL4, a gene en-
coding for a DNA helicase, is mutated (17), however, in contrast to TP53 and RB1, the
gene is not a frequent target for sporadic mutations in osteosarcoma (18).
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The EuroBoNeT high-grade osteosarcoma database
The aim of this thesis was to study osteosarcomagenesis by bioinformatics analysis of a
high-throughput dataset consisting of microarray data from high-grade osteosarcoma spec-
imens. A relatively large cohort of naïve, preoperative diagnostic osteosarcoma biopsies
was collected as a collaborative eort by EuroBoNeT, a European Network of Excellence
for studying primary bone tumors. This clinically well dened cohort consisted of samples
from 84 patients. For most of these patients, clinical data were available on patient sex,
age at diagnosis of the primary tumor (in months), tumor location, histological subtype
of the tumor, and response to neoadjuvant chemotherapy (Huvos grade) (19). Follow-up
data (metastasis-free survival and overall survival, measured in months from diagnosis)
was available for 83/84 patients. Clinical characteristics of this cohort can be found in
Table 7.1. In addition to the clinical samples, we used data from two osteosarcoma model
systemsosteosarcoma cell lines (characterized and published by Ottaviano et al. (20))
and xenografts (21), see Table 3.1 for clinical characteristics of the original tumors of
these model systems. The entire osteosarcoma database consisted of data obtained from
three dierent microarray platformsgenome-wide gene expression data, data obtained
with a kinome screen, and Single Nucleotide Polymorphism (SNP) microarrays. Table 1.1
illustrates the dierent data types, numbers of osteosarcoma and control samples, and the
dierent comparative analyses which are described in this thesis. Raw and processed data
are deposited in online databases (22, 23).
Data type mRNA Kinome SNP
Company Illumina PamGene Aymetrix




Software Bioconductor BioNavigator, Genotyping Console,
Bioconductor Nexus Copy Number
OS samples 84 diagnostic biopsies, 2 cell lines 32 diagnostic biopsies,
19 cell lines, 12 cell lines
18 xenografts
Control samples 12 MSC cultures, 12 MSC cultures 27 normal samples
3 osteoblast cultures
Analysis methods LIMMA, pamr LIMMA Cut-o for aberration
frequency
Comparative Clinical parameters, Tumor vs controls Clinical parameters,
analyses Tumor vs controls Tumor vs controls
Table 1.1: Layout of the high-grade osteosarcoma database. MSC: mesenchymal stem cell.
High-throughput platforms to study osteosarcoma
Genome-wide gene/mRNA expression proling can be performed using RNA isolated from
a sample, such as tumor tissue or a cell culture. Generally, cDNA or cRNA is prepared
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from the RNA and is labeled with a uorescent dye. This is then hybridized to a microar-
ray chip containing oligonucleotide probes, which are short sequences of DNA, comple-
mentary to most or all specic transcripts, capable of binding the labeled cDNA/cRNA.
For measuring genome-wide gene expression, single- and dual channel microarrays are
available. With dual channel microarrays, samples, e.g. paired tumor samples and nor-
mal tissues, can be directly compared on one chip, by labeling the cDNA/cRNA with
two dierent uorescent dyes. For the research described in this thesis (Chapters 38),
single channel microarrays were used, which means that control samples were hybridized
on dierent chips. We used Illumina Human-6 v2.0 BeadChips (Illumina, San Diego,
CA). These microarrays contain over 48, 000 probes, of which approximately half are rec-
ognized by well-annotated Reference Sequence (RefSeq) genes (24). Illumina BeadChips
have a special structure: probes are present on beads, which are randomly arranged on
the chip. Every bead type is replicated on each chip with a mean of approximately 3540













Figure 1.1: Schematic overview of A, the Illumina BeadChip and B, the Aymetrix SNP 6.0
array. Figure adapted from Hupé, P., http://commons.wikimedia.org.
cated beads make robust measurements possible (27). The software designed by Illumina
for data analysis, BeadStudio, does not take advantage of the large number of replica-
tions of beads present on these chips. Therefore, various methods have been specically
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developed for analyzing Illumina BeadChips, such as Bioconductor (28) packages beadar-
ray (27), beadarraySNP (29) (specically for Illumina SNP data), and lumi (30), which
will be described in the next section.
Peptide microarrays can be used for studying kinase activity in a sample. For the
research performed in Chapter 6 of this thesis, we used PamGene R© serine/threonine
(Ser/Thr) PamChips (PamGene, 's-Hertogenbosch, the Netherlands). These chips consist
of porous membranes, which contain 142 dierent peptides derived from phosphorylation
sites for Ser/Thr kinases of the human proteome. Cell or tissue lysates are supplemented
with ATP and subsequently pumped through these membranes, so that kinases in the
lysates have access to, and can phosphorylate the peptides on the chip. Phosphorylation
is measured over a time span of 30 to 60 minutes by the detection of light emitted by
uorescently-labeled, phospho-specic antibodies. Figure 1.2 gives an overview of the
experimental workow of PamGene.
Single Nucleotide Polymorphisms (SNPs) are genetic changes or variations of a single
base pair, which occur in at least 1% of the population (31). SNP microarrays contain so-
called allele-specic oligonucleotide probes (Figure 1.1B), which are used to discriminate
between specic SNPs in the sample, because of the dierent binding properties of the
sample DNA, which is again labeled with a uorescent dye. SNP microarrays can be
employed to genotype a sample, which is used to identify small variations between genomes
(to determine e.g. disease susceptibility), but can also be utilized to infer copy number
aberrations and allelic states of regions in the genome. The SNP microarrays used in
this thesis (Chapters 78) are Aymetrix Genome-Wide Human SNP Array 6.0 chips
(Aymetrix, Santa Clara, CA). These high-density chips contain over 900, 000 SNPs and
over 900, 000 probes for the detection of copy number variation.
Microarray data preprocessing
The three dierent platforms described above have in common that, after hybridization of
DNA/cDNA/cRNA to the chip, or after phosphorylation of peptides on the microarray,
a uorescent signal is emitted, which is measured by a scanner. The image les that are
returned by the scanner can be utilized for deducing intensity signals and the location
of the specic spots/beads. This is usually performed directly by the software provided
by the company which distributes the arrays, and generally overlays a grid and returns
median intensity signals for each spot/bead. Alternatively raw image les can be analyzed
(for example using beadarray (27)), thereby allowing additional methods of data process-
ing. In the following paragraphs, we will discuss data preprocessing and subsequent data
analysis of data generated with the above described microarray chips.
Preprocessing of microarray data is performed in order to correct for experimental bias
and to reduce the signal to noise ratio. Numerous methods of microarray data prepro-









Figure 1.2: Peptides can serve as sub-
strates for kinases present in the sample.
Phosphorylation is detected by uorescently
labeled phopho-specic antibodies (A). The
microarrays consist of a porous ceramic
membrane (B), on which 142 dierent pep-
tide substrates are present (C). Four ar-
rays are combined into one chip (D). The
phosphorylation reaction occurs by an up
and down movement of the sample solution
through the array, giving the kinases maxi-
mal opportunity to phosphorylate the pep-
tides on each array (E). When the solution
is underneath the array, the CCD camera in
the workstation takes an image of each ar-
ray, which is later used by the software to
generate kinetic data curves (F). The incu-
bation, washing, dispensing of reagents and
imaging of the arrays is done in fully au-
tomated workstations (G). Figure adapted
from PamGene R©.
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of microarray data can be performed using the software provided by the company that
produced the arrays, or can be analyzed with open source programs, such as the statistical
software R (32), for which several packages have been made available in the Bioconduc-
tor (28) framework to specically analyze the raw data of various microarray platforms.
An optional start of preprocessing the raw data is a global or local background sub-
traction step. This can eliminate signals due to nonspecic binding, thereby reducing
noise in the data. However, when applying this step, probes of low signal will be dis-
carded, resulting in missing values. Some researchers convert these missing values into
zero expression. Illumina's scanner software, BeadScan, automatically subtracts local
background measures from the foreground intensities to generate bead level text les
les including intensities and location information obtained from the original .ti les
produced by the scanner software. These bead level les can be used for downstream data
analysis. The standard local background subtraction method provided by Illumina results
in a very low estimate of the background, which is thought to be mostly related to the
optical properties of the array surface (33). Additional background subtracting methods
can be applied, such as background normalization in BeadStudio, which subtracts the
mean intensity of negative control beads from the foreground intensities. This method
increases variability, and also introduces a signicant number of negative values (33). Es-
pecially for small sample sizes it is crucial to achieve a homogeneous variance, and thus,
as background subtraction introduces additional variation in the data, this may not be
benecial for the detection of dierences between two or more groups (34). Apart from
the local background subtraction by BeadScan (for mRNA expression data), we did not
use other background subtraction methods in the preprocessing of our microarray data.
Data transformation is necessary because of the complicated error structure of mi-
croarray data, which is intensity-dependent and nonlinear (35). Often, a simple log trans-
formation is used, but other methods exist that are milder in transforming signals near
background, which are inated by standard log transformations. Examples of such meth-
ods are variance stabilizing normalization (vsn) (36), which both transforms the data and
performs normalization of the data between the dierent arrays, and variance stabilizing
transformation (vst) (37), a method similar to vsn, specically developed for preprocessing
Illumina BeadChips. vst has been shown to be advantageous over log transformation when
large changes in expression are expected (38, 39). Normalization of the data is applied
to reduce bias that may arise due to dierences in sample preparation, and production
(batch eects) and processing of the arrays. Various normalization methods exist, of which
complete data methods, such as quantile normalization, are preferred over methods that
use a baseline array in order to normalize the data (40). We used vst and robust spline
normalization (rsn), a normalization method specically designed to normalize variance
stabilization transformed data, on mRNA expression data (Chapters 38). Transforma-
tion and normalization of peptide chips (Chapter 5) was performed using vsn, while SNP
microarray data were log2 transformed and quantile normalized. SNP microarray data
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(Chapters 78) were further corrected for the guanine-cytosine (GC) content, as dierent
percentages in GC content can cause waviness in the log2 ratio data, which can increase
false positive and false negative segment calls. We used the Regional GC correction
algorithm in Genotyping Console to correct for this waviness (41).
Quality control
A very important microarray data preprocessing step is outlier detection. When correctly
performed, this step can signicantly improve data quality and thereby improve the out-
come of the experiment, e.g. the detection of dierential expression (42, 43). Defective
probes from Aymetrix chips can be detected and subsequently removed (44). In Illumina
data, spatial artifacts can be detected and removed using BeadArray Subversion of Harsh-
light, or BASH (45). Although the detection of large spatial artifacts may be helpful for
determining whole outlier chips, the BASH algorithm only improves results very mildly.
This can be described to the extremely robust structure of the Illumina BeadChips (tested
for Human-6 and GoldenGate BeadChips, Kuijjer et al., unpublished results). The more
recently developed HumanHT-12 Expression BeadChips contain fewer replicates per bead
type, and this preprocessing step may therefore be valuable for removing outliers in these
newer chips. Other artifacts in Illumina data have been reported, such as particularly
bright beads showing a bleed over eect on neighboring beads, raising their associated
values (46). One can adjust for such spatial artifacts by masking aected beads using the
beadarray package (27).
Regularly, it is necessary to remove entire chips of poor quality, since such chips can im-
pair overall statistical and biological signicance (43). Poor quality chips can be identied
by visually checking the scanner images, the distribution of both raw and normalized data
(e.g. by plotting density plots, boxplots, and MA-plots), and by performing unsupervised
hierarchical clustering or visualizing the data using principal components analysis (PCA,
reducing the data dimensionality to e.g. its rst two or three principle components). Such
methods can for example be applied using Bioconductor package arrayQualityMetrics (47)
(used for quality control of mRNA and kinome proling in this thesis) or using quality
control functions in the package ay (48). Another method to control the inuence of poor
quality chips is assigning weights to all chips, so that arrays of better quality will have
a higher inuence on the analysis than poor quality arrays (arrayWeights (49)). Such an
approach is, however, not intended to replace a quality check identifying catastrophically
poor quality chips, and these should still be discarded. In a comparative study of remov-
ing poor quality chips with arrayQualityMetrics, assigning arrayWeights to the data, or
applying both methods on the LIMMA analysis described in Chapter 4, we determined
more dierentially expressed probes at a false-discovery rate (FDR, see next section for
an explanation) of 0.05 without assigning weights, but this depended on the FDR (for
0.05 < FDR ≤ 0.1 arrayWeights or a combination of both methods performed slightly
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better, Kuijjer et al., unpublished results).
In SNP microarray quality control, one can determine the ability of an experiment to
resolve SNP signals into three genotype clusters (AA, AB, BB). The Aymetrix Genotyp-
ing Console Contrast Quality Control test metric is a measure for this ability (50), and
was used in this thesis (Chapters 78). This test uses 10, 000 random SNPs to measure
the dierence between peaks in the distributions of homozygote genotypes (AA and BB),
and the valleys these distributions share with the heterozygote peak (AB). When this
dierence approaches zero, the experiment poorly distinguishes between homozygous and
heterozygous genotypes. Such chips should be removed from further data analysis.
Microarray data analysis
After having performed the preprocessing steps necessary for the specic type and plat-
form of microarray data, the actual data analysis can be performed.
Unsupervised hierarchical clustering of microarray data may not only be used as a
quality check (as described in the previous section), but can also be applied to detect
dierent subgroups of samples, which may be associated with a clinical feature. In a
supervised approach, dierences between groups of samples can be determined using a
moderated t-test, such as the LIMMA analysis (used in this thesis for detection of dier-
ential expression and phosphorylation) (51). Important to note is that with the testing of
multiple hypotheses, the amount of true null hypotheses that are rejected will increase. In
microarray experiments, often large numbers of probes/peptides are tested for dierential
expression or phosphorylation, and therefore, an excessive amount of false-positives may
be returned from conventional statistical tests. Hence, a correction for multiple testing
should be performed (42). Examples of such methods are conservative familywise error
rate procedures, such as the Bonferroni method (52), or the less stringent false discovery
rate (FDR) controlling methods, e.g. the Benjamini and Hochberg (53), and Benjamini
and Yekutieli (54) approaches. Other methods use permutations to estimate the FDR,
such as Signicant Analysis of Microarrays (SAM) (55).
SNP data is analyzed in a dierent manner. Genotyping can be performed by specic
genotyping algorithms, such as the Birdseed v2 algorithm in Genotyping Console, which
uses unsupervised learning to t the data, producing genotype calls and returning con-
dence scores for each SNP (56). Copy number data analysis is performed by comparing
the intensity signals for each marker and each sample against a reference genome, which
usually consists of a set of in-house or publicly available control samples. A cut-o for
gains and losses is used to determine whether probes are present in a region of ampli-
cation or deletion (in this thesis, an absolute log2 ratio cut-o of 0.2, equivalent to an
absolute fold change of approximately 1.15, was used). Using the genotyping information,
calls can also be made for allelic ratios. In Nexus Copy Number software, this is done
by determining the B-allele frequency. Regions on the genome which show LOH will not
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reveal any AB signals (a B-allele frequency of 0.5, at least in theory, if there are no normal
cells present in the tumor tissue). This also makes the identication of allelic imbalance
possible, which, over a genomic region, will show multiple B-allele frequencies in between
0 and 1, depending on the amounts of copy number of each allele.
A drawback in SNP data analysis is that copy number changes are detected relative
to the overall DNA content in the sample (57). In addition, normal cell populations, such
as stromal and inammatory cells, and heterogeneity within the tumor itself can further
impede the detection of the true copy number alterations in the tumor cell. In epithelial
tumors, a DNA index can be determined by ow-sorting tumor cells, which can separate
these from mesenchymal cells, and which can identify subpopulations of tumor cells with
dierent chromosomal aberrations. To infer true copy numbers and allelic states, the
algorithm lesser allele intensity ratio (LAIR, included in beadarraySNP (29)) integrates
the DNA index in the analysis of SNP data (58). Unfortunately, this approach can not be
applied to SNP data analysis of high-grade osteosarcoma samples, as osteosarcoma is a
mesenchymal tumor for which no specic markers are available. However, the amount of
stroma in osteosarcoma is not as extensive as in epithelial tumors, and the percentage of
stroma as determined by the pathologist could in principle be used in order to approximate
the DNA index of these tumors.
SNP microarray data show a high degree of noise, and not all markers reect the
true copy number of the region. Segmentation is performed in order to identify the
chromosomal segments with actual copy number aberrations. Most frequently used al-
gorithms for segmentation are Circular binary segmentation (CBS)-based (59) or Hidden
Markov Model (HMM)-based methods. CBS-based methods divide the genome into al-
ways smaller segments until no region can be further segmented, taking into account
a minimum amount of probes per segment. The SNPRank segmentation algorithm in
Nexus Copy Number Software is CBS-based, and ranks log ratio probe values and B-
allele frequencies in a segment. If the distribution of these probe ranks is signicantly
dierent from those of an adjacent segment, the region is segmented out, meaning the
region probably has a dierent median copy number than that of the adjacent segment.
HMM-based methods, such as the SNP-FASST segmentation algorithm in Nexus Copy
Number software, perform faster than CBS-based methods, but require an estimate of
signalcopy number relationship, as it works with integer copy numbers. Because of the
heterogeneity present in tumor samples, this is probably not an optimal way to segment
tumor data (60). We used SNPRank segmentation to segment the copy number data,
with a minimum of 5 probes per segment. After segmentation, a cut-o for frequency of
copy number changes can be set, so that the most recurrent alterations will be detected.
One can also specically look for focal or broad events, as is described in Chapter 9 of this
thesis. As with the analysis of other microarray data types, permutations can be used
to determine whether there are signicant dierences in copy number or LOH proles of
groups with dierent features (e.g. in Nexus Copy Number software).
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Downstream data analysis
Deducing a biological interpretation from large lists of signicant genes may be challeng-
ing, and validation of all signicant genes is often very labor intensive. Several methods
have been developed which determine whether specic signal transduction pathways, bio-
logical processes, or other groups of genes with similar functions, are aected. Genes mak-
ing up such pathways or processes are often taken from public databases, such as the Gene
Ontology (GO) (61) or the Kyoto Encyclopedia of Genes and Genomes (KEGG) (62), or
are available as commercial software, such as Ingenuity Pathways Analysis (IPA, Ingenu-
ity Systems), which is manually curated. The hypergeometric test (a one-tailed Fisher's
exact test) is most often used to obtain information on the enrichment of signicant genes
in specic pathways or biological processes. This test determines whether there is more
overlap between the list of signicant genes and the set of genes of interest (e.g. the
pathway) than would be expected by chance. The hypergeometric test can be applied
on microarray data in IPA (used in Chapter 6) and in the Bioconductor topGO package
(used in Chapters 3 and 7) (63). A disadvantage of this simple test is that it requires a
hard denition of signicance (e.g. a p-value cut-o), and discards information on the
exact p-values of the genes tested. The hypergeometric test also assumes independence
of genes, which is not accurately representing the biology of a cell, since the expression
of functionally related genes is often correlated. Because of this assumption, the hyper-
geometric test may understate the true p-values. It is therefore recommended to use a
very low p-value (e.g. 0.001 or lower) as cut-o for signicance when applying this test.
Another problem of the hypergeometric test is that it assumes independence of categories.
GO terms are certainly not independent, as these terms are set up in a hierarchical struc-
ture of nodes, with parent terms representing a broader GO term, and child terms a more
specic subset of its parent terms (61, 64). Algorithms which can identify the GO term
which better represents the biological situation (signicantly aected genes) than other
terms from its neighborhood have been developed, such as the weight algorithm in the
topGO package (63).
A method which takes into account a continuous measure of signicance is gene set
enrichment analysis (GSEA) (65). This method ranks genes based on their associated
p-values and subsequently determines an enrichment score based on the rank of the genes
present and not present in a specic pathway or category. The signicance of this enrich-
ment score is subsequently tested by permuting phenotype labels to determine the null
distribution of the enrichment score.
Another approach to determine which biological pathways are signicantly aected
is the globaltest (used in Chapter 5). Based on a logistic regression model, this test
determines whether a prespecied group of genes is dierentially expressed, and thus
tests groups of genes instead of single genes (66). This test is particularly intended for
identifying gene sets for which many genes are associated with a phenotype in a small way.
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Using this approach may be especially fruitful in case no overall dierential expression
is detected due to small sample sizes, as this approach signicantly reduces the multiple
testing problem (67). The globaltest has much more power than self-contained tests (tests
which compare a gene set with its complement), such as the hypergeometric test (68). To
apply the globaltest on GO terms, Goeman et al. also developed a method that preserves
the specic graph structure of the Gene Ontology (69). In addition, this algorithm can
be used in combination with follow-up data (67).
A nal method to extract biological information from lists of signicantly aected
genes is performing network analysis. Networks are assembled de novo, based on con-
nectivity (e.g. binding or functional properties) between aected molecules. In IPA,
networks are assembled using decreasingly connected molecules from the signicant genes
in the dataset which is analyzed, and are annotated with functional categories, which are
manually curated. In contrast to pathway analysis, these IPA networks do not have direc-
tionality (but network analysis methods which include directionality between molecules
also exist). We used network analysis to interpret dierential gene expression between
various histological subtypes of osteosarcoma (Chapter 3).
Supervised learning
Generating a prediction prole which can classify tumors based on mRNA expression or
specic copy number aberrations may also be used in microarray analysis of a cancer
dataset. Classication may for example help to diagnose a tumor based on its microarray
data prole, or may predict event-free or overall survival of patients. Some examples of
supervised learning approaches are nearest shrunken centroids classication (e.g. avail-
able in Bioconductor package pamr (70)), support vector machine (SVM) learning (e.g.
available in R package e1701 (71)), and random forest classication (e.g. available in R
package varSelRF (72)).
In this thesis, we used nearest shrunken centroids classication to develop a classier of
the main histological subtype of conventional osteosarcoma. We validated this classier
on an independent dataset, and applied it on data obtained from osteosarcoma model
systems (Chapter 3). Nearest centroids classication determines centroids for each class
by dividing average expression of a gene signature by the standard deviation. New samples
are classied to that specic class, of which the centroid is closestin squared distance
to the expression of the genes in the prediction prole. Nearest shrunken centroids is an
adaptation of this methodit shrinks each centroid toward the overall centroid for all
classes by a certain threshold. This shrinkage automatically selects genes and reduces the
eect of noisy genes. The prole with the lowest prediction error is then selected as the
nal classier. Internal cross-validation, which divides the training set in dierent parts,
is subsequently used to compute a cross-validated error. This approach, however, leads
to an underestimation of the error rate, as the same data is used to select features and to
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estimate the error rate. An extra external cross-validation step would thus be appropriate,
or, given that there is often only a limited number of samples available for training, the
feature selection (genes to include in the prole) should be newly computed for each
separate cross-validation step (73, 74). External cross-validation is performed in order
to correct for overtting of the data by the model. This can be done on an independent
cross-validation set, or by using methods such as one-leave-out cross-validation (75). Also
regularization may be used to prevent overtting, but this is not often used in microarray
data analysis, and is therefore beyond the scope of this thesis.
In prediction proling, the way the distance between the actual sample and the class
is calculated may be very dierent, and this has important consequences for biological
interpretation of the prole. In a prediction prole where the magnitude (e.g. of gene
expression) is important, Euclidian distance is best used, while correlation (e.g. Pearson
or Spearman) coecients are more useful when the way the genes depend on each other,
so the pattern of expression, is important for the specic gene list (76). This may be one
of the reasons why the CINSARC prole, a gene expression signature which was generated
on sarcomas (77) and which uses Spearman correlation as a measurement for distance, did
not show signicant results on our osteosarcoma dataset (centroids for classier needed
to be retrained, because we used data of a dierent platform than the original CINSARC
signature, Kuijjer et al., unpublished results), while the Carter signature (78), which clas-
sies data based on average expression of genomic instability genes, could predict for
metastasis-free survival in our data (as shown in Chapter 7).
Data integration
As explained in the next chapter, the integration of dierent data types is particularly
relevant when studying a highly genomically unstable tumor. We used superimposed in-
tegration of mRNA expression and kinome proling data in Chapter 6. This approach
was taken, because kinase activity usually does not have a direct downstream eect on
mRNA expression (generally, there are several intermediate molecules which confer sig-
naling), and the other way around. It may therefore be more relevant to determine how
these data complement each other, instead of identifying only overlapping genes.
For integration of copy number and gene expression (Chapters 78) data, we identied
genes with aberrations occurring in both data types, as the copy number state of a gene
can have a direct eect on its expression. We specically chose to identify cooccurrence
and not correlation of copy number and expression signals, because these signals do not
have to show a linear correlation, i.e. correlation will miss our genes which are also
regulated at other dimensions, such as epigenetics and feedback mechanisms.
A conservative approach was takenonly genes which were signicantly dierentially
expressed between osteosarcoma tumors and presumed osteosarcoma progenitors were
analyzed, and the cut-o for recurrence was set to 35%. We tested this approach in a
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paired and nonpaired way to determine cooccurrence of copy number aberrations and
dierential expression in Chapter 7, and used paired analysis of cooccurrence of LOH,
copy number gains, and dierential expression in Chapter 8.
Aims and outline of this thesis
In this thesis, a systems biology approach to study high-grade osteosarcoma is described.
Chapter 1 starts with an introduction on cancer genomics and high-grade osteosarcoma,
and introduces the EuroBoNeT high-grade osteosarcoma database, on which the research
in the following chapters is based. In addition, dierent platforms used in this thesis
are described, and dierent types of high-throughput data analyses are explained (this
chapter).
In Chapter 2, published literature on microarray studies on high-grade osteosarcoma
is reviewed. This review also discusses challenges in high-throughput data analysis of os-
teosarcoma and introduces dierent model systems which have been used in osteosarcoma
research. In addition, information on dierent comparative analyses and a rationale for
integrating dierent data types are given. The review concludes with a section on how
bioinformatics can be translated into functional studies.
The following six chapters of the thesis describe the work which has been performed
to answer dierent research questions regarding osteosarcoma biology and possible tar-
gets for therapy. Specically, we aimed to study molecular dierences between clinically
dierent tumors, such as tumors of dierent histological subtypes, and of tumors with
dierent metastasis-free survival proles. These research questions are answered in Chap-
ters 3 and 4, respectively. In addition, in Chapter 3, a histological subtype-specic gene
expression prole is tested on osteosarcoma model systems. High-grade osteosarcoma is
also compared with controls, in order to detect what signal transduction pathways may
be targeted in osteosarcoma to identify potential adjuvant drugs for treatment of this
aggressive tumor (Chapters 5 and 6). Chapter 5 reports on the analysis of gene expres-
sion data, while Chapter 6 determines active pathways based on kinome proling, and
integrates gene expression data with kinome proling results. Finally, we performed in-
tegrative data analysis of SNP and gene expression data, to detect osteosarcoma driver
genes (Chapters 7 and 8). In Chapter 7, copy number aberrations are integrated with
overexpression and downregulation, while in Chapter 8 we specically look at the combi-
nation of Loss of Heterozygosity (LOH), DNA copy number gain, and dierential mRNA
expression.
In Chapter 9, results described in Chapters 3 to 8 are discussed and future perspectives
for high-throughput data analysis on high-grade osteosarcoma are given. Chapter 10
includes a Dutch summary, Curriculum Vitae, and a list of publications.
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Abstract
High-grade osteosarcoma is an extremely genomically unstable tumor. This, together with
other challenges, such as the heterogeneity within and between tumor samples, and the
rarity of the disease, renders it dicult to study this tumor on a genome-wide level. Now
that most laboratories change from genome-wide microarray experiments to Next-Gener-
ation Sequencing it is important to discuss the lessons we have learned from microarray
studies. In this review, we discuss the challenges of high-grade osteosarcoma data analy-
sis. We give an overview of microarray studies that have been conducted so far on both
osteosarcoma tissue samples and cell lines. We discuss recent ndings from integration of
dierent data types, which is particularly relevant in a tumor with such a complex genomic
prole. Finally, we elaborate on the translation of results obtained with bioinformatics
into functional studies, which has lead to valuable ndings, especially when keeping in
mind that no new therapies with a signicant impact on survival have been developed in
the past decades.
Introduction
High-grade osteosarcoma, a rare, genomically complex and unsta-
ble tumor
High-grade osteosarcoma is the most prevalent primary malignant bone tumor. The dis-
ease occurs most often in children and adolescents and is the sixth leading cause of death
in children under the age of 15 years. Notwithstanding, osteosarcoma is a rare disease,
with an incidence of ve to ten new cases per 1, 000, 000 per year (1, 2). Osteosar-
coma is composed of extremely genomically complex and unstable mesenchymal tumor
cells, generally exhibiting both complex clonal and numerous nonclonal aberrations (1),
which are characterized by the direct production of osteoid (2, 3). The tumor is highly
aggressive, with distant metastases developing in approximately 45% of all patients (4)
although patients are treated with intensive neoadjuvant treatment consisting of high
doses of multiple chemotherapeutic drugs. Better surgery has improved survival slightly
but no other signicant improvement has been made since decades, and increasing dose
or the administration of more than three chemotherapeutic regimens does not increase
overall survival (57). Hence, new therapeutics are seriously needed. Studying the tumor
biology and pathology in a systematic manner can result in a better understanding of
osteosarcomagenesis and can potentially identify new targets for treatment.
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Caveats and challenges
Several challenges and caveats are encountered when studying a rare, highly genomically
unstable tumor on a genome-wide level. The rst challenge is apparent when collecting
osteosarcoma tumor samples. Osteosarcoma is a rare disease and therefore often large
interinstitutional eorts have to be achieved to collect the substantial amount of samples
that is needed for analyses in computational biology. For most purposes, studying os-
teosarcoma pretreatment diagnostic biopsies is preferred over using resection material of
the primary tumor. Presurgery chemotherapy causes substantial necrosis, even in poor
responders, thereby rendering the tissue unsuitable for high quality nucleic acid retrieval.
Moreover, biopsies are more representative of the state of the tumor before any treatment
as chemotherapy changes the distribution of subclones present in the primary tumor, and
can cause clonal evolution (8). Biopsies are taken to establish a histopathological diag-
nosis, and are unfortunately often very small and not always available for research. In
addition, material is often collected retrospectively, which can introduce heterogeneity
owing to, for example, dierent treatment procedures, unless patients are collected who
have been enrolled in the same clinical trial. Thus, the collection of clinical data and the
grouping of clinical parameters have to be carried out very carefully. For a rare entity
such as osteosarcoma, collaborations are indispensable to collect signicant cohorts, an
example of this being the European Network of Excellence EuroBoNeT, in which various
European institutes collaborated to collect a large, homogeneous set of, among other bone
tumors, high-grade osteosarcoma biopsies.
Primary osteosarcoma is subdivided into numerous dierent low- and high-grade sub-
types (9). In this review, we concentrate on high-grade conventional osteosarcoma, which
is by far the most prevalent variant. Although there is often intratumor heterogeneity,
high-grade conventional osteosarcoma can be grouped into various histological subtypes,
based on the produced extracellular matrix of the tumor (9). Osteoblastic, chondroblastic
and broblastic osteosarcoma are the most common histological subtypes of high-grade
conventional osteosarcoma. Some correlation of the distinct histological subtypes to spe-
cic clinical outcomes has been observed (10, 11) and it may thus be dicult to collect
a homogeneous set of samples. In fact, often it is not clearly described which exact his-
tological subtypes are used in a specic study, and in what percentages these subtypes
are present in the data set. In addition, the subclassication is hindered by the occur-
rence of mixed cases containing two dierent matrix types. Nonetheless, a concordance
of 98% has been found between the histological subtype of osteosarcoma biopsies and the
corresponding resections (10).
A general problem in studying tumor cell biology is that the true cell of origin is
often not dened, rendering it dicult to select a representative control tissue or control
cells. Osteosarcoma cells are osteoblast-like cells of mesenchymal origin. Of the dierent
histological subtypes that exist, multiple subtypes can be present within a single tumor.
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Considering the dierentiation capacity of the mesenchymal stem cell (MSC), this cell
type is the most probable candidate for being the osteosarcoma progenitor (12, 13). It
was recently found that osteosarcoma tumors can be spontaneously formed when mouse
MSCs are transferred into mice (14, 15) and zebrash (16, 17). This does, however, not
exclude osteoblasts as putative progenitor cells, as osteoblasts might redierentiate into
the primitive osteoblast-like tumor cells of osteosarcoma.
Osteosarcoma models
As collecting fresh frozen osteosarcoma tumor samples can be a challenge, performing
analyses on data derived from osteosarcoma cell lines or xenografts may be a good al-
ternative (17). Osteosarcoma cell lines are frequently used in biological studies, because
they generally grow fast and are easy to maintain in culture and hence osteosarcoma cell
lines are easily available. One caveat of using cell cultures is that slight dierences in
culture conditions, for example the percentage of cells in the culture dish or ask, or the
medium that is used, can lead to signicant dierences in protein expression or signal
transduction pathway activities, and these specic conditions may dier per cell line. Us-
ing a large panel of cell lines cultured under standard settings can overcome this problem.
Cell culture may furthermore introduce additional mutations and genomic aberrations in
the cell genome, because of selection based on the in vitro conditions (18), but in general,
cell lines are reported to adequately represent the tumor from which they are derived. In
vitro, they preserve the genetic aberrations of the parent tumor, while acquiring additional
locus-specic alterations (19).
A panel of 19 osteosarcoma cell lines was recently characterized genetically by MLPA
on 38 tumor suppressor gene loci (20). A screen for TP53 mutations, MDM2 ampli-
cation, CDKN2A/B deletion and genomic deletions of 38 additional tumor suppressor
genes was performed on these cell lines. As three cell lines of this panelHOS, 143B and
MNNG-HOS have common ancestry, we report the following percentages based on 17
cell lines. Homozygous deletion of the CDKN2A/B locus was detected in 35%, whereas
hemizygous deletion of this locus was found in 24% of osteosarcoma cell lines. An addi-
tional homozygous deletion was found for TP73 in one cell line. Mutation in TP53 was
detected in 41%, whereas MDM2 amplication was detected in 17% of cell lines. These
percentages are higher than those in osteosarcoma tumor tissues that are reported in the
previously published literature (21), which may be explained by an advantage for primary
tumor cells harboring such mutations to be eectively immortalized, or by the acquisi-
tion of additional mutations owing to long-term culture. MDM2 amplication and TP53
mutations were mutually exclusive in this cell line panel. This has also been observed
in osteosarcoma tumor data (22). The dierentiation capacity of this cell line panel has
been determined as well (23). All 19 cell lines were able to dierentiate toward at least
one of the three testedosteoblastic, chondroblastic and adipocyticlineages. Most cell
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lines (14/19) could dierentiate to at least two lineages, whereas 3/19 cell lines had full
dierentiation capacity.
In vivo osteosarcoma model systems include transplantation of a human tumor in
mice (24, 25), subcutaneous or orthotopically injections of osteosarcoma cells or late-
passage transformed MSCs into mice (15) or zebrash (16). Transgenic mouse models of
osteosarcoma can be developed by overexpression of c-fos (26), or conditional inactivation
of TP53 and RB1 (27). These dierent models have been shown to resemble osteosarcoma
phenotypically (15, 16, 2328). For example, subcutaneous and intramuscular injection
of osteosarcoma cells in nude mice resulted in high-grade sarcoma, resembling tumors
which produced osteoid (23) for 8/19 cells from the above-described panel. The in vivo
lineage-specic dierentiation capacity of these cells, however, was limited, reecting the
importance of stomal or microenvironmental stimulation for this process.
As with cell lines, xenograft tumor cells may acquire additional changes owing to selec-
tion, and often, xenografts lose matrix after several passages (24). This will probably not
have a signicant eect on genomic proles, but does inuence expression and methyla-
tion patterns. High-resolution microassay-based array comparative genomic hybridization
(aCGH) including nine osteosarcoma patientxenograft pairs showed that genomes of hu-
man tumors transplanted into immunodecient mice, which were repeatedly passaged in
new mice, where comparable to genomes of their tumor of origin, with the acquisition of
only a small number additional signicant changes in the xenograft genomes (25). Dier-
ent microarray studies have shown that osteosarcoma cell lines and xenografts resemble
the primary tumor from which they are derived. Gene expression proling of a subset of
the EuroBoNeT cell line panel, for which the original histological subtype of the primary
tumor was known, and of osteosarcoma xenografts and pretreatment biopsies showed that,
despite the lower amounts of matrix, histological subtypespecic mRNA signatures are
retained in these model systems, and therefore may be a useful tool for expression analysis
(Chapter 3, (28)). Despite the similarities between genome and expression proles of the
model systems described above and the tumors of origin, the absence (cell lines) or lower
amounts (xenografts) of stromal cells and extracellular matrix, the absence of interaction
with the immune system (cell lines and some xenograft models) and the higher degree
of clonality remain important limitations for studying tumor biology using these model
systems.
Genome wide proling to study osteosarcoma
In the next sections, we describe dierent methods to analyze specic types of microar-
ray data, and give examples of how results from bioinformatics can be translated into
functional studies. This review is not aiming to give a comprehensive overview of all
genome-wide studies on osteosarcoma, but rather illustrates and summarizes the major


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2.1. With the purpose to review bioinformatic analyses on osteosarcoma, we only
review studies where at least three samples were included, and only refer to articles where
robust statistical analyses have been applied.
Single platform analyses of osteosarcoma genome-wide
data
Dierent approaches for single-way analyses
In a typical supervised genome-wide data analysis, signicant dierences, for example
signicantly dierentially expressed genes/miRNAs or dierential methylation, are deter-
mined between two or more groups of samples. These groups can exist of dierent clinical
parameters, of tumor samples and their nontumorigenic counterpart or of experimentally
induced and noninduced samples as shown in Figure 2.1. Copy number proling data
are analyzed somewhat dierently, as copy number proles of tumor samples do not nec-
essarily have to be compared to their specic nontumorigenic counterparts, but can be
compared to, for example, a public reference set, such as HapMap samples (29). Usually,
a cuto for frequency is used to determine whether an amplication or deletion is recur-
rently present in a specic region. Unsupervised analysis, on the other hand, can give
information on quality of the data, and on whether there are certain subgroups within
the tumor samples that behave dierently.
Each of these distinct ways to analyze genome-wide data has been applied to high-
grade osteosarcoma data sets. An overview of these dierent approaches in osteosarcoma
on gene expression, microRNA (miRNA), methylation and copy number data is given
in the following paragraphs. Functional verication of the results obtained with these
studies will be discussed in a later section of this review.
Genome-wide gene expression data, comparison of clinical param-
eters
Comparisons between dierent clinical subgroups of osteosarcoma have resulted in a pre-
diction prole that can classify the main histological subtypes of conventional high-grade
osteosarcoma in biopsy material, but also in cell lines and in osteosarcoma xenografts
(Chapter 3, (28)). Protein interaction networks illustrated that chondroid matrix-associ-
ated proteins were overexpressed in chondroblastic osteosarcoma, whereas NFκBSTAT5
signaling showed higher expression in broblastic osteosarcoma. The absence of a specic
network for osteoblastic osteosarcoma indicates that the features of the main osteoblast-























Data type Comparative analysis Result
Figure 2.1: Dierent supervised comparisons in genome-wide data analysis. Flow chart describ-
ing single-way bioinformatic analyses that are most typically performed on genome-wide data.
For mRNA, miRNA and methylation data analysis, the comparative analysis usually exists of
tumor samples versus nontumorigenic counterparts, of dierent groups of tumor samples, dened
by clinical parameters or samples which are experimentally altered compared to samples which
are not, although tumor samples of a specic group are also sometimes compared to a pool of
all samples (not illustrated in this gure). Copy number data are most often compared to a
reference set, which may be an in-house, or a public reference set, and which does not have to
consist of the nontumorigenic counterpart of the tumor that is studied. Additional comparative
analyses may determine the dierences between dierent subgroups within the samples that are
studied. Although for mRNA, miRNA and methylation data, often signicant dierential ex-
pression/methylation is returned by statistical tests, for copy number data researchers mostly
look at frequency of the aberration in the studied groups.
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A second example of a comparison between dierent clinical parameters is the com-
parison of samples with dierent outcomes in event-free survival or overall survival. It is
important to note that when designing an analysis for such a study, a uniform set of clini-
cal follow-up parameters should be employed, instead of directly comparing patients with
or without metastases, or patients who are alive or deceased. In one study, dierential ex-
pression was determined between biopsy material of patients developing metastases within
5 years and patients who did not develop metastases within this time frame. This study
demonstrated that, in osteosarcoma, an expression prole associated with macrophages
correlated with better overall survival (Chapter 4, (30)). To identify genes playing a role
in metastasis, comparisons between osteosarcoma cell lines that can or cannot metastasize
upon passaging into mice have also been made. A recent study identied downregulation
of IGFBP5, or insulin-like growth factor binding protein 5, in the metastatic cell line
MG63.2 and in tumors derived from this cell line (31). Interestingly, this gene was also
signicantly downregulated in our analysis, comparing osteosarcoma biopsies with control
tissues (32)). Metastasis progression can be studied by comparing metastatic resections
to the primary tumor. This has been performed in one study, where higher expression of
genes involved in immunological processes was detected in the metastasis samples (33).
This may correlate with our ndings that more CD14+ cells are present in metastatic
lesions than in pretreatment biopsies (30).
Another important clinical parameter that has been studied in human osteosarcoma is
response to chemotherapy, which is predictive for overall survival (3436). Dierentially
expressed genes discriminating between good and poor responders to chemotherapy have
been detected by dierent groups, but with little consensus in the gene lists. Most studies
did not use robust statistics with correction for multiple testing, a shortcoming that is
too often seen in biomedical research (37). When dierential expression was determined
between poor and good responders in two studies where correction for multiple testing
was applied (Chapter 3, (28), and (32)), no signicant genes were detected although
larger sample sizes and homogeneous data sets were used (17 poor vs 8 good responders
in Cleton-Jansen et al. (32) and 36 poor vs 33 good responders in Kuijjer et al. (28)).
Although these sample sizes are not comparable to what is often used for studying less
rare tumor types, the distribution of the nonadjusted p-values did not show any trend
for the lower p-values to be more prevalent (Additional Figure 2.1). This indicates that
in a comparison between two groups no eect is detected, and increasing sample size will
not lead to a signicant increase in power (38). A major issue with comparing responders
with nonresponders in gene expression analysis is that resistance to chemotherapy may
be caused by the alteration of a single gene. A specic gene causing resistance in a subset
of samples will not be picked up by a comparison of responders and nonresponders (39).
In human osteosarcoma xenografts, signicant dierential expression has been detected
between good and poor responders to single chemotherapeutic agents (40). A pitfall of
this study, however, was that the studied sample set included xenografts derived from
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biopsies, resections as well as from metastases. Surviving cells of pretreated tumors are
resistant to chemotherapy. Thus, the dierences in gene expression between poor and good
responders to these chemotherapeutic agents may actually reect an eect of presurgery
therapy. It was indeed demonstrated that xenografts of these implanted pretreated tumors
often responded poorly to multiple chemotherapeutic agents (41).
Genome-wide gene expression data, comparison with control tis-
sues
mRNA expression levels in osteosarcoma samples can also be compared to expression
in control tissues. The control tissues that have been used for this purpose are normal
bone, osteoblastoma, osteoblasts, MSCs, or, for example, a pool of dierent cell lines.
One comparison of high-grade osteosarcoma biopsy specimens with control samples is de-
scribed in Cleton-Jansen et al. (32), who made dierent comparisons of 25 osteosarcoma
biopsies with ve osteoblastomas, with ve MSCs and with ve osteoblast cultures. Gene
set enrichment detected cell-cycle regulation and DNA replication pathways as the most
signicantly aected pathways in osteosarcoma. A DNA replication network was also
identied in an analysis of gene expression microarrays of six osteosarcoma biopsies as
compared to one osteoblast culture although a caveat of this study is the small sample
size of the control set (n = 1) (42). A larger set of osteosarcoma biopsies (n = 84) was
compared to 12 MSCs and separately with three osteoblast cultures (Chapter 7, (43)).
Intersection of the dierentially expressed genes in both analyses identied antigen pro-
cessing and presentation as well as angiogenesis as signicantly dierent between tumor
samples and control cell lines, most probably because of the amount of stroma present in
the tumor samples. In addition, altered apoptosis and signal transduction were detected.
Genome-wide gene expression data, experimentally induced dier-
ences
We give a nal example of genome-wide gene expression analyses in osteosarcoma, which is
experimentally induced dierential expression. This is, for example, reported in the study
by Kansara it et al. (44), who compared a set of ve human osteosarcoma cells treated with
a demethylating agent to untreated cells, after having shown that demethylating agents
can induce growth arrest and dierentiation in osteosarcoma. The list of candidate genes
was then ltered for expression in human osteoblasts and loss of expression in primary




Several studies have been published, describing miRNA microarray data analysis on os-
teosarcoma tissues or cell lines as compared to osteoblasts or normal bone, but in most
studies no robust statistics were applied. Jones et al. (45) and Namløs et al. (46) pub-
lished the only miRNA microarray studies in which false discovery rate corrections were
applied. In the article by Jones et al. (45), miRNA expression was compared between
18 osteosarcoma resections or biopsies and 12 normal bone samples, which lead to the
detection of a downregulated tumor suppressive miRNA and of a prometastatic miRNA
(these miRNAs will be discussed in the Integrative analyses section). Namløs et al. (46)
compared miRNA expression in 19 osteosarcoma cell lines with expression in normal bone
(n = 4) and integrated these results with mRNA expression data. Results from this study
will therefore be discussed in the Integrative analyses section. Sarver et al. (47) published
an online accessible Sarcoma miRNA expression database (S-MED), which includes 15
osteosarcoma samples and six normal bone samples.
Genome-wide methylation data
Only three studies have been published so far on genome-wide methylation in high-grade
osteosarcoma (42, 48, 49). These studies describe an integrative analysis with dierent
data types, without presenting conclusions on specic genes, or on results obtained with
gene set enrichment on single-way methylation analyses although Kresse et al. (49) found
overall more hypermethylation in osteosarcoma cell lines than hypomethylation. We will
discuss the results from these studies under the Integrative analysis section of this review.
Genomic copy number data
The genomic instability of high-grade osteosarcoma, which is more pronounced in this
tumor than in many other tumor types, hampers the identication of specic genomic
regions. Several array comparative genomic hybridization (aCGH) studies (25, 5055)
and single-nucleotide polymorphism (SNP) microarray studies (43, 5659) on osteosar-
coma specimens have been published. Copy number proles clearly show that high-grade
osteosarcoma samples are characterized by a high level of aneuploidy, and that there is
heterogeneity between dierent tumor samples. There is a general consensus about copy
number alterations for some regions, such as gains on chromosome arms 6p, 8q and 17p,
which have been detected by classical karyotyping and conventional CGH as well (2, 60),
but it is dicult to directly compare studies as the denition of a recurrent alteration
varies.
In three separate studies, a focal deletion of the region 3q13.31, which harbors a
putative tumor suppressor gene, LSAMP, was detected (54, 56, 59). siRNA-mediated
silencing of LSAMP promoted proliferation of normal osteoblasts (59), and low expression
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of the gene was associated with poor overall survival in one of these studies (54). Gene
set enrichment on an aCGH study showed an enrichment of amplied genes of the VEGF
signaling pathway of which VEGFA amplication also correlated with poor prognosis,
showing that gene set enrichment on copy number data can identify pathways associated
with tumorigenesis (53).
Copy number proles of osteosarcoma cell lines roughly resemble proles of tumor
biopsies, but show an increased overall aneuploidy (Kuijjer et al., unpublished data) and
increased expression of genomic instability genes (Chapter 7, (43)). Also, as described
above, genomic proles of xenografts are highly similar to primary tumors although some
deviations may occur owing to additional genetic alterations during passaging, or owing
to general tumor progression (25). In some data sets, specic copy number alterations
have not been detected for dierent clinical groups of interest (43) although both a high
degree of genomic alterations and a loss of heterozygosity were found to be associated
with poor event-free survival (43, 58). Yen et al. (56) found that specic aberrations
were more frequent in recurrences and metastases than in primary tumorsdeletion of
6q14.1-q22.31 and 8p23.2-p12 and amplication of 8q21.12-q24.3 and 17p12and vice
versaXp11.22 gain and 13q31.3 deletion (56).
Integrative analyses
For high-grade osteosarcoma, integration of dierent data types is of specic importance.
Integrative analysis can narrow down the large lists of signicantly aected genes to a
gene list containing the major tumor driver genes. An integrative approach on copy
number and gene expression data, for example, typically returns a more specic list of
driver genes because passenger- and tissue-specic genes will be largely eliminated (61).
Dierent methods exist for the integration of dierent types of data. Figure 2.2 shows an
overview of direct dependencies between copy number, methylation, miRNA and mRNA






Figure 2.2: Flow chart showing direct
dependencies between dierent data types,
which can be utilized for the interpretation
of integrative analyses. Arrow-headed and
bar-headed lines show positive and negative
inuences, respectively. DNA copy num-
ber positively aects miRNA and mRNA
copies, whereas miRNA expression can cause
downregulation of target mRNAs, and DNA
methylation can inhibit transcription.
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correlation or cooccurrence.
Cooccurring genomic alterations and gene expression changes have been recently de-
termined to identify putative driver genes in high-grade osteosarcoma (Chapter 7, (43)).
A paired integrative analysis of 29 pretreatment biopsies returned a list of 31 genes with
recurrence frequency of at least 35%, which showed an overall signicant upregulation as
compared to control cell lines in case of a gain, and downregulation in case of a deletion.
Genes aecting genomic stability were overrepresented, which may point to a role of this
process in osteosarcoma. Nonpaired analysis on the same series, but extended with more
cases in both the SNP and the gene expression data sets resulted in a smaller set of sig-
nicantly aected genes, with substantial overlap with the list of genes detected by the
paired analysis, thereby showing that the paired analysis was more powerful on this data
set. This is especially of interest for the data analysis of osteosarcoma pretreatment biop-
sies because these samples are rare. By performing a paired analysis, fewer samples can
be used. Nonpaired integrative analysis of high-level amplications in 22 osteosarcoma
specimens with gene expression data of eight osteosarcoma xenografts as compared to 19
normal tissue controls identied 43 genes with high-level amplication and overexpression
in osteosarcoma. CCNE1, the gene encoding for cyclin E1, showed correlation of copy
number levels and gene expression in an additional panel of ten osteosarcoma cell lines,
and therefore could play an oncogenic role in osteosarcoma (55).
miRNA expression data can be integrated with mRNA expression data to determine
whether the miRNAs of interest aect mRNA expression of their target genes. This is
generally performed by correlation of expression levels, as was performed by Baumhoer
et al., (62) Namløs et al. (46) and Jones et al. (45) (discussed above). The latter sub-
sequently performed pathway analysis on target genes of the detected dierentially ex-
pressed miRNAs, which illustrated the eects of these miRNAs on transcriptional reg-
ulation, cell-cycle control and known cancer signaling pathways (45). In the study by
Namløs et al. (46), cell line miRNA data were integrated with mRNA targets which
were signicant in both osteosarcoma pretreatment biopsies and cell lines. Among the
inversely correlated miRNA/mRNA pairs, miRNAs regulating TGFBR2, IRS1, PTEN
and PI3K subunits were detected. Methylation data are also typically integrated with
mRNA expression data to evaluate the eect of the methylation on gene expression, but
few studies described two-way comparisons of methylation and mRNA microarray data
in osteosarcoma. Kresse et al. (49) detected hypermethylation and underexpression of
chemokine ligand 5 (CXCL5) by two-way comparison in both osteosarcoma cell lines and
tumor samples.
Integration of more than two dierent data types is reported by Sadikovic et al. (48) in
two articles, where copy number, methylation and gene expression data were integrated.
In one of these articles, the authors described cooccurrent epigenetic, genomic and gene
expression changes in two osteosarcoma cell lines as compared to an osteoblast culture,
and detected a region of gain on chromosome 8q encompassing the c-MYC oncogene,
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which was also detected in a network analysis, conrming overexpression and hypomethy-
lation of genes connected to c-MYC. In the second article, the authors used the same
integrative approach to perform a three-way analysis on ve osteosarcoma pretreatment
biopsies, and to compare gene regulation networks of single-way analyses including more
samples. In this way, a number of candidate genes were characterized, including RUNX2,
a transcription factor involved in osteoblastic dierentiation (42). A shortcoming of both
studies, however, is that as a control for methylation and mRNA expression in osteosar-
coma, material from only one osteoblastic culture was used. Another integrative analysis
on copy number, methylation and mRNA data reported 350 genes, showing two types
of aberrations (e.g. gain and overexpression, or hypermethylation and underexpression).
This set of genes was enriched in genes with a function in skeletal system development
and extracellular matrix remodeling, such as RUNX2 and DLX5 (49).
Translating bioinformatics into functional studies
Functional validation of candidate genes
Several of the candidate tumor suppressor genes and oncogenes that have been identi-
ed with microarray studies have been functionally validated. IGFBP5 was signicantly
downregulated in metastatic cell lines and derivative tumors as compared to nonmetastatic
cell lines, and also showed lower protein expression in metastatic lesions than in primary
tumor samples of osteosarcoma patients. The eects of overexpression or knockdown of
IGFBP5 on cell proliferation, migration, wound healing and invasion conrmed the role
of this IGF-binding protein in preventing metastasis, which was furthermore validated in
a xenograft model (31).
The candidate tumor suppressor gene WIF1 was found to regulate dierentiation and
suppress cell growth in vitro. WIF1 knockout mice developed radiation-induced osteosar-
coma earlier than their littermate controls (44). From miRNA expression proling studies,
miR-16 was validated as a tumor suppressive miRNA, whereas miR-27a was validated as
a prometastatic miRNA, using colony formation assays, and wound healing and invasion
assays, respectively. Overexpression of these miRNAs in vivo resulted in smaller tumors
for miR-16, and in higher numbers of pulmonary metastases for miR-27a (45).
Functional validation of pathway activity and enriched gene sets
Pathways important in the development of bone biology have been returned from gene ex-
pression analysis as compared to controls. Genes upstream canonical Wnt signaling were,
for example, found to be downregulated as compared to osteoblasts (32). A subsequent
functional study, where nuclear β-catenin staining was determined on osteosarcoma biop-
sies, and Wnt luciferase activity and mRNA expression of the specic downstream Wnt
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target gene Axin2 were measured in cell lines, illustrated that canonical Wnt signaling is
indeed often downregulated in osteosarcoma (63). Loss of canonical Wnt signaling causes
failure to commit to dierentiation of MSCs, as has been reported in malignant brous
histiocytoma (also undierentiated pleomorphic sarcoma), which could be reprogrammed
by re-establishing Wnt signaling (64). Also in osteosarcoma, reactivation of the Wnt sig-
naling pathway with a GSK3β inhibitor triggered a more dierentiated phenotype, or a
reduced proliferation capacity, depending on the osteosarcoma cell line (63).
These results seem contradictive to the nding that WIF1 can inhibit cell growth
and increase dierentiation in osteosarcoma cells (44). A possible explanation for this
discrepancy is that WIF1 inhibits both canonical and noncanonical Wnt signaling (65),
whereas GSK3β also plays a role in additional signal transduction pathways, such as
NFκB signaling (66). However, the role of Wnt signaling remains contradictory, as this
pathway was recently described to be active in multiple sarcoma subtypes, which also
included osteosarcoma (67). The use of dierent methods to assess active Wnt signaling
may be the cause for the discrepancies between these studies.
TGF-β/BMP signaling was found to be aected in osteosarcoma by pathway analysis
on mRNA expression data. Activity of these pathways was validated by immunohisto-
chemistry of phosphorylated Smad1 and Smad2, and nuclear staining of these intracellular
eectors was detected in 70% of all osteosarcoma samples. Cases with very low or ab-
sent phosphorylated Smad2 had worse overall survival. In vitro pathway modulation did
not aect proliferation or dierentiation, but lower TGFβ/BMP activity might aect the
prevention of metastasis in these patients (68).
The macrophage signature that was prominent upon comparing mRNA proles of
metastatic and nonmetastatic osteosarcoma was conrmed by qPCR and immunohisto-
chemistry, and it was shown in additional cohorts that the sum of M1 and M2 types of
macrophages was predictive for better overall survival (Chapter 4, (30)). Treating pa-
tients with macrophage-activating agents may reduce metastases of osteosarcoma (69).
This is corroborated by clinical trials in dogs and humans, where treatment with mi-
famurtide, a macrophage-activating agent, has been reported to positively aect overall
survival (70, 71).
Conclusions and future directions
In this review, we have presented and discussed the results of studies on high-grade os-
teosarcoma material using bioinformatic analysis on microarray data of three or more
samples. Although studying such a very heterogeneous and genomically unstable tumor
remains challenging, and sample sizes are often small owing to the rarity of the disease,
structured microarray data analysis has provided interesting results and has given fur-
ther insight into the biology and progression of osteosarcoma. This information could
not have been obtained from functional studies only. Studying copy number aberrations,
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dierential expression, and epigenetics in a genome-wide manner and subsequent integra-
tion leads to new hypotheses regarding tumor development and progression, which can
subsequently be validated in functional studies. This provides a motivation to take the
study of high-grade osteosarcoma to the next level, and to analyze this tumor into fur-
ther detail using Next Generation Sequencing methods, such as whole-genome, exome or
transcriptome sequencing. Whole-genome sequencing has recently been performed in a
study of dierent cancer types, which showed that a subset of osteosarcomas (three out
of nine) undergo chromothripsisa single catastrophic genomic instability event, result-
ing in hundreds of genomic rearrangements (72). This may explain the sudden onset of
osteosarcoma and the complexity and heterogeneity of the osteosarcoma genome. Next
Generation Sequencing will provide us with many forms of new information. In addition
to copy number changes, mutations, translocations, unannotated genes, splicing variants,
and so on, can be detected in a high-throughput manner. Transcriptome sequencing ex-
hibits higher sensitivity and increased dynamic range than mRNA expression microarray
data, thereby providing higher power for the detection of dierential gene expression (73).
Now that the rst Next Generation Sequencing studies including large numbers of high-
grade osteosarcoma are ongoing or being planned, it is important to reect on the previous
genome-wide studies in osteosarcoma. When keeping in mind the lessons we have learned
on study design in microarray data analysisusing a sucient amount of samples, den-
ing homogeneous groups, and analyzing the data with robust statisticswe will be given
new opportunities in unraveling the biology of this complex disease and in providing future
clinical trials with robust data to incorporate into novel therapeutic strategies.
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Additional Figure 2.1: This gure illustrates a histogram of nonadjusted, moderated p-values
and the empirical cumulative distribution of p-values for the studies of A, Cleton-Jansen et
al. (32) and B, Kuijjer et al. (28), both describing no signicant dierence in mRNA expression
in pretreatment biopsies of patients with poor versus good response to chemotherapy. The gures
were generated using Bioconductor package SSPA (38).
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Chapter 3
mRNA expression proles of primary
high-grade central osteosarcoma are
preserved in cell lines and xenografts
This chapter is based on the publication: Kuijjer ML, Namløs HM, Hauben EI, Machado I,
Kresse SH, Serra M, Llombart-Bosch A, Hogendoorn PCW, Meza-Zepeda LA, Myklebost
O, Cleton-Jansen AM. BMC Med Genomics. 2011 Sep 20;4:66
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Abstract
Background: Conventional high-grade osteosarcoma is a primary malignant bone tumor,
which is most prevalent in adolescence. Survival rates of osteosarcoma patients have not
improved signicantly in the last 25 years. Aiming to increase this survival rate, a variety
of model systems are used to study osteosarcomagenesis and to test new therapeutic
agents. Such model systems are typically generated from an osteosarcoma primary tumor,
but undergo many changes due to culturing or interactions with a dierent host species,
which may result in dierences in gene expression between primary tumor cells, and tumor
cells from the model system. We aimed to investigate whether gene expression proles of
osteosarcoma cell lines and xenografts are still comparable to those of the primary tumor.
Methods: We performed genome-wide mRNA expression proling on osteosarcoma
biopsies (n = 76), cell lines (n = 13), and xenografts (n = 18). Osteosarcoma can be
subdivided into several histological subtypes, of which osteoblastic, chondroblastic, and
broblastic osteosarcoma are the most frequent ones. Using nearest shrunken centroids
classication, we generated an expression signature that can predict the histological sub-
type of osteosarcoma biopsies.
Results: The expression signature, which consisted of 24 probes encoding for 22 genes,
predicted the histological subtype of osteosarcoma biopsies with a misclassication error
of 15%. Histological subtypes of the two osteosarcoma model systems, i.e. osteosarcoma
cell lines and xenografts, were predicted with similar misclassication error rates (15%
and 11%, respectively).
Conclusions: Based on the preservation of mRNA expression proles that are charac-
teristic for the histological subtype we propose that these model systems are representative
for the primary tumor from which they are derived.
Background
Conventional high-grade osteosarcoma is the most frequent primary malignant bone tu-
mor, with a peak occurrence in children and adolescents and a second peak in patients
older than 40 years. It is a highly genetically unstable tumor, of which karyotypes often
show aneuploidy, high level amplication and deletion, and translocations (1). No pre-
cursor lesion is known, although part of the osteosarcomas in patients over 40 years is
secondary, and is induced by radiation, chemicals, or by an underlying history of Paget's
disease of bone (2). The leading cause of death of osteosarcoma patients are distant metas-
tases, which despite aggressive chemotherapy regimens still develop in approximately 45%
of all patients (3). Overall survival of osteosarcoma patients has increased from 1020%
before the introduction of preoperative chemotherapy in the 1970s, to about 60% (4).
However, survival has reached a plateau, and treating with higher doses of chemotherapy
does not lead to better overall survival (5).
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Osteosarcoma is a heterogeneous tumor type, which can be subdivided into various
subtypes (6). Conventional high-grade osteosarcoma is the most common subtype, and
can be further subdivided in dierent histological subtypes, of which osteoblastic (50%),
chondroblastic (25%), and broblastic osteosarcoma (25%) are the most frequent ones.
Other subtypes of conventional high-grade osteosarcoma, such as chondromyxoid broma-
like, clear cell, epitheliod, sclerosing, and giant cell rich osteosarcoma, are extremely
rare (2). Often, osteosarcoma tissue contains a mixture of morphologically diering cell
types, and the classication is based on the most dominant type (7). The three main
histological subtypes have dierent survival proles. Patients with broblastic osteosar-
coma have a signicantly better response to preoperative chemotherapy, which is a known
predictor for improved survival, than do osteoblastic osteosarcoma patients (8). Although
patients with chondroblastic osteosarcoma are relatively poor responders to preoperative
chemotherapy (7, 9), which is probably caused by the impermeability of the chondroid
areas of the tumor, there is a trend for these patients to have better 5-year survival
proles (7), but also a higher risk for late relapse (10).
The search for new (targeted) therapies to treat osteosarcoma is ongoing (11). Because
the disease is relatively rare, large eorts need to be done in order to collect a considerable
amount of patient samples. Moreover, material is usually scarce due to necrosis in resec-
tions of the primary tumor, which is mostly present in tumors of patients who respond
fairly well to neoadjuvant chemotherapy. No necrosis is present in prechemotherapy biop-
sies, but these are often very small and are not readily available for research because they
are needed for diagnosis. Because of these limitations, model systems are widely used to
study osteosarcomagenesis and for preclinical testing of candidate drugs. Osteosarcoma
cell lines, especially SAOS-2 and U-2 OS are frequently used as model systems, remark-
ably not only to study osteosarcoma, but all types of in vitro cell biological processes, as
these cell lines grow fast and are relatively easy to transfect. Recently, the EuroBoNeT
(www.eurobonet.eu) osteosarcoma panel of 19 cell lines was characterized, which allows
us to study osteosarcoma in a high-throughput manner (12). This panel of osteosarcoma
cell lines has been shown to resemble osteosarcoma phenotypically and functionally (13).
Other established model systems include xenografts from primary tumors or osteosar-
coma cell lines in immunodecient nude mice, which subsequently develop into tumors
resembling osteosarcoma (1315). Osteosarcomagenesis can also be induced in mice by
radiation or orthotopically implanting chemical carcinogens (16). We have previously
shown that DNA copy number proles of xenografts resemble those of the corresponding
primary tumor, although some signicant changes for osteosarcoma were observed (15).
Established cancer cell lines are often thought not to be representative for the orig-
inating primary tumor. Since there could have been a selection for their propensity to
grow in culture, they lack interaction with stroma and may have acquired additional mu-
tations in culture (17). Xenografts do have tumorhost interactions, but can lose matrix
as well after several passages. It is not clear whether such changes in matrix composition
56 Chapter 3
of xenografts are caused by the tumor cells, or by changes in mouse stroma (14). Despite
these biological dierences, model systems are useful for studying signal transduction
pathways important in tumor biology, of which mRNA expression, as measured by qPCR
or using gene expression microarrays, is frequently used as a readout. It is therefore
highly important to determine whether gene expression levels of these model systems are
comparable to those of the corresponding primary tumors, which we aimed to do in this
study. We performed gene expression analysis on a panel of 76 conventional high-grade
osteosarcoma pretreatment biopsies. We set out to recapitulate representative expression
proles from primary untreated osteosarcoma biopsies in corresponding models i.e. cell
lines and xenografts. We could demonstrate that both model systems still express genes
that are characteristic for the specic histological subtype of the primary tumor. We
therefore endorse that, despite biological dierences, both xenografts and cell lines are
representative model systems for studying mRNA expression in high-grade osteosarcoma.




All biological material was handled in a coded fashion. Ethical guidelines of the indi-
vidual European partners were followed and samples and clinical data were stored in the
EuroBoNet biobank. For xenograft experiments, informed consent and sample collection
were approved by the Ethical Committee of Southern Norway (Project S-06132) and the
Institutional Ethical Committee of Valencia University.
Patients cohorts
Genome-wide expression proling was performed on pretreatment diagnostic biopsies of
76 resectable highgrade osteosarcoma patients from the EuroBoNet consortium (www.
eurobonet.eu). Clinicopathological details of these 76 samples can be found in Table 3.1.
Samples with a main histological subtype (n = 66) were selected for subsequent subtype
analyses. These 66 samples included 50 osteoblastic, 9 chondroblastic, and 7 broblastic
osteosarcomas. Five additional osteosarcoma biopsies (1 chondroblastic and 4 osteoblas-
tic osteosarcomas), 12 mesenchymal stem cell (MSC) and 3 osteoblast cultures, and 12



















































































































































































































































































































































































































































































































































































































































































Out of the EuroBoNeT panel of 19 cell lines, 13 cell lines were recorded to belong to a
main histological subtype. This set of 13 cell lines contained 4 cell lines derived from
broblastic, and 9 cell lines derived from osteoblastic osteosarcomas. The 13 osteosar-
coma cell lines IOR/MOS, IOR/OS10, IOR/OS14, IOR/OS15, IOR/OS18, IOR/OS9,
IOR/SARG, KPD, MG-63, MHM, OHS, OSA, and ZK-58 were maintained in RPMI
1640 (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal calf serum and 1%
Penicillin/Streptomycin (Invitrogen) as previously described (12). Clinical details of the
tissue from which these cell lines were derived are shown in Table 3.1 and are described
previously (12).
Osteosarcoma xenografts
The osteosarcoma xenograft model is described in Kresse et al. (15). In short, human
tumors were implanted directly from patient samples and successively passaged subcuta-
neously in nude mice. Eighteen dierent xenografts were used, of which 3 were derived
from chondroblastic, and 15 from osteoblastic osteosarcomas. Clinical data on primary
tumor samples and xenograft passages that were used are shown in Table 3.1.
Determination of histological subtypes
Histological subtyping was performed by two pathologists (PCWH, EH) on hematoxylin
and eosin (HE) stained slides of all biopsies and of all primary tumors from which the
osteosarcoma cell lines and xenografts were derived. Osteoblastic, chondroblastic, and -
broblastic osteosarcoma samples were selected for further study. Other subtypes (anaplas-
tic, chondromyxoid broma-like, broblastic MFH-like, giant cell rich, pleomorphic, and
sclerosing osteosarcoma) were excluded because these subtypes are rare.
RNA isolation, cDNA synthesis, cRNA amplication, and Illumina
Human-6 v2.0 Expression BeadChip hybridization
Osteosarcoma and xenograft tissue was handled as previously described (18). Osteosar-
coma cell lines were prepared as in Ottaviano et al. (12). RNA isolation, synthesis of
cDNA, cRNA amplication, and hybridization of cRNA onto the Illumina Human-6 v2.0
Expression BeadChips were performed as previously described (18).
Microarray data preprocessing
Microarray data processing and quality control were performed using the statistical lan-
guage R (19) as described previously (18). MIAME-compliant data have been deposited in
the GEO database (www.ncbi.nlm.nih.gov/geo/, accession number GSE30699). High
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correlations between these microarray data and corresponding qPCR results have been
demonstrated previously (18).
Detection of signicantly dierentially expressed genes
We performed LIMMA analyses (20) in order to determine dierential expression for the
following clinical parameters: sex (52 male vs 24 female), tumor location (36 femur, 10
humerus, 26 bula/tibia), response to preoperative chemotherapy (36 poor responders, or
Huvos grade 12, vs 33 good responders, or Huvos grade 34), and histological subtype (an
analysis comparing 50 osteoblastic, 9 chondroblastic, and 7 broblastic osteosarcomas).
Genes that play a role in metastasis-free survival are described in Buddingh et al. (18).
Probes with Benjamini and Hochberg False discovery rate-adjusted p-values (adjP) < 0.05
were considered to be signicantly dierentially expressed.
Prediction analysis
The gene expression prole was generated on the dataset of biopsies using Bioconduc-
tor (21) package pamr (22). Internal cross-validation was performed 50 times. A threshold
was selected where the error rate of the prediction prole was minimal. The minimum er-
ror rate was representative of 50 independent simulations. In order to minimize optimiza-
tion bias (23), we validated the prole on an independent dataset of osteosarcoma biopsies
(n = 5), containing 1 chondroblastic osteosarcoma and 4 osteoblastic osteosarcomas. In
addition, we applied the prole on datasets containing positive controlsmesenchymal
stem cells (MSC, n = 12), osteoblasts (n = 3), and chondrosarcoma biopsies (n = 12,
previously published in (24), GEO accession number GSE12532). We subsequently ap-
plied the validated prediction prole to two independent datasets, the rst consisting of
gene expression data of osteosarcoma cell lines, the second of xenografts. Expression of
the probes that composed the prediction prole was veried using a LIMMA analysis,
comparing chondroblastic, broblastic, and osteoblastic osteosarcoma biopsy samples.
Gene set enrichment
Network analysis was performed using Ingenuity Pathways Analysis (IPA, Ingenuity Sys-
tems, www.ingenuity.com). For both chondroblastic-specic and broblastic-specic
analyses, data for all reference sequences containing expression values and FDR-adjusted
p-values were uploaded into the application. Each identier was mapped to its corre-
sponding object in Ingenuity's Knowledge Base. An adjP cut-o of 0.05 was set to select
genes whose expression was signicantly dierentially regulated. The Network Eligible
molecules were overlaid onto a global molecular network developed from information con-
tained in Ingenuity's Knowledge Base. Networks of Network Eligible Molecules were then
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algorithmically generated based on their connectivity. GO term enrichment was tested us-
ing Bioconductor package topGO (25). Lists of signicantly aected genes were compared
with all genes eligible for the analysis. GO terms with Fisher's exact p-values < 0.001, as
calculated by the weight algorithm from topGO, were dened signicant.
Results
Histological subtypes of osteosarcoma biopsies have dierent gene
expression proles
We determined dierential expression for dierent clinical parameters. Of all comparisons
of clinical parameters only histological subtypes appeared to give a sucient number of
dierentially expressed genes to design a prediction prole. LIMMA analyses resulted in
one location-specic dierentially expressed gene: HOXD4, which was overexpressed in
tumors at the humerus versus at bula/tibia and femur. Between tumors from male and
female patients, 18 genes were signicantly dierentially expressed, all belonging to X- and
Y-chromosome-specic genes, which are not considered as representative for osteosarcoma,
yet this nding validates the analysis. No signicantly aected genes were returned with
regards to response to preoperative chemotherapy. To determine dierential expression
between the three main histological subtypes, we excluded all samples with unknown
or rare subtypes. This resulted in a dataset of 66 conventional high-grade osteosarcoma
biopsies with a main histological subtype. Using a LIMMA analysis, we determined 1, 338
signicantly dierentially expressed genes (adjP < 0.05) that were specic for a certain










Figure 3.1: Venn diagram represent-
ing numbers of broblastic- (green),
chondroblastic- (red), and osteoblastic
(blue)-specic dierentially expressed genes
obtained with LIMMA analysis, considering
chondroblastic versus osteoblastic (chondro
vs osteo), broblastic versus osteoblastic
(bro vs osteo), and chondroblastic versus
broblastic (chondro vs bro) analyses.
Subtype-specic genes are genes that are
either both upregulated or both downreg-
ulated in the subtype of interest in the
dierent comparisons.
probe was dened as a probe that had the same sign of log fold change in both analyses,
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e.g. the probe was upregulated in chondroblastic samples versus osteoblastic, and in
chondroblastic versus broblastic samples.
Gene set enrichment shows specic sets of genes are aected in
broblastic and chondroblastic osteosarcoma
Network analysis using IPA showed that broblastic osteosarcoma-specic networks most-
ly had a role in cellular growth and proliferation, which was also the most signicant
biological function as detected by IPA (see Additional File 1 (available online (26)) for all
aected networks and biological functions). The most signicant network is illustrated in
Additional File 2A (available online (26)) and shows that mRNA of various genes with a
connection to the NF-κB pathway and STAT5A signaling are upregulated in broblastic
osteosarcoma biopsies, as compared with both osteoblastic and chondroblastic osteosar-
coma. The most signicant network specic for the chondroblastic subtype consisted of
genes important in skeletal connective tissue development and function (Additional File
2B (available online (26))), and shows that, also on the gene expression level, chondroblas-
tic osteosarcoma is mainly distinguished from osteoblastic and broblastic osteosarcoma
based on the composition of the extracellular matrix of the tumor (Additional File 1
(available online (26)) shows all aected networks and biological functions).
Results from network analysis were conrmed using topGO, a gene set enrichment
approach analyzing the signicance of GO terms in a specic dataset. These analyses
resulted in two signicant broblastic specic GO terms in osteosarcoma: regulation of
tyrosine phosphorylation of Stat5 protein (GO:0042522, p-value = 4.8 · 10−4) and regu-
lation of survival gene product expression (GO:0045884, p-value = 8.2 · 10−4). Signi-
cantly dierentially expressed genes from both GO terms partly overlap the broblastic
osteosarcoma-specic network detected with IPA. Two GO terms were signicant in the
chondroblastic-specic analysis as well: skeletal system development (GO:0001501), and
extracellular matrix organization (GO:0030198), which strengthen the results found in
the IPA network analyses. GO term subgraphs of the ve most signicant GO terms for
both analyses are shown in Additional File 3 (available online (26)).
Gene set enrichment on genes specic for osteoblastic osteosarcoma was not performed,
because only one osteoblastic osteosarcoma-specic probe was detected that distinguishes
the osteoblastic subtype from broblastic and chondroblastic. This probe matches to
UNQ1940, or FAM180A, a protein-coding gene with a yet unknown function.
Generation and validation of the prediction prole
Because we could not directly compare subtype-specic genes between our dierent model
systems due to small sample sizes, we generated a prole that could predict the histo-
logical subtype of osteosarcoma. The prediction prole was generated on 66 high-grade
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conventional osteosarcoma prechemotherapy biopsies, using nearest shrunken centroids
classication. Optimal control of error rate in the prediction prole was found at delta
thresholds of 4.9 − 5.1 (Figure 3.2A), where merely 10 out of 66 samples (15%) in the




Figure 3.2: A, Illustration of training the pamr prediction prole on osteosarcoma biopsies. At
thresholds of 4.9 − 5.1, the misclassication error rate was minimal. B, True versus predicted
values from the nearest shrunken centroid t. C, Probabilities of each biopsy to belong to any of
the three histological subtypes. Samples are separated (dotted lines) based on their true subtypes.
Cross-validated probabilities for each histological subtype are shown on the y-axis, so that for
every sample three open circles are present (blue, red, and green circles for osteo-, chondro-,
and broblastic osteosarcoma, respectively). A sample is classied into a specic subtype if the
probability to belong to that specic subtype is higher than the probabilities to belong to the
other subtypes. D, The FDR plotted against dierent thresholds of the prediction prole. At
a threshold of 5.0, 24 genes are included in the prediction prole. These 24 genes have a FDR
< 5%.
representative for a set of 50 simulations, which resulted in error rates between 13.5% and
15%. Subtype-specic error rates were 22%, 43%, and 10% for chondroblastic, broblas-
tic, and osteoblastic subtypes, respectively (Figure 3.2B). Probabilities of each sample to
belong to any of the three histological subtypes are shown in Figure 3.2C. At a threshold
delta of 5.0, the prediction prole consisted of 24 probes encoding for 22 genes. All genes
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were below a FDR threshold of 5% (Figure 3.2D). Expression of the 24 probes of the
prole were veried in a LIMMA analysis which was corrected for multiple testing. All 24
probes were conrmed to be signicantly dierentially expressed in the LIMMA analysis
as well. Results from pamr and LIMMA analyses are shown in Table 3.2. A supervised
heatmap depicting expression of the 24 probes in all samples is shown in Additional File 4
(available online (26)). The prediction prole was validated at threshold delta of 5.0 in an
independent dataset of osteosarcoma biopsies and positive controls. Histological subtypes
of biopsies had a prediction error of 0% (0/5). Mesenchymal stem cells and osteoblasts
all tted in the osteoblastic group, while 11/12 chondrosarcoma samples were best cor-
responding to the group of chondroblastic osteosarcoma. The remaining chondrosarcoma
sample was a dedierentiated chondrosarcoma and was predicted in the broblastic group,
probably because of the high amount of spindle cells present in the biopsy. Additional File
5 (available online (26)) shows prediction probabilities for each subtype of these additional
datasets.
A prediction prole based on osteosarcoma biopsy data can predict
histological subtypes of cell lines and xenografts
Unsupervised clustering of all biopsies, xenografts, and cell lines demonstrated that
xenografts and cell lines show dierent overall expression proles from most biopsies, and
that there are no subtype-specic clusters based on overall expression (Additional File 6
(available online (26))). In order to determine whether histological subtypes of cell lines
and xenografts could be predicted as well with the 24-gene prediction prole, we applied
this prole to two independent datasets. In the rst dataset, consisting of osteosarcoma
cell line data, 2 out of 13 samples (15%, Figure 3.3A) were wrongly classied. These
samples were MG63, a cell line derived from a broblastic osteosarcoma, which was sub-
typed as being osteoblastic, and IOR/OS18, derived from an osteoblastic osteosarcoma,
which was subtyped by the prediction prole as a broblastic osteosarcoma. Interestingly,
HOS, HOS-MNNG, and HOS-143B, all cell lines derived from the HOS cell line, which
is derived from broblastic and epithelial osteosarcoma and therefore was not added to
our set of 13 osteosarcoma cell lines, were all predicted as broblastic osteosarcoma (data
not shown). Two out of 18 xenograft samples (11%, Figure 3.3B) were wrongly classied.
One of these samples was OKx, a xenograft derived from a chondroblastic tumor, which
was subtyped as an osteoblastic osteosarcoma. The other sample was KPDx, a xenograft
derived from an osteoblastic tumor, which was subtyped as broblastic. The KPD cell

















































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 3.3: Probabilities of A, cell lines and B, xenografts to belong to any of the three
histological subtypes. For an explanation of what is represented by these graphs, see Figure 3.2C.
Discussion
In this study, we aimed to compare gene expression proles of osteosarcoma biopsies
with cell lines and xenografts, in order to investigate whether these model systems are
representative for the primary tumor. We have determined dierential gene expression
for dierent clinical parameters important in high-grade osteosarcoma on a dataset con-
sisting of 76 conventional high-grade osteosarcoma samples. Importantly, pretreatment
biopsies were used instead of resected specimens, because preoperative chemotherapy may
cause tumor necrosis in responsive patients, thus altering gene expression and hampering
the generation of high quality mRNA. We intended to generate a gene expression prole
that could not only predict a specic clinical parameter in biopsies, but in osteosarcoma
cell lines and xenografts as well. The metastasis/survival prole is described previously
and may serve as a tool to predict prognosis and as a target for therapy (18). How-
ever, since most of the genes associated with osteosarcoma metastasis were macrophage
associated, and no stroma or inltrate is present in cell lines, this prole could not be
applied to osteosarcoma cell lines. We therefore compared gene expression proles of
these dierent sample sets based on other clinical parameters. No signicant dieren-
tially expressed genes were found between poor and good responders to chemotherapy.
Several reports on genome-wide expression proling in osteosarcoma have been published
describing detection of dierential expression between poor and good responders of preop-
erative chemotherapy (2730). However, the cohorts used in these studies are all relatively
small (n = 1330), and, more importantly, the reported p-values were not corrected for
multiple testing in these studies. Remarkably, only two of the genes that were found to
correlate with response to chemotherapy in these studies overlap, and one of these two
genes was upregulated in poor responders in one study, whereas it was upregulated in
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good responders in the other study (27, 30). Another report described dierential expres-
sion between a metastatic and a nonmetastatic cell line, for which metastatic capacity
correlates with response to chemotherapy (31). In that particular study, four genes out
of 252 were found to overlap with a patient study by Mintz et al. (27). However, the
up- and downregulation of these four genes were not consistent between the two studies.
We clearly show in a large cohort that there are no dierences between these groups of
patients, as the most signicant probe had an adjP of 0.9998. These results are in line
with our previous ndings obtained by analyzing an osteosarcoma cohort on a dierent
platform (32). The parameter `histological subtypes' resulted in a considerable number
of dierentially expressed genes. Our prediction prole is not directly applicable to other
platforms, but there is no real need to have a prediction prole for primary osteosarcoma
histological subtype, since pathologists are very well able to assess this on an HE-section,
even on a biopsy, with a concordance of 98% between histological subtype of biopsies and
corresponding resections (7). Yet, we here show a quite important use of this prole, i.e.
to determine the histological subtype of cell lines and xenografts. In vitro 2-dimensional
growing cells lack extra cellular matrix formation, which is the characteristic feature to
distinguish histological subtypes in high-grade central osteosarcoma.
The gene expression proles as detected by analyzing osteosarcoma biopsy data show a
large number of subtype-specic dierentially expressed genes. In particular, broblastic
osteosarcoma diered most from the two other main subtypes. Using gene set enrichment,
we detected a network of genes upregulated in broblastic osteosarcoma, with a role in
cellular growth and proliferation, and connection to the NF-κB pathway. This may be a
readout of the high cellularity and low matrix composition of broblastic osteosarcoma in
comparison with osteoblastic and chondroblastic osteosarcoma (2). GO term enrichment
analysis conrmed these results. These pathways may explain why it is comparatively
easy to culture broblastic osteosarcoma cells, which also may explain why the percentage
of broblastic osteosarcoma is relatively high in our cell line dataset (31%, compared to
11% in the biopsy dataset). Next to this link to cellular growth and proliferation, the most
signicant network with broblastic-specic upregulated genes showed a connection to the
immune system. GO analysis of the ve most signicant GO terms pointed to involvement
of the immune system as well (GO term GO:0006955, p-value = 3.9 · 10−3, see Additional
File 3 (available online (26)) for GO term subgraphs). Forty-four genes in this GO term
were signicant, of which 43 were upregulated in broblastic osteosarcoma. An elevated
immune response might be the reason why patients with broblastic osteosarcoma tend to
have better survival proles, as a proinammatory environment has an important role in
osteosarcoma metastasis-free survival. This prole is dierent from the previously found
macrophage-specic prole which was associated with better metastasis-free survival of
osteosarcoma patients (18). The overrepresentation of pathways involved in chondrogene-
sis in the chondroblastic prole is in line with the high amount of chondroid matrix in this
subtype. We only detected one osteoblastic-specic gene, UNQ1940, or FAM180A, with
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a yet unknown function. Since 50 osteoblastic osteosarcoma samples were compared with
only 9 chondroblastic and 7 broblastic osteosarcoma samples, we suggest that broblas-
tic and chondroblastic osteosarcoma have specic characteristics that distinguishes these
tumors from osteoblastic osteosarcoma, and that the latter does not have such an extra
feature in comparison with chondro- and broblastic osteosarcoma.
Our histological subtype prediction prole consists of 24 probes encoding for 22 genes,
all with a specic score which depends on the signicance of each gene. The genes that
make up the chondroblastic-specic part of this expression prole are mostly chondroid
matrixassociated genes, such as ACAN, COL2A1, and MATN4, and are all upregulated
in chondroblastic osteosarcoma. Fibroblastic-specic genes that make up the predic-
tion prole are up- or downregulated. An example of a gene upregulated in broblastic
osteosarcoma is NFE2L3, a transcription factor which heterodimerizes with small mus-
culoaponeurotic brosarcoma factors and for which a protective role was suggested in
hematopoietic malignancies (33). DLX5, a transcription factor involved in bone forma-
tion, is downregulated in broblastic osteosarcoma, and reects the lower amounts of
matrix present in broblastic osteosarcoma. No known function is yet available for the
two osteoblastic-specic genes. The misclassication error of the prediction prole in the
training set of biopsies was 15%. Cell lines and xenografts were predicted with misclassi-
cation errors of 15% and of 11%, respectively. It seems most likely that these prediction
errors are inherent to the error rate of the prediction prole, which is also 15%. Thus,
because these misclassication errors are in the same range, we suggest that gene expres-
sion of these model systems is highly similar to gene expression of the tumor from which
they are derived. This is especially of interest for studies in cell lines, since no stroma is
present on which subtyping can be performed, but repeatedly passaged xenografts often
lose stroma as well. Most genes of the prediction prole are matrix-associated genes.
Even though these cell lines do not secrete any matrix, and xenografts have diminished
amounts of matrix, we can still detect histological subtype markers on an mRNA level,
and are able to distinguish dierent histological subtypes of cell lines and xenografts using
this prole.
Conclusions
As osteosarcoma xenografts and cell lines still express histological subtype-specic mRNAs
that are characteristic of the primary tumor, these model systems are representative for
the primary tumor from which they are derived, and will be useful tools for studying
mRNA expression and pathways important in high-grade osteosarcoma.
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Abstract
Purpose: High-grade osteosarcoma is a malignant primary bone tumor with a peak inci-
dence in adolescence. Overall survival (OS) of patients with resectable metastatic disease
is approximately 20%. The exact mechanisms of development of metastases in osteosar-
coma remain unclear. Most studies focus on tumor cells, but it is increasingly evident
that stroma plays an important role in tumorigenesis and metastasis. We investigated
the development of metastasis by studying tumor cells and their stromal context.
Experimental Design: To identify gene signatures playing a role in metastasis,
we carried out genome-wide gene expression proling on prechemotherapy biopsies of
patients who did (n = 34) and patients who did not (n = 19) develop metastases within
5 years. Immunohistochemistry (IHC) was performed on pretreatment biopsies from 2
additional cohorts (n = 63 and n = 16) and corresponding postchemotherapy resections
and metastases.
Results: A total of 118/132 dierentially expressed genes were upregulated in pa-
tients without metastases. Remarkably, almost half of these upregulated genes had im-
munological functions, particularly related to macrophages. Macrophage-associated genes
were expressed by inltrating cells and not by osteosarcoma cells. Tumor-associated
macrophages (TAM) were quantied with IHC and associated with signicantly better
overall survival (OS) in the additional patient cohorts. Osteosarcoma samples contained
both M1- (CD14/HLA-DRα positive) and M2-type TAMs (CD14/CD163 positive and
association with angiogenesis).
Conclusions: In contrast to most other tumor types, TAMs are associated with re-
duced metastasis and improved survival in high-grade osteosarcoma. This study provides
a biological rationale for the adjuvant treatment of high-grade osteosarcoma patients with
macrophage activating agents, such as muramyl tripeptide.
Introduction
High-grade osteosarcoma is a malignant bone tumor characterized by the production of os-
teoid. The highest incidence is in adolescent patients, with a second peak in patients older
than 40 years (1). Despite wide-margin surgery and intensication of chemotherapeutic
treatment, overall survival (OS) rates have reached a plateau at about 60% (24). Novel
administration modalities are needed, but data on critical biological mechanisms allowing
the development of novel therapeutic agents are scarce for this relatively rare tumor. In
addition to conventional chemotherapeutic agents, recent trials have explored immunos-
timulatory strategies. The ongoing EURAMOS-1 trial randomizes for treatment with
IFN-α in patients with good histological response to neoadjuvant chemotherapy (5). A
recently published clinical trial has shown improved OS for osteosarcoma patients treated
with the macrophage activating agent muramyl tripeptide (MTP) added to the standard
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chemotherapy regimen (6). However, only limited information on macrophage inltration
and activation in osteosarcoma is available (7).
Tumor-associated macrophages (TAM) may promote tumorigenesis through immuno-
suppression, expression of matrix-degrading proteins and support of angiogenesis. In nu-
merous cancer types, high numbers of M2 or `alternatively activated' TAMs are associated
with a worse prognosis (813). M2 macrophages have important functions in wound heal-
ing and angiogenesis, express high levels of the immunosuppressive cytokines interleukin
(IL)-10 and TGF-β, and express scavenger receptors such as CD163 (14, 15). `Classical
activation' of macrophages by IFN-γ or microbial products results in polarization toward
M1-type macrophages. M1 macrophages express high levels of proinammatory cytokines
such as IL-12, IL-1, and IL-6 and have potent antitumor ecacy, both by reactive oxygen
species and cytokine-induced cytotoxicity and by induction of natural killer (NK) and
T cell activity (16). Rarely, high numbers of TAMs are associated with better progno-
sis (17, 18). In these cases, TAMs are presumably polarized toward an M1 phenotype,
although macrophage subtypes were not reported in these two studies. Alternatively,
macrophages may directly phagocytose tumor cells, as has been shown in acute myeloid
leukemia (19).
To investigate the role of stroma and stromatumor interactions important in metas-
tasis of osteosarcoma, we investigated the development of metastasis by studying tumor
cells and their stromal context. By using genome-wide expression analysis, we showed that
high expression of macrophage-associated genes in pretreatment biopsies was associated
with a lower risk of developing metastases. In addition, we quantied and characterized
TAMs in two independent cohorts, including pretreatment biopsies, postchemotherapy
resections, and metastatic lesions. In contrast to the tumor-supporting role for TAMs in
most epithelial tumor types, higher numbers of inltrating TAMs correlated with better
survival in osteosarcoma. Our ndings suggest that macrophages have direct or indirect
antiosteosarcoma activity and provide a possible explanation for the benecial eect of
treatment with macrophage activating agents in osteosarcoma.
Materials and methods
Patient cohorts
Genome-wide expression proling was performed on snap-frozen pretreatment diagnostic
biopsies containing viable tumor material of 53 resectable high-grade osteosarcoma pa-
tients from the EuroBoNet consortium (www.eurobonet.eu; cohort 1). For immunohisto-
chemical validation, a tissue microarray containing 145 formalin-xed paran-embedded
(FFPE) samples of 88 consecutive high-grade osteosarcoma patients with primary re-
sectable disease (cohort 2) and 29 FFPE samples of a cohort of 20 consecutive high-grade
osteosarcoma patients with resectable disease were used (cohort 3), including material
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from pretreatment biopsies, postchemotherapy resections, and metastatic lesions (20).
Clinicopathological details can be found in Supplemental Table S1 (available online (21)).
All biological material was handled in a coded fashion. Ethical guidelines of the indi-
vidual European partners were followed and samples and clinical data were stored in the
EuroBoNet biobank.
Cell lines
The 19 osteosarcoma cell lines 143B, HAL, HOS, IOR/MOS, IOR/OS10, IOR/OS14,
IOR/OS15, IOR/OS18, IOR/OS9, IOR/SARG, KPD, MG-63, MHM, MNNG-HOS, OHS,
OSA, SAOS-2, U-2 OS, and ZK-58 were maintained in RPMI 1640 (Invitrogen) supple-
mented with 10% fetal calf serum and 1% penicillin/streptomycin (Invitrogen) as previ-
ously described (22).
RNA isolation, cDNA synthesis, cRNA amplication, and Illumina
Human-6 v2.0 Expression BeadChip hybridization
Osteosarcoma tissue was snap-frozen in 2-methylbutane (Sigma-Aldrich) and stored at
70◦C. By using a cryostat, 20mm sections from each block were cut and stained with
hematoxylin and eosin to ensure at least 70% tumor content and viability. RNA was
isolated with TRIzol (Invitrogen), followed by RNA cleanup using the QIAGEN Rneasy
mini kit with on-column DNase treatment. RNA quality and concentration were measured
using an Agilent 2100 Bioanalyzer and Nanodrop ND-1000 (Thermo Fisher Scientic),
respectively. Synthesis of cDNA, cRNA amplication, and hybridization of cRNA onto
the Illumina Human-6 v2.0 Expression BeadChips was carried out as per manufacturer's
instructions.
Reverse transcriptase quantative PCR
Reverse transcriptase quantative PCR (qPCR) analysis of selected target genes was per-
formed as previously described (23). Each experiment was conducted in duplicate by
using an automated liquid-handling system (Tecan, Genesis RSP 100). Data were nor-
malized by geometric mean expression levels of 3 reference genes, i.e. SRPR, CAPNS1,
and TBP using geNorm (medgen.ugent.be/~jvdesomp/genorm/). Primer sequences can
be found in Supplemental Table S2 (available online (21)).
Enzymatic and uorescent immunostainings
Enzymatic and uorescent immunostainings were performed on 4mm sections of FFPE tis-
sue as previously described (20). Details regarding antibodies and procedures can be found
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in Supplemental Table S3 (available online (21)). In case of double immunohistochem-
istry (IHC), incubation with anti-CD45 and development with DAB+ (Dako) occurred
rst, followed by a second antigen retrieval before incubation with either anti-CD163 or
anti-HLA-DRα and development using the alkaline phosphatase substrate Vector Blue
(Vector Labs). In case of double immunouorescent (IF) stainings, primary antibodies
were coincubated overnight. As a positive control, normal and formic acid decalcied
tonsil was used, and as a negative control, no primary antibody was added. Tissue mi-
croarray slides were scanned using the MIRAX SCAN slide scanner and software (Zeiss,
Mirax 3D Histech). Numbers of positively stained cells and vessels were counted using
ImageJ (National Institutes of Health, Bethesda, MD) and averaged per 0.6mm core. IF
and double IHC images were acquired using a Leica DM4000B microscope tted with
a CRI Nuance spectral analyzer (Cambridge Research and Instrumentation, Inc.) and
analyzed using the supplied colocalization tool to determine the percentage of single and
double positive pixels per region of interest.
Microarray data analysis
Gene expression data were exported from BeadStudio version 3.1.3.0 (Illumina) in Gene-
Spring probe prole format and processed and analyzed using the statistical language
R (24). As Illumina identiers are not stable and consistent between dierent chip ver-
sions, raw oligonucleotide sequences were converted to nuIDs (25). Data were trans-
formed using the variance stabilizing transformation algorithm to take advantage of the
large number of technical replicates available on the Illumina BeadChips (26). Trans-
formed data were normalized using robust spline normalization, an algorithm combining
features of quantile and loess normalization, specically designed to normalize variance-
stabilized data. All microarray data processing was carried out by Bioconductor package
lumi (27, 28). Quality control was performed using Bioconductor package arrayQuality-
Metrics (29). MIAME (minimum information about a microarray experiment) compliant
data have been deposited in the GEO database (www.ncbi.nlm.nih.gov/geo/, accession
number GSE21257).
Statistical analysis
Dierential expression between patients who did (n = 34) and did not (n = 19) develop
metastases within 5 years from diagnosis of the primary tumor was determined using
linear models for microarray data (LIMMA (30)), applying a Benjamini and Hochberg
false discovery rate-adjusted p-value cuto of 0.05. Other univariate statistical analyses
were performed using GraphPad Prism Software (version 5.01). Multivariate survival
analyses were carried out according to the Cox proportional hazards model in SPSS
(version 16.0.2). Two-sided p-values < 0.05 were determined to be signicant; p-values
between 0.05 and 0.15 were dened to be a trend.
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Results
High expression of macrophage-associated genes in osteosarcoma
biopsies of patients who did not develop metastases within 5 years
from diagnosis (cohort 1)
Comparison of genome-wide gene expression in tumors of patients who did and did not
develop metastases within 5 years resulted in 139 signicantly dierentially expressed
(DE) probes, of which 125 corresponded to 118 upregulated and 14 to downregulated
genes in patients who did not develop metastases. A summary of DE genes and detailed
descriptions of all probes can be found in Table 4.1 and Supplemental Table S4 (avail-
able online (21)), respectively. Two DE genes were specic for macrophages (CD14 and
MSR1) and 30/132 of the DE genes were associated with macrophage functions such
as antigen processing and presentation (e.g. HLA-DRA and CD74) or pattern recogni-
tion (e.g. TLR4 and NLRP3). Overall, approximately 20% of the upregulated probes
corresponded to genes that were associated with macrophage function and development
and an additional 25% of the upregulated probes corresponded to genes with other im-
munological functions, such as cytokine production and phagocytosis. Four genes were
selected for validation of the microarray data using qPCR: CD14, HLA-DRA, CLEC5A,
and FCGR2A. Expression levels as determined by qPCR correlated well with expression
levels obtained by microarray analysis (Supplemental Figure S1 (available online (21))).
Metastases-free survival curves of the same cohort, generated using median expression
of the probe of interest as a cuto determining low and high expression, are shown in
Figure 4.1B and Supplemental Figure 2 (available online (21)). Cox proportional hazards
analysis revealed expression of macrophage-associated genes CD14 and HLA-DRA to be



















































































































































































































































































































































































































































































































































































































































































































































































































Macrophage-associated genes are expressed by inltrating hema-
topoietic cells and not by tumor cells
The most probable source of expression of the DE macrophage-associated genes was in-
ltrating immune cells and not osteosarcoma cells. To conrm this, we performed qPCR
of CD14 and HLA-DRA on osteosarcoma cell lines (n = 19) and biopsies (n = 45, a sub-
set of cohort 1). CD14 and HLA-DRA expression was variable in osteosarcoma biopsies,
but almost undetectable in cell lines. This indicates that these macrophage-associated
genes were not expressed by tumor cells but by inltrating cells because only osteosar-
coma biopsies contain macrophage inltrate, whereas RNA from cell lines is exclusively
from tumor cells (Figure 4.1A, Mann-Whitney U test p-value < 0.0001). In addition, we
performed double IHC for the hematopoietic cell marker CD45, which is not expressed
by osteosarcoma tumor cells, and the macrophage marker CD163 or the macrophage-
associated protein HLA-DRα (Figure 4.1C). We chose this approach because no reliable
osteosarcoma markers are available (1). Our results conrmed that inltrating hematopoi-
etic cells were the source of the macrophage-associated gene expression levels. Together,
these data show that osteosarcoma tumor cells do not express macrophage-associated
genes, neither in vitro nor in vivo.
Macrophage numbers in osteosarcoma biopsies correlate with CD14
gene expression levels and are positively associated with localized
disease and better outcome (cohorts 2 and 3)
To conrm the presence of TAMs in osteosarcoma, we stained a tissue microarray contain-
ing 145 samples of 88 patients for the macrophage marker CD14 and counted the number
of positive cells per tissue microarray core (cohort 2; Figure 4.2A). CD14 was chosen as
opposed to CD68 because the latter marker is not expressed by monocytes and often
shows cross-reactivity with mesenchymal tissue (data not shown). Number of CD14-posi-
tive cells per tissue microarray core correlated signicantly with CD14 mRNA expression
levels (14 samples overlap with gene expression analysis, Spearman correlation coecient
0.64, p-value = 0.01). Similar to the gene expression data, there was a trend for patients
with primary localized disease to have higher numbers of macrophages in pretreatment
diagnostic biopsies than patients with metastatic disease at presentation (mean number
of macrophages per core, 55 vs 27; Mann-Whitney U test p-value = 0.09). Also, patients
with high macrophage counts at diagnosis tended to be less likely to develop metastases
within 5 years (χ2, p-value = 0.13).
We subdivided this cohort into four quartiles based on numbers of CD14-positive cells
to determine the group with the best OS. No signicant dierences were found between
quartiles 2 and 4, but patients belonging to this group had better OS than patients with




Figure 4.1: Macrophage-associated genes are not expressed by osteosarcoma tumor cells. A,
qPCR of osteosarcoma cell lines and biopsies of CD14 and HLA-DRA demonstrating lack of
expression by osteosarcoma cells. Mann-Whitney U test p-value < 0.0001, ∗∗ ∗. B, High expres-
sion of macrophage associated genes was associated with a better metastasis-free survival (cohort
1, Kaplan-Meier curve, p-value obtained by Logrank test, patients with metastasis at diagnosis
have an event at t = 0. These patients are included, because patients who develop metastases
later on may as well have micrometastases at the time of diagnosis). Metastasis-free survival
curves for HLA-DRA, CLEC5A, and FCGR2A can be found in Supplemental Figure S2 (avail-
able online (21)). C, Double immunohistochemical staining of CD163 with the hematopoietic cell
marker CD45 was performed and analyzed using spectral imaging microscopy. The pseudo-IF
image (pseudo-IF) shows CD163-positive cells in red, CD45-positive cells in green, and colocal-
ization of both markers in orange. Lack of expression of CD163 and CD45 on surrounding tumor




Figure 4.2: A, Example of representative stainings of high-grade osteosarcoma with high (left)
versus low (right) levels of macrophage inltration (CD14 staining) and vascular density (CD31
staining). B, High numbers of inltrating macrophages (left, dened as the 3 upper quartiles,
or more than 12 CD14-positive cells per tissue array core) are associated with better OS (right,
Logrank test p-value = 0.02, cohort 2). Q1: lowest quartile, Q2, 3, 4, 3: highest quartiles.
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Figure 4.2B, Logrank test p-value = 0.02). In another cohort of 16 patients, IF staining
of CD14, CD163, and HLA-DRα was performed, again conrming a potential prognostic
value of high macrophage numbers (cohort 3, Figure 4.3, Logrank test p-value = 0.01,
Supplemental Figure S3 (available online (21))).
Macrophages in osteosarcoma have both M1 and M2 characteris-
tics
To determine the phenotype of macrophages present in osteosarcoma, we performed dou-
ble IHC with CD14 and either the M1-associated marker HLA-DRα or the M2-associated
marker CD163. Not all CD163 and HLA-DR-positive inltrating cells expressed CD14
(Figure 4.3A and Supplementary Figure S3A). The total number of macrophages as de-
termined by quantifying CD14-positive macrophages was associated with good survival
(Figure 4.3B), but the phenotype of the macrophages (CD14/CD163 double positive ver-
sus CD14/HLA-DRα double positive) was not (Supplemental Figure S3B (available on-
line (21)); data not shown). Another M2 characteristic is support of angiogenesis. The
number of CD14-positive macrophages correlated with the number of CD31-positive ves-
sels (Figure 4.2A and Figure 4.4), but vascularity did not correlate with prognosis (data
not shown).
Macrophage numbers in diagnostic biopsies may predict histolog-
ical response to chemotherapy and macrophage number increases
following chemotherapy treatment
There was a trend for high macrophage count (highest three quartiles or more than 12
CD14-positive cells per tissue array core) in prechemotherapy diagnostic biopsies of the
primary tumor to predict for good histological response to neoadjuvant chemotherapy
(dened as more than 90% nonvital tumor tissue upon nal resection), since 46% of
patients with high macrophage numbers and 18% of patients with low macrophage num-
bers had a good histological response (cohort 2; χ2 = 0.09). The prognostic benet of
macrophage counts in osteosarcoma was not independent of histological response using
Cox proportional hazard analysis. Macrophage numbers were higher in postchemotherapy
resections of the primary tumor than in prechemotherapy biopsies (Supplemental Figure
S4 (available online (21))). Moreover, gene expression analysis showed upregulation of
macrophage-associated probes in postchemotherapy resections (n = 4) as compared with




Figure 4.3: A, Osteosarcoma samples are inltrated with CD14 and CD163 single and double
positive macrophages. Spectral imaging was used to reduce autouorescence of osteosarcoma
cells. In the composite image, CD14-positive cells are represented in green, CD163-positive
cells are represented in red, and CD14/CD163 double positive cells are represented in yellow.
Background autouorescence of tumor cells is represented in gray. B, In an independent cohort
of 16 patients (cohort 3), high macrophage inltration as determined by IF CD14 staining was
associated with signicantly improved OS. p-values obtained using Logrank test, cuto at the
median.
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Figure 4.4: Macrophage inltration as de-
termined by CD14-positive cell count cor-
related with vascularity as determined by
CD31-positive vessel count. Data of all os-
teosarcoma samples (pre- and posttreatment
primary tumor and metastatic samples, co-
hort 2) are shown. Q1: lowest quartile, Q2,
3, 4: three highest quartiles. Kruskal-Wallis
test p-value < 0.0001. ∗, Dunn's posttest p-
value < 0.05, ∗ ∗ ∗, Dunn's posttest p-value
< 0.001.
Discussion
OS of high-grade osteosarcoma patients with resectable metastatic disease is poor at about
20% (31). Mechanisms for the development of metastases in osteosarcoma are elusive. To
identify genes that play a role in this process, we performed genome-wide expression
proling on prechemotherapy biopsies of osteosarcoma patients. We compared patients
who developed clinically detectable metastases within 5 years with patients who did not
develop metastases within this time frame (cohort 1). About 20% of genes overexpressed
in patients without metastases were macrophage-associated, whereas an additional 25% of
genes had other immunological functions (e.g. in phagocytosis, complement activation or
cytokine production and response) but could still be attributed to macrophages (Table 1
and Supplemental Table S4 (available online (21))). Thus, in total, almost half of the DE
genes belonged to one specic process, i.e. macrophage function. Macrophage-associated
genes were expressed by inltrating hematopoietic cells and not by osteosarcoma tumor
cells (Figure 4.1), indicating a possible role for macrophages in preventing metastasis in
osteosarcoma. To conrm these ndings, we quantied inltrating macrophages in two
additional cohorts (cohorts 2 and 3) and found an association with better OS in both
cohorts.
The antimetastatic eect of TAMs in osteosarcoma is remarkable because TAMs sup-
port tumor growth in a substantial number of other cancers, which are mostly tumors of
epithelial origin. For example, macrophages are associated with the angiogenic switch in
breast cancer (32). We nd an association between macrophage inltration and higher
microvessel density, which suggests that the inux of macrophages may support certain
aspects of tumor growth in osteosarcoma as well. However, in the case of osteosarcoma,
direct or indirect antitumor activity of macrophages apparently outweighs their possible
tumor-supporting eects. Macrophages can alter their phenotype from M2 to M1 and
become the tumor's foe instead of its friend, given the right circumstances (3335). The
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TAMs that were identied in this study in osteosarcoma had both M1 and M2 character-
istics. The expression of CD163 and the association with angiogenesis are M2 character-
istics (32, 36). Some of the DE genes, such as MSR1 and MS4A6A are specic for M2
macrophages in vitro (37). Others, such as the proinammatory cytokine IL1B, are more
indicative of an M1 phenotype (16). How macrophages inhibit osteosarcoma metastasis
and whether a balance between M1- and M2-type functions is responsible is unknown.
In a multivariate regression model, the survival benet of high TAM numbers was
at least partly dependent on histological response to chemotherapy. Chemotherapy can
cause `immunogenic cell death' of cancer cells, resulting in the release of endogenous
danger signals (38, 39). The binding of these dangerous signals to pattern recognition
receptors on macrophages can skew polarization of M2- to M1-type TAMs. The inter-
action between dying tumor cells and resident TAMs may facilitate clearance or inhibit
outgrowth of metastatic tumor cells. However, patients with localized disease at diagno-
sis tended to have a larger macrophage inltrate than patients with metastatic disease at
diagnosis (mean number of macrophages per core 55 vs 27). At this point, patients have
not undergone chemotherapeutic treatment yet and an interaction between chemother-
apy and macrophages can therefore not be responsible for the antimetastatic eect of
macrophages. Perhaps, the antimetastatic eect of TAMs in these patients is due to the
constitutive presence of macrophages with an M1 phenotype. Alternatively, the presence
of macrophages might be a reection of a microenvironment not conducive for metastasis.
Although preliminary analysis of a clinical trial investigating the eect of treatment
with the macrophage activating agent MTP yielded conicting results, subsequent analy-
sis revealed that treatment with MTP improved 6-year OS from 70% to 78% in a cohort of
patients with primary localized disease (6, 40). Similar results were obtained in canine os-
teosarcoma (41). MTP is a synthetic derivative of muramyl dipeptide (MDP), a common
bacterial cell wall component. Muropeptides bind to intracellular pattern recognition re-
ceptors of the nucleotide binding and oligomerization domain (NOD)-like receptor (NLR)
family, expressed by macrophages (42). In our study, 5 genes associated with NLR family
signaling and the associated `inammasome' were highly expressed in pretreatment biop-
sies of patients who do not develop metastases. The DE genes NLRP3, NAIP, NLRC4,
and PYCARD are components of the inammasome, LYZ is a lysozyme that processes
bacterial cell wall peptidoglycan into MDP, a ubiquitous natural analogue of MTP, and
IL1B is the downstream eector cytokine of the inammasome pathway. Further research
is needed to clarify whether only patients with high numbers of TAMs benet from MTP
treatment, or whether MTP treatment is eective regardless of macrophage number or
activation status pretreatment. Also, it is unknown whether treatment with agents pro-
moting macrophage migration or with other macrophage activating agents like toll-like
receptor ligands or IFNs has a similar benecial eect on outcome.
Previous genome-wide expression proling studies in osteosarcoma focused on identi-
fying genes that predict histological response to neoadjuvant chemotherapy (4346). As
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a consequence, the importance of macrophages in controlling metastases was not recog-
nized. However, we previously compared gene expression proles of osteosarcoma biopsies
and cultured mesenchymal stem cells and determined which genes are expressed by tumor
stroma and not by tumor cells (47). There is a considerable overlap between the stromal
genes identied in our previous study and the macrophage-associated genes identied in
the present study (including HLA class II genes as the most prevalent DE group of genes
and the macrophage-associated genes MSR1, MS4A6A, and FCGR2A).
In conclusion, we showed the presence and clinical signicance of TAMs in pretreat-
ment samples of high-grade osteosarcoma. TAMs in osteosarcoma are a heterogeneous cell
population with both M1 antitumor and M2 protumor characteristics. Although the exact
mechanism by which macrophages exert their antimetastatic functions is still unknown,
this study provides an important biological rationale for the treatment of osteosarcoma
patients with macrophage activating agents.
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IR/IGF1R signaling as potential target
for treatment of high-grade
osteosarcoma
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Abstract
Background: High-grade osteosarcoma is an aggressive tumor most often developing
in the long bones of adolescents, with a second peak in the 5th decade of life. Better
knowledge on cellular signaling in this tumor may identify new possibilities for targeted
treatment.
Methods: We performed gene set analysis on previously published genome-wide gene
expression data of osteosarcoma cell lines (n = 19) and pretreatment biopsies (n = 84).
We characterized overexpression of the insulin-like growth factor receptor (IGF1R) sig-
naling pathways in human osteosarcoma as compared with osteoblasts and with the hy-
pothesized progenitor cells of osteosarcomamesenchymal stem cells. This pathway plays
a key role in the growth and development of bone. Since most profound dierences in
mRNA expression were found at and upstream of the receptor of this pathway, we set
out to inhibit IR/IGF1R using OSI-906, a dual inhibitor for IR/IGF1R, on four osteosar-
coma cell lines. Inhibitory eects of this drug were measured by Western blotting and
cell proliferation assays.
Results: OSI-906 had a strong inhibitory eect on proliferation of 3 of 4 osteosarcoma
cell lines, with IC50s below 100nM at 72hrs of treatment. Phosphorylation of IRS-1, a di-
rect downstream target of IGF1R signaling, was inhibited in the responsive osteosarcoma
cell lines.
Conclusions: This study provides an in vitro rationale for using IR/IGF1R inhibitors
in preclinical studies of osteosarcoma.
Background
High-grade osteosarcoma is the most prevalent primary malignant bone tumor. The
disease occurs most frequently in children and adolescents at the site where proliferation
is most active, i.e. the metaphysis adjacent to the epiphyseal plate (1). The 5-year
overall survival of osteosarcoma patients has raised from 1020% to about 60% after
the introduction of preoperative chemotherapy in the 1970s. However, about 45% of all
patients still die because of distant metastasis. No additional treatments have been found
that can increase survival signicantly, and administering higher doses of preoperative
chemotherapy does not result in improved outcomes (2, 3). Better knowledge on cellular
signaling in high-grade osteosarcoma may identify new possibilities for targeted treatment
of this highly aggressive tumor.
We have previously described the roles of bone developmental pathways Wnt, TGFβ-
BMP, and Hedgehog signaling in osteosarcoma, but unfortunately so far could not identify
suitable targets for treatment (4, 5). In addition to these signal transduction pathways,
insulin-like growth factor 1 receptor (IGF1R) signaling plays a key role in the growth and
development of bone. Aberrant signaling of this pathway has been implicated in various
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cancer types, among others sarcomas (6, 7). Key players of insulin-like growth factor
(IGF) signaling are the ligands IGF1, IGF2, which are circulating polypeptides that can
be expressed in endocrine, paracrine, and autocrine manners, and the tyrosine kinase
receptor IGF1R, which forms homodimers, or hybrid receptors with the insulin receptor
(IR) (8). IGF1R and IR/IGF1R hybrids are activated by both IGF1 and -2, which trigger
autophosphorylation of IGF1R and subsequent downstream signal transduction. A second
IGF receptor, IGF2R, can bind IGF2, but does not confer intracellular signaling, thereby
diminishing the bioavailability of IGF2 to IGF1R (9). Autophosphorylation of IR/IGF1R
receptors recruits the signaling proteins insulin receptor substrate (IRS) and Src homol-
ogy 2 domain containing transforming protein (Shc) to the cell membrane, which get
phosphorylated and subsequently activate the downstream PI3K/Akt and Ras/Raf/ERK
signaling pathways, both of which are known to be important in cancer. These pathways
ultimately act on several biological processes, such as transcription, proliferation, growth,
and survival (911). Interestingly, treatment targeted against IGF1R signaling has shown
to be eective in a subset of Ewing sarcoma, another bone tumor that manifests at young
age (12).
The role of the IGF1R pathway in growth has been illustrated in studies of knockout
mice. It was shown that IGF1 null mice are 40% smaller than littermates, while IGF1R
null mice are approximately 55% smaller (13). In dogs, the size of dierent breeds was
demonstrated to be dependent on IGF1 plasma levels (7). Additionally, a specic IGF1
SNP haplotype was described to be common in small breed dogs and nearly absent in
giant breeds (14). Interestingly, large and giant dog breeds are more prone to develop
osteosarcoma (15), which in dogs is biologically very similar to the human disease (16).
Two recent studies on human osteosarcoma suggest a positive correlation between patient
birth weight and height at diagnosis and the development of the disease (17, 18). In-
volvement of some members of IGF1R signaling in osteosarcoma has been described (as
has been reviewed in Kolb et al. (19)), but the activity of this pathway remains to be
determined.
We have analyzed genome-wide gene expression in high-grade osteosarcoma cell lines
and pretreatment biopsies, and observed signicantly altered activity of genes involved in
IGF1R signaling when compared to proles of mesenchymal stem cells and osteoblasts.
Specically, upstream inhibitors of IGF1R signaling were found to be downregulated in
osteosarcoma, and low expression of these genes correlated with worse event-free sur-
vival. We inhibited IR/IGF1R signaling with the dual IR/IGF1R inhibitor OSI-906.
This showed inhibition of phosphorylation of IRS-1 and of strong inhibition of prolifera-
tion in 3/4 osteosarcoma cell lines. Interestingly, the cell line which could not be inhibited
with OSI-906, 143B, has a KRAS oncogenic transformation, which is a component of the
Ras/Raf/ERK pathway, one of downstream eectors of IGF1R signaling. These results





The 19 high-grade osteosarcoma cell lines that were used in this study were characterized
and are described by Ottaviano et al. (20). The 12 mesenchymal stem cell and 3 osteoblast
cultures were previously described (21). MSCs have been previously (22) characterized
through FACS analysis and have been tested for their ability to be committed under
proper conditions towards adipogenesis, chondrogenesis and osteogenesis as described in
Bernardo et al. (23). Osteoblast cultures were derived from MSCs which were treated to
undergo osteogenic dierentiation. Cell line DNA was short tandem repeat proled to
conrm cell line identity with use of the Cell ID system of Promega (Madison, WI). For
Western blotting experiments, cells were maintained in RPMI 1640 (Invitrogen, Carlsbad,
CA), supplemented with 10% fetal bovine serum (F7524, Sigma-Aldrich, St. Louis, MO)
and 1% glutamax (Gibco 35050, Invitrogen, Carlsbad, CA).
Microarray experiments, preprocessing, and data analysis
For genome-wide gene expression analysis, we used Illumina Human-6 v2.0 BeadChips.
Microarray experiments and data preprocessing are described in Kuijjer et al. (21). Pre-
viously deposited genome-wide gene expression data of mesenchymal stem cells (MSCs)
and osteoblasts can be found in the Gene Expression Ombinus (GEO accession num-
bers GSE28974 and GSE33382, respectively). Data from osteosarcoma cell lines have
been published before (24), but since we normalized and processed all raw data to-
gether, we deposited normalized values in the Gene Expression Omnibus (GEO, accession
number GSE42351, superseries accession GSE42352). Data from the 84 high-grade os-
teosarcoma pretreatment biopsies have been previously published (GEO accession number
GSE33382) (21). Ethical guidelines of the individual European partner institutions were
followed and samples and clinical data were handled in a coded fashion and stored in the
EuroBoNeT biobank. We determined signicant dierential expression between osteosar-
coma cell lines (n = 19) and mesenchymal stem cells (n = 12), and between osteosarcoma
cell lines and osteoblasts (n = 3) using Bioconductor (25) package LIMMA (26) in statis-
tical language R (27). Probes with Benjamini and Hochberg false discovery rate-adjusted
p-values < 0.05 were considered to be signicant. Gene set analysis was performed on
KEGG pathways (28) (Release 63.0, July 1, 2012) using R-package globaltest (29). For
each analysis, the top 15 signicant KEGG pathways were returned. All returned path-
ways had a Benjamini and Hochberg false-discovery rate-corrected p-value < 1 · 10−5. To
visualize dierential expression in the IGF1R pathway, we performed Core analyses using
Ingenuity Pathways Analysis (IPA, Ingenuity Systems, www.ingenuity.com).
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Antibodies and reagents
Rabbit monoclonal and polyclonal antibodies against IGF1R and IRS-1, respectively
(both 1 : 1, 000) were obtained from Cell Signaling (Danvers, MA). Rabbit polyclonal
antibody against phospho-IRS-1 (Y612, 1 : 1, 000) was purchased from Biosource, In-
vitrogen (Carlsbad, CA). A mouse monoclonal antibody against α-tubulin from Abcam
(Cambridge, UK) was used as a loading control (1 : 3, 000). Secondary antibodies (both
1 : 10, 000, BD Transduction Laboratories, Lexington, KY) were horseradish peroxi-
dase (HRP) conjugated polyclonal goat-anti-rabbit IgG for components of the IR/IGF1R
pathway, and HRP conjugated polyclonal goat-anti-mouse for α-tubulin. OSI-906 was
purchased from Selleck Chemicals LLC (Houston, TX).
Western blotting
Osteosarcoma cell lines OHS, KPD, SAOS-2, and 143B were treated with 0.5% DMSO
or with 1µM OSI-906 for 3hrs, and were subsequently lysed using Mammalian Protein
Extraction Reagent (Thermo Scientic 78503), to which Halt Phosphatase and Protease
Inhibitor Cocktails (Thermo Scientic 78420 and 78418, respectively) were added accord-
ing to the manufacturer's protocol. Concentrations of cell lysates were determined using
the BioRad DC Protein Assay Kit (Biorad, Hercules, CA). Per sample, 20µg of protein
was loaded on SDS-PAGE gels. Lysate of HepG2-A16 cells transfected with IR and stim-
ulated with insulin, containing 10µg of protein, was taken along as a positive control.
Western blotting was performed as described by Schrage et al. (30).
Proliferation assays
OSI-906 was diluted in DMSO and stored at -20◦C. OHS, SAOS-2, KPD, and 143B
cells were plated in 96 wells plates, using 4, 000, 2, 000, 12, 000, and 2, 000 cells per well,
respectively. After 24hrs, OSI-906 was added in triplicate at dierent concentrations
0nM, 0.01nM, 0.1nM, 1nM, 10nM, 100nM, 1µM, and 10µM. The inhibitor was incubated
for 72hrs and 96hrs, in dierent experiments. The results shown are representative results
from at least three independent experiments. Cell proliferation reagent WST-1 (Roche)
was incubated for 2hrs and subsequently measured using a Wallac 1420 VICTOR2 (Perkin
Elmer, Waltham, MA). Data were analyzed in Graphpad Prism 5.0 (www.graphpad.com).
Relative IC50s were calculated using results from the dierent concentrations up to the
highest dose where toxicity was not yet present.
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Results
Enrichment of IGF1R signaling in high-grade osteosarcoma
Genome-wide gene expression data were of good quality for all cell lines. LIMMA anal-
ysis resulted in 7, 891 probes encoding for dierentially expressed (DE) genes between
osteosarcoma cell lines and MSCs, and 2, 222 probes encoding for DE genes between os-
teosarcoma cells and osteoblasts. We tested the global expression patterns of KEGG
pathways using globaltest (29) and determined the intersection of the pathways most
signicantly dierent in osteosarcoma cell lines as compared with MSCs, and of osteosar-
coma cell lines as compared with osteoblasts. This approach resulted in ve signicantly
aected pathwaysinsulin signaling pathway, oocyte meiosis, ubiquitin mediated prote-
olysis, progesterone-mediated oocyte maturation, and glycerophospholipid metabolism.
Details of the globaltest are shown in Table 5.1.



























































Table 5.1: The top ve signicant pathways with aberrant expression in both osteosarcoma cell
lines versus osteoblasts (OScellvsOB) and osteosarcoma cell lines versus mesenchymal stem cells
(OScellvsMSC). adjP: FDR-adjusted p-value, Statistic: test statistic of the globaltest, Expected:
expected test statistic of the globaltest, Std.dev: standard deviation under the null hypothesis.
IGF1R signaling is involved in three out of the ve detected KEGG pathways (insulin
signaling pathway, oocyte meiosis, and progesterone-mediated oocyte maturation). In-
terestingly, a globaltest on mRNA expression of previously published pretreatment biop-
sies (21) compared with normal bones (31) also returned insulin signaling as the most
signicantly aected pathway (data not shown). Notably, there is no specic IGF1R sig-
naling pathway in the KEGG database (28). Because of the overrepresentation of IGF1R
signaling, and because of its known role in cancer, we decided to study expression of
members of this pathway in detail.
Dierentially expressed genes of the IGF1R pathway
To determine which genes have the most specic up- or downregulation in osteosarcoma,
we combined lists of signicantly dierentially expressed genes of osteosarcoma cell lines
(n = 19) and a previously published set of osteosarcoma pretreatment biopsies (n = 84,
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GEO accession GSE33382) in comparison with mesenchymal stem cells (n = 12) and
osteoblasts (n = 3) by four-way Venn analysis of all signicantly aected probes with the
same direction of fold change (upregulated or downregulated in all four analyses). We
identied IGFBP4 and GAS6 as the most downregulated genes in osteosarcoma (average
log fold changes of −4.43 and −4.29, respectively). IGFBP2 was also present in the top 20
results from this four-way analysis. In addition, IGFBP3 and -7 were signicantly down-
regulated, and IGF2BP3 was signicantly upregulated in three out of the four analyses.
Both IGFBP4 and GAS6 show high variability in expression in osteosarcoma cell lines












































































































Figure 5.1: A, Normalized gene expression levels of GAS6 and IGFBP4 in osteosarcoma biop-
sies, cell lines, mesenchymal stem cells (MSCs), and osteoblasts (OB). Expression of both proteins
is considerably higher in the controls (FDR-adjusted p-value < 0.001 for both genes in all four
analyses). B, Kaplan-Meier curves depicting metastasis-free survival in years for 83 high-grade
osteosarcoma patients (for 1/84 patients, we did not have follow-up data available), based on
quartiles of mRNA expression of the genes of interest.
had poor event-free survival proles (Logrank test for trend, p-value = 0.01 for IGFBP4
and p-value = 0.04 for GAS6, Figure 5.1B). To visualize mRNA expression of the IGF1R
signaling pathway members, we used Ingenuity Pathways Analysis on LIMMA toptables
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from osteosarcoma cells as compared with mesenchymal stem cells and from osteosarcoma
cells as compared with osteoblasts (Figure 5.2). As can be seen in this gure, overlap of





Figure 5.2: This gure shows the IGF1R signaling pathway, with signicantly upregulated genes
in red, downregulated genes in green, and genes that did not meet our criteria for signicance in
gray. The left part of the symbols shows the analysis of osteosarcoma cell lines as compared with
mesenchymal stem cells, the right part as compared with osteoblasts. Most consensus in gene
expression is found upstream IGF1R signaling, in the expression of the IGF binding proteins.
OSI-906 inhibits phosphorylation of IRS-1
Gene expression levels of IGF1R and IRS-1 were validated at the protein level by Western
blot analysis (data not shown). We used phosphorylated IRS-1 as a readout for IR/IGF1R
signal transduction activity, as IRS-1 is a direct downstream target of these receptors. We
performed Western blot analysis on cell lysates of OHS, KPD, SAOS-2, and 143B, using
antibodies against IRS-1 and phosphorylated IRS-1, before and after treatment with OSI-
906a selective small molecule dual kinase inhibitor of both IR and IGF1R. An inhibition
of intrinsic IRS-1 phosphorylation at Y612 was detected after treatment with OSI-906 in
all cell lines (Figure 5.3), indicating that this inhibitor could aect signaling downstream
IGF1R in osteosarcoma cells.
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Figure 5.3: Western blot of IRS-1 and p-
IRS-1 of lysates of untreated () osteosar-
coma cell lines OHS, KPD, SAOS-2, and
143B, and of these cells treated for 3hrs with
1µM of OSI-906 (+).
OSI-906 inhibits proliferation of 3 of 4 osteosarcoma cell lines
In 3 of 4 osteosarcoma cell lines tested, inhibition with OSI-906 was dose-dependent
(Figure 5.4). Except for a toxic response at the maximum dose of 10µM (data not shown),
there was no eect on 143B. Because of this toxicity, relative IC50s were determined using
measurements until 1µM. OHS, SAOS-2, and KPD had an IC50 of 25nM, 92nM, and 90nM
at 72hrs, respectively, and of 37nM, 57nM, and 23nM at 96hrs of inhibition, respectively.
At 1µM OSI-906, approximately 60% of proliferation of OHS, SAOS-2, and KPD cells
was inhibited, while 143B proliferation was not inhibited (Figure 5.4).
Discussion
Genome-wide gene expression and subsequent gene set analysis on osteosarcoma cell lines
and biopsies indicated increased insulin-like growth factor signaling in high-grade osteosar-
coma as compared with the hypothesized osteosarcoma progenitors, which is currently the
best control, since there is no benign precursor and no certainty of the normal counterpart
of osteosarcoma. Because IGF1R signaling can be exploited as a therapeutic target, and
osteosarcoma patients are in severe need of new therapies, we examined mRNA expres-
sion of members of this signaling pathway in detail. IGFBP4 and GAS6, which code for
proteins that inhibit IGF1R signaling, showed the highest signicant downregulation (log
fold changes < −4) in a four-way analysis, in which osteosarcoma pretreatment biopsies
or cell lines were compared with osteoblastic cultures (n = 3) or MSCs (n = 12). In-
sulin-like growth factor binding proteins (IGFBPs) generally inhibit IGF1R signaling by
competitively binding IGFs, but can under certain circumstances also stimulate IGF1R
signaling (32). IGFBP4 is a negative regulator of IGF signaling in various tissues, in-
cluding bone (33). GAS6, or growth arrest-specic 6, was shown to inhibit the growth
promoting eects of IGF signaling and to stimulate dierentiation in the chondrogenic
cell line ATDC5 (34). Both IGFBP4 and GAS6 expression have previously been shown
to be downregulated in osteosarcoma cell lines (IGFBP4 in MG-63 (35), GAS6 in MG-
63 and SAOS-2 cells (36)). Next to GAS6 and IGFBP4, IGFBP2 was also signicantly
downregulated in all four analyses, with log fold changes of approximately −3. IGFBP2


































































Figure 5.4: Osteosarcoma cell lines were inhibited with dierent concentrations of OSI-906,
for 72 (gray line) or 96 (black line) hours. OHS (A), KPD (B), and SAOS-2 (C) showed a
dose-dependent inhibition, while 143B (D) did not respond to OSI-906.
Chapter 5 99
tion (33). IGFBP3 was highly downregulated in three out of four analyses, and has been
shown to elicit anticancer eects by inhibiting IGF1R signaling in Ewing sarcoma (37).
IGFBP7 activity has not yet been reported in sarcoma, but has been associated with
e.g. hepatocellular carcinoma (38). Interestingly, IGF2BP3 was highly overexpressed in
3 of 4 analyses. This binding protein can bind IGF2 mRNA, thereby probably activating
the translation of IGF2 (39). Overexpression of IGF2BP3 has been reported in several
cancer types (40, 41). Figure 5.2 shows that dierential expression is most pronounced in
upstream regulators of IGF1R, while downstream components, such as SHC and FOS, are
slightly downregulated, although for most genes this only holds when compared with mes-
enchymal stem cells, and not with osteoblasts. This may be caused by negative feedback
loops, triggered by the active IGF1R signaling pathway. These results suggest that, in
osteosarcoma, the IGF1R signaling pathway can be inhibited at the level of the receptor.
We therefore validated protein levels of IGF1R and of IRS-1, a direct downstream compo-
nent of IGF1R and IR signaling using Western blotting. IGF1R and IRS-1 protein levels
correlated fairly well with mRNA expression levels. Most importantly, phosphorylated
IRS-1, which is a measure for pathway activity, was detected in all four osteosarcoma
cell lines, indicating that IGF1R signaling is active in osteosarcoma, and is possibly reg-
ulated upstream of IGF1R. Accordingly, targeting this receptor may be an eective way
to inhibit this pathway.
OSI-906 is a selective small molecule dual kinase inhibitor of both IR and IGF1R (42).
We specically chose to treat osteosarcoma cells with a dual inhibitor, because the in-
sulin receptor can activate the same downstream signaling pathways as IGF1R, therefore
providing cells a way to circumvent single inhibition of IGF1R. This has formerly been
demonstrated in osteoblasts (43) and in Ewing sarcoma cells (44). In fact, this dual
inhibitor has been shown to cause enhanced inhibition of the Akt signaling pathway
when compared with a selective monoclonal antibody against IGF1R, which could inhibit
IR/IGF1R hybrids, but not IR homodimers (45). OSI-906 is currently being tested by
OSI Pharmaceuticals in a Phase III trial in adrenocortical carcinoma and in a Phase I/II
clinical trial in ovarian cancer. Treatment of osteosarcoma cells with OSI-906 at physi-
ological levels leads to decreased phosphorylation of IRS-1 at Y612. Inhibition of IRS-1
at Y612 after treatment with OSI-906 was previously reported by Buck et al. in direct
complementation breast cancer cells for IGF1R-IGF2 and IR(A)-IGF2 (45). Interestingly,
we also detected a small shift in the size of p-IRS-1 on the Western Blot, indicating that
multiple phosphorylation groups are removed after treatment with OSI-906. Surprisingly,
total IRS-1 levels were highest in 143B, and were downregulated after treatment with
OSI-906 in this cell line, although this had no eect on cell growth in this line, as opposed
to the three others, which showed low IC50s. Proliferation of 143B was only inhibited
most likely unspecically at high and toxic levels of the drug. The 143B cell line is a
derivative of the osteosarcoma cell line HOS, transformed by a KRAS oncogene. Consti-
tutive activation of the Ras/Raf/ERK pathway can explain why proliferation of this cell
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line cannot be inhibited by OSI-906. Of the cell lines that were responsive to OSI-906,
KPD and OHS showed that treatment of 96hrs was most eective, while SAOS-2 already
reached maximum inhibition at 72hrs.
IGF1R signaling has been previously modulated in sarcoma in preclinical and clinical
models. Several phase I and II clinical trials including treatment with IGF1R monoclonal
antibodies are currently being conducted in sarcoma, especially in Ewing sarcoma (an
overview of these trials is given in Olmos et al. (46)). Monoclonal antibodies against
IGF1R have modest activity against Ewing sarcoma, as was observed in a phase I/II study
of gitumumab (partial response in 14.2% of all subjects) (47) and in a phase II study
using R1507 (complete/partial response rate of 10%) (48). Results of a phase II study
of ganitumab in subjects with Ewing sarcoma and desmoplastic small round cell tumors
were published very recently, and reported clinical benet in 17% of all patients (49).
Preclinically, treatment with dierent monoclonal antibodies against IGFR1 has been
performed in osteosarcoma xenograft models, in which a response was detected in at
least 60% of all cases studied (5052). However, no objective responses were observed
in phase I trials testing monoclonal antibodies in osteosarcoma (47, 53, 54), although 2
of 3 patients treated with R1507 had prolonged stable disease (53). Clinical data using
dual IGF1R/IR inhibitors osteosarcoma is still very limited (55). Because resistance to
highly specic IGF1R inhibitors may develop through IR (44), blocking both IGF1R and
IR with a dual kinase inhibitor will most likely lead to better inhibition of downstream
IRS-1 signaling. We thus expect clinical outcomes to improve for osteosarcoma patients
treated with dual IGF1R/IR inhibitor OSI-906. The eects of combination of OSI-906
with chemotherapeutics in osteosarcoma still need to be assessed before such a treatment
can be clinically tested.
Phosphorylated IRS could be used as a biomarker in order to determine whether pa-
tients would respond to IGF1R inhibition. Patients with tumors exhibiting an activating
mutation in downstream pathways will most likely not respond to IGF1R inhibition. Fur-
ther research needs to be performed in order to assess these candidate biomarkers for
response to treatment. The IGF1R pathway acts on several biological mechanisms that
promote tumor progressionmitogenesis, protection from apoptosis, malignant transfor-
mation, and metastasis (6). It is therefore possible that inhibiting these pathways with
a dual IR/IGF1R kinase inhibitor, such as OSI-906, may reduce tumor sizes, as well as
osteosarcoma metastasis, the leading cause of death in these patients.
Conclusions
Using gene set analysis of genome-wide gene expression data of high-grade osteosarcoma
biopsies and cell lines, we detected an overrepresentation of IGF1R signaling. Specically,
dierent upstream inhibitors of IGF1R signaling, e.g. several IGF binding proteins, were
downregulated. As this indicated the IGF1R receptor as a potential target for treatment
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of osteosarcoma, we set out to inhibit this receptor in four osteosarcoma cell lines. We used
OSI-906, a selective small molecule dual kinase inhibitor of both IR and IGF1R, since
the insulin receptor can activate the same downstream signaling pathways as IGF1R,
thereby providing a way to circumvent single inhibition of IGF1R. Treatment with OSI-
906 resulted in inhibition of phosphorylation of IRS-1 Y612, a direct downstream target
of IGF1R, and in strong inhibition of proliferation in 3 of 4 osteosarcoma cell lines. The
nonresponsive cell line, 143B, has a KRAS oncogenic transformation, and may therefore
not respond to this treatment. In conclusion, we have shown that IGF1R signaling is active
in osteosarcoma, and that dual inhibition of IR/IGF1R inhibits downstream signaling and
proliferation of these cells. Responsiveness to this treatment may be evaluated by Western
blotting against phosphorylated IRS. This study provides an in vitro rationale for using
dual IR/IGF1R inhibitors in preclinical studies of osteosarcoma.
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Chapter 6
Kinome and mRNA expression
proling of osteosarcoma identies
genomic instability, and reveals Akt as
potential target for treatment
This chapter is based on the manuscript: Kuijjer ML, van den Akker BEWM, Hilhorst R,




Background: High-grade osteosarcoma is a primary malignant bone tumor mostly occur-
ring in adolescents and young adults, with a second peak at middle age. Overall survival
is approximately 60%, and has not signicantly increased since the introduction of neoad-
juvant chemotherapy in the 1970s. The genomic prole of high-grade osteosarcoma is
complex and heterogeneous. Integration of dierent types of genome-wide data may be
advantageous in extracting relevant information from the large number of aberrations
detected in this tumor.
Methods: We analyzed genome-wide gene expression data of osteosarcoma cell lines,
and integrated these data with a kinome screen. Data were analyzed in statistical lan-
guage R, using LIMMA for detection of dierential expression/phosphorylation. We sub-
sequently used Ingenuity Pathways Analysis to determine deregulated pathways in both
data types.
Results: Gene set enrichment indicated that pathways important in genomic stability
are highly deregulated in these tumors, with many genes showing upregulation, which
could be used as a prognostic marker, and with kinases phosphorylating peptides in
these pathways. Akt and AMPK were identied as active and inactive, respectively.
As these pathways have an opposite role on mTORC1 signaling, we set out to inhibit
Akt with the allosteric Akt inhibitor MK-2206. This resulted in inhibition of proliferation
of osteosarcoma cell lines U-2 OS and HOS, but not of 143B, which harbors a KRAS
oncogenic transformation.
Conclusions: We identied both overexpression and hyperphosphorylation in path-
ways playing a role in genomic stability. Kinome proling identied active Akt signaling,
which could inhibit proliferation in 2/3 osteosarcoma cell lines. This study provides a
rationale for further testing inhibitors of the PI3K/Akt/mTORC1 pathway in preclinical
studies of osteosarcoma.
Background
High-grade osteosarcoma is the most prevalent primary malignant bone tumor. Most
frequently, the long bones of adolescents and young adults are aected, with a yearly
incidence of approximately 5 cases per million per year (1). Patients are generally treated
with high doses of neoadjuvant chemotherapy to prevent the outgrowth of micrometas-
tases. In 1525% of all patients, however, metastatic disease is clinically detectable at
diagnosis and despite the intensive treatment, 45% of all patients develop distant metas-
tases, the leading cause of death of osteosarcoma patients (2, 3). The introduction of
neoadjuvant chemotherapy in the 1970s has increased survival from 1020% to approxi-
mately 60%. However, survival has reached a plateau, and new treatments are urgently
needed (46). Osteosarcoma is an extremely genomically unstable tumor, with karyotypes
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harboring numerous numerical and structural changes (7, 8). In addition, osteosarcoma
genotypes show a considerable degree of heterogeneity, both intra- and intertumoral. Both
the complex genotype and its heterogeneity render it dicult to determine which genomic
alterations are important in osteosarcomagenesis, as not all alterations may lead to a dif-
ference in mRNA, protein levels, or enzyme activity in the tumor tissue. Integration
of dierent data types is therefore of particular relevance for studying a heterogeneous
tumor with a complex genomic prole such as osteosarcoma. Previously, genomic and
expression data of osteosarcoma pretreatment biopsies have been integrated, in order to
detect highly recurrent osteosarcoma driver genes. The list of driver genes obtained with
this study was enriched in genes playing a role in genomic stability (9). Yet, even though
recurrent driver genes may provide knowledge on what pathways are aected that help
tumor cells survive, such driver genes may not always be accessible as targets for treat-
ment. This especially holds for pathways involved in genetic stability, since the damage
is already done.
Oncogenic kinases are often active in tumor cells, and a number of kinases can be phar-
macologically inhibited. Therapies targeting oncogenic kinases have provided promising
results in inhibiting proliferation of cancer cells, and some kinases have been targeted in
preclinical and clinical studies in childhood sarcomas (as reviewed in Wachtel et al. (10)),
e.g. IGF1R and mTOR (11, 12). An unbiased approach to identify active kinases in
cancer is to perform kinome-wide screens. Such screens have previously been eectively
used in other types of sarcoma and have led to the detection of specic targets for treat-
ment (13, 14). As combining the analysis of dierent data types using systems biology
approaches can give a more complete impression of the state of a tumor cell, we set out
to integrate genome-wide gene expression data of osteosarcoma cell lines with kinome
proling data. Osteosarcoma cell lines are widely available and have been shown to be
representative for the tumor of origin, both on a genome-wide as on a functional level,
and are therefore a good model to study osteosarcoma preclinically (15, 16). We previ-
ously have performed genome-wide expression analysis on a panel of 19 osteosarcoma cell
lines (17). In the present study, we compared expression proles with the dierent putative
progenitor cells of osteosarcomamesenchymal stem cells (MSCs) and osteoblastsin or-
der to dene the common denominator pathways that are deregulated in osteosarcoma.
Pathways with a role in genomic stability appeared to be enriched in overexpressed genes.
By integrating expression data with a serine/threonine (Ser/Thr) kinome screen, we show
that these pathways are enriched in hyperphosphorylation as well, conrming that ge-
nomic stability is highly deregulated in osteosarcoma, both on a transcriptional level and
on phosphorylation activity.
In order to detect overactive kinases in osteosarcoma, which may be potential targets
for treatment, we identied the most signicant pathways in the kinome proling data,
which indicated active PI3K/Akt and inactive AMPK signaling. These pathways play
an opposite role in mTORC1 signaling, with Akt promoting and AMPK inhibiting signal
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transduction (18). We pharmacologically inhibited Akt in osteosarcoma cell lines, which
reduced proliferation of 2/3 cell lines. In summary, this study describes integration of
mRNA and phosphorylation data, and gives a rationale for treatment of osteosarcoma
with inhibitors of the PI3K/Akt pathway.
Methods
Cell culture
Osteosarcoma cell lines were previously characterized and described (17). Human bone-
marrow-derived MSCs were obtained from two osteosarcoma patients, and were char-
acterized and handled as described (19). For kinome proling of osteosarcoma versus
MSCs, cells were cultured in Dulbecco's Modied Eagle Medium (DMEM; Invitrogen,
Carlsbad, CA), supplemented with 10% fetal bovine serum (Greiner Bio-one, Fricken-
hausen, Germany), in order to eliminate dierences in kinase activity caused by culture
conditions. For inhibition experiments and kinome proling of inhibition experiments,
osteosarcoma cell lines 143B, U-2 OS, and HOS were maintained in RPMI 1640 supple-
mented with 10% fetal calf serum (both from Invitrogen, Carlsbad, CA). The human
pre-B acute lymphoblastic leukemia cell line NALM-6 cell line was kindly provided by
Mw. N. Duinkerken (Department of Hematology, Leiden University Medical Center, the
Netherlands), and was maintained in Iscove's Modied Dulbecco's Medium (IMDM) sup-
plemented with GlutaMAX-1 (Life Technologies, Carlsbad, CA) and 10% fetal bovine
serum (Greiner Bio-one, Frickenhausen, Germany). All cells were regularly tested for
mycoplasm and were genotyped using the Powerplex 1.2 system (Promega, Leiden, the
Netherlands), as described previously (16).
Cell lysates
Kinome proling was performed on osteosarcoma cell lines 143B and U-2 OS and on two
MSCsMSC001 and MSC006. Cells at 80% conuence were washed twice with Phosphate
buered Saline and lysed with M-PER Mammalian Extraction Buer, supplemented with
Halt Phosphatase Inhibitor Cocktail and EDTA free Halt Protease Inhibitor Cocktail
(Pierce Biotechnology, Rockford, IL), according to the manufacture's protocol. Cells
were incubated on ice for at least 30 minutes before collecting the lysates and centrifuging
these for 15 minutes at 4◦C at > 10, 000 · g. Protein concentration was measured using a
detergent-compatible Protein Assay (Bio-Rad Laboratories, Hercules, CA) according to
the manufacturer's protocol. Samples were snap-frozen and stored at -70◦C.
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Proliferation assays
MK-2206 was dissolved in DMSO at a concentration of 10mM and stored at -20◦C. For
143B, U-2 OS, and HOS, 2, 000, 4, 000, and 2, 000 cells/well respectively, were plated in
a 96-wells plate. NALM-6, a human pre-B acute lymphoblastic leukemia (ALL) cell line,
was included as a positive control, as ALL cell lines have been shown to be highly sensitive
to MK-2206 (20). This cell line grows in suspension and was plated at 50, 000 cells/well.
After 24hrs, MK-2206 was added in triplicate in dierent concentrations0nM, 0.5nM,
1nM, 5nM, 10nM, 50nM, 100nM, 500nM, 1µM, 5µM, and 10µM. For 143B and HOS, the
eect of concentrations of 2, 3, 4, and 5nM was assessed as well. Cells were grown in
the presence of inhibitor for 120hrs. Cell proliferation was determined by incubating the
cells with reagent WST-1 (Roche, Basel, Switzerland) for 2hrs and subsequently measured
using a Wallac 1420 VICTOR2 (Perkin Elmer, Waltham, MA). Data were analyzed in
Graphpad Prism 5.01 (www.graphpad.com). Relative IC50s were calculated using results
from the dierent concentrations up to the highest dose where toxicity was not yet present.
The results shown are representative results from at least three independent experiments.
Genome-wide gene expression proling
We analyzed our previously published data of osteosarcoma cell lines (n = 19), MSCs
(n = 12), and osteoblasts (n = 3) (GEO superseries, accession number GSE42352) (9).
Microarray data processing and quality control were performed in the statistical language
R version 2.15 (21) as described previously (22).
Kinome proling
Kinome proling was performed on 1µg of cell lysate on the serine/threonine (Ser/Thr)
Kinase PamChip R©peptide microarrays (PamGene, 's-Hertogenbosch, the Netherlands)
according to the manufacturer's protocol, essentially as described in Hilhorst et al. (23).
This peptide microarray comprises 142 peptide sequences derived from human phospho-
rylation sites. Peptide phosphorylation is detected in time with a mixture of uorescently
labeled antiphosphoserine/threonine antibodies. We used at least three technical repli-
cates for each MSC line, and four technical replicates for the osteosarcoma cell lines.
Images were taken every 5 minutes, over the course of 60 minutes. Signal quantication
on phosphorylated peptides was performed in BioNavigator software (PamGene Interna-
tional, 's Hertogenbosch, the Netherlands). Subsequently, data were normalized in R (24)
using the vsn package (25). Median signals at 60 minutes of incubation with the cell
lysates were analyzed in Bioconductor (26) package arrayQualityMetrics (27) to identify
poor quality samples, which were removed from further analysis. Technical replicates
of good quality were averaged. To determine whether these data were reproducible, we
analyzed data from dierent cycles (0, 10, 20, 30, 40, 50, and 60 minutes incubation with
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cell lysates).
In the second kinome proling experiment we compared lysates of untreated cells with
lysates of cells treated with MK-2206. Dierent treatment durations and concentrations
were usedno treatment, treatment for 5, 30, 180, and 960 minutes with 1µM MK-2206,
and treatment for 180 minutes with 10µM of the drug. Kinome proling was performed as
described above, with the dierence that we used 15 technical replicates per condition.
Of this experiment, we analyzed signals at 30 minutes of incubation with the lysates.
Statistical analyses of microarray data
We performed LIMMA analysis (24) in order to determine dierential mRNA expres-
sion between osteosarcoma cell lines (n = 19) and control cell linesMSCs (n = 12)
and osteoblasts (n = 3) and to determine dierential phosphorylation of peptides on the
PamChip R©microarray between osteosarcoma cell lines (n = 2) and MSCs (n = 2). We
used a Benjamini and Hochberg False Discovery Rate (FDR) of 0.05 as cut-o for sig-
nicance. Kinome proling signals obtained for the dierent treatment conditions were
analyzed in a paired approach, in which signals from untreated cells were subtracted from
the signals from treated cells. For both kinome proling experiments, we used a cut-o of
0.1 for the absolute log fold change (logFC). Heatmaps were generated using the function
heatmap.2 of R package gplots.
Pathway analysis
In order to reveal pathways which were signicantly aected on mRNA levels in osteosar-
coma cell lines, we intersected the toptables obtained by LIMMA analysis of osteosarcoma
cell lines versus MSCs and of osteosarcoma cell lines versus osteoblasts. Gene symbols for
all probes were imported into the software Ingenuity Pathways Analysis (IPA, Ingenuity
Systems, www.ingenuity.com), together with FDR adjusted p-values (adjP) and average
logFCs. Only the gene symbols of probes that were both signicantly upregulated or both
signicantly downregulated in osteosarcoma cell lines as compared with MSCs and with
OBs (adjP < 0.05) were selected to be considered as signicantly dierentially expressed
in the IPA analysis. For dierential phosphorylation, we imported the results from the
LIMMA analysis on kinome proling data, with a cut-o of 0.05 for adjusted p-value
and a cut-o of 0.1 for logFC. The signicance of the association between the data set
and the canonical pathways was measured as described previously (28). Pathways with
adjP < 0.05 were considered to be signicantly aected. In addition, transcription factor
analyses were performed on gene expression data in IPA in order to predict activated
or inhibited transcription factors based on expression of target genes, returning p-values
(with a cut-o of 0.05 for signicance) and regulation z-scores.
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Results
Genome-wide gene expression proling of high-grade osteosarcoma
cell lines
We started by comparing gene expression signatures of 19 osteosarcoma cell lines, 12 MSC,
and 3 osteoblast cultures using unsupervised hierarchical clustering. Two separate clusters
were detectedone containing all tumor cell samples and one containing control samples.
Within the control sample cluster, osteoblasts clustered separately from MSCs (data not
shown). LIMMA analysis resulted in 7, 891 probes encoding for dierentially expressed
(DE) genes between osteosarcoma cell lines and MSCs, and 2, 222 probes encoding for DE
genes between osteosarcoma cells and osteoblasts. Intersecting of these gene lists showed
1, 410 probes that were signicant in both analyses, of which 1, 390 were upregulated in
both analyses, or downregulated in both analyses (Figure 6.1). These probes, encoding
for 1, 312 genes, were selected for subsequent pathways analysis, in order to determine








Figure 6.1: Venn diagram showing the sig-
nicant probes in the analysis of osteosar-
coma cell lines vs MSC (vsMSC) and vs
osteoblasts (vsOB), and the intersection of
these signicant probes with the subset of all
probes (both signicant and nonsignicant)
that shows both up- or both downregulation
in these two analyses (same sign). In total,
1, 410 probes are signicant in both analyses,
of which 1, 390 have the same sign of logFC.
Gene expression is altered in pathways regulating genomic stability
Pathway analyses on the 1, 312 dierentially expressed genes resulted in 17 signicantly
aected pathways (Figure 6.2). Fourteen out of these 17 pathways play a direct or indirect
role in genomic stability. Unsupervised hierarchical clustering of all cell line data and data
from 84 osteosarcoma biopsies (GEO accession number GSE33382 (9)) was performed on
all DE genes present in these 17 signicantly aected pathways, which resulted in a cluster
of control cells and biopsies, and larger cluster of osteosarcoma cell lines and biopsies
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Figure 6.2: Stacked bar chart depicting all signicantly aected pathways as identied by gene
expression proling of osteosarcoma cell lines, showing percentages of downregulated (green),
not signicantly altered (gray), and upregulated (red) genes, and genes which were not present
on the microarray (white). The -log(adjP) (-log(B-H) p-value) is plotted in orange, and is above
1.3 for adjP < 0.05.
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(Additional Figure 6.1). Patients whose biopsies had expression proles of these pathways
similar to osteosarcoma cell lines showed worse metastasis-free survival than patients
with intermediate expression proles, and than patients whose biopsies had expression
proles more similar to the control cultures, i.e. nontransformed primary mesenchymal
cell cultures and osteoblast cultures (Logrank test for trend, p-value = 0.049, Figure 6.3).
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Figure 6.3: Kaplan-Meier metastasis-free
survival analysis on data obtained from pa-
tient biopsies which clustered with osteosar-
coma cell lines, biopsies clustering with con-
trol cell lines, and an intermediate group,
based on gene expression of genes all present
in the 17 signicantly aected pathways (as
in Additional Figure 6.1). Logrank test for
trend, p-value = 0.049.
target genes are shown in IPA. The most activated transcription factor was MYC, while
the most inactivated transcription factor was TP53.
Kinome proling of osteosarcoma cell lines
To obtain more information on the activity of the pathways which showed aberrant
mRNA expression, we integrated mRNA expression data with data obtained with ki-
nase PamChip R©peptide microarrays. These peptide microarrays were incubated with
lysates of the osteosarcoma cell lines 143B and U-2 OS, and with lysates of two MSC cul-
tures. Kinases present in the cell lysates can, in the presence of ATP, phosphorylate the
peptides present on the microarray, which is detected by uorescently labeled antibodies.
We compared kinome proling data at dierent incubation times by intersecting lists of
dierentially phosphorylated peptides between osteosarcoma cells and MSCs, obtained by
LIMMA analyses, as shown in Figure 6.4. This data analysis demonstrated a large over-
lap in the detected dierentially phosphorylated peptides, and a build-up of dierentially
phosphorylated peptides over time. Most peptides showed dierential phosphorylation
after 20 minutes of incubation with cell lysates. After 60 minutes of incubation on the
peptide microarray, 49 peptides were detected to be signicantly dierentially phospho-
rylated between osteosarcoma cell lines and mesenchymal stem cells. These peptides are
represented in Figure 6.5. As a reference, we performed an unsupervised hierarchical
clustering including all technical replicates (data not shown), which showed that phos-

















Figure 6.4: Comparison of peptide
phosphorylation at dierent time points.
LIMMA analyses were performed on dier-
ent time points, ranging from 0 to 60 min-
utes of incubation with cell lysates. Venn
diagrams show overlap of signicantly dif-
ferentially phosphorylated peptides between
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Figure 6.5: Supervised clustering of all 49 signicantly dierentially phosphorylated peptides
identied by the comparison of two osteosarcoma cell lines with two MSC cultures. Peptides
are sorted on logFC, from lower phosphorylation to higher phosphorylation in osteosarcoma cell
lines. Orange: higher phosphorylation levels, blue: lower phosphorylation levels.
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Altered phosphorylation in genomic stability pathways
The signicance of the 17 pathways that were returned from the pathway analysis on
mRNA expression data was tested on kinome proling results in IPA. In total, 7/17
pathways were signicant in kinome proling as well. These seven pathways were a subset
of the 14 pathways with a known role in genomic stability. Most signicantly dierentially
phosphorylated peptides in these seven pathways showed higher phosphorylation levels
in osteosarcoma cell lines (Figure 6.6), indicating that kinases aect phosphorylation of
molecules playing a role in genomic stability.
Figure 6.6: Stacked bar chart showing kinome proling pathway analysis on the subset of
pathways which were signicant on gene expression proling. Percentages of downregulated
(blue), not signicantly altered (gray), and upregulated (orange) genes, and genes which were
not present on the microarray (white) are shown. The -log(adjP) (-log(B-H) p-value) is plotted
in orange, and is above 1.3 for adjP < 0.05.
PI3K/Akt and AMPK signaling in osteosarcoma
Unsupervised pathway analysis on the kinome proling results returned the IPA path-
way PI3K/Akt signaling as the most signicantly aected pathway in osteosarcoma cells
(Figure 6.7) and the AMPK pathway as second most signicantly aected pathway.
Specically, molecules directly downstream of Akt showed higher phosphorylation in os-
teosarcoma than in MSCs, while molecules downstream of AMPK showed lower phospho-
rylation levels. As these results indicate that Akt signaling is active in osteosarcoma and
might be driving its high proliferative capacity, we set out to pharmacologically inhibit
Akt using the compound MK-2206.
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Figure 6.7: The Akt signaling pathway in IPA. Blue: signicantly lower, orange: signicantly
higher phosphorylation in osteosarcoma cell lines, gray, no signicant dierence in phosphoryla-
tion, white: no phosphorylation sites of the particular protein on the PamGene Ser/Thr chip.
Blue lines indicate known downstream phosphorylation by the upstream kinase.
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MK-2206 inhibits proliferation of U-2 OS and HOS, but not of
143B
We inhibited osteosarcoma and control cells for 120hrs with allosteric inhibitor MK-2206.
Inhibition of the positive control leukemia cell line NALM-6, and of osteosarcoma cell
line U-2 OS with MK-2206 was dose-dependent, with IC50s of 0.38µM and 2.5µM, and
maximal responses of 94% and 71%, respectively (Figure 6.8). 143B did not show any
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Figure 6.8: Proliferation of osteosarcoma cell lines was inhibited with dierent concentrations
of MK-2206, for 120hrs. NALM-6, U-2 OS, and HOS showed a dose-dependent inhibition, while
143B did not respond.
response at concentrations below 5µM. Because 143B exhibits an oncogenic KRAS trans-
formation, we assessed MK-2206 specicity on the parental cell line of 143B, HOS, which
does not exhibit this transformation. HOS indeed responded similar to U-2 OS, with an
IC50 of 2.6µM and maximal response of 62%.
Dierent phosphorylation patterns upon treatment with MK-2206
As 143B and U-2 OS showed dierent sensitivities to MK-2206, we performed a paired
analysis between kinome proling data obtained from lysates of cells, which were treated
with dierent concentrations of MK-2206, and for dierent treatment lengths. Overall,
the phosphorylation patterns diered between both cell lines, and distances between treat-
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ment options within each cell line were smaller than between the cell lines (Figure 6.9).
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and untreated cells, depicting all peptides of the PamGene chip which are downstream
of PI3K/Akt (Figure 6.10). This gure shows that the inhibition pattern of MK-2206 is
dierent in the two osteosarcoma cell lines, suggesting that other upstream kinases may
be aected by inhibition of Akt with MK-2206 as well.
Discussion
Osteosarcoma is a highly genomically unstable tumor. The identication of specic molec-
ular targets that drive oncogenesis and that might be targets for therapy may thereby be
hampered. Genome-wide gene expression proling of high-grade osteosarcoma cell lines,
in fact, showed an enrichment in dierential expression in pathways important in ge-
nomic stability (Figure 6.2), with a role in cell cycle and checkpoint regulation (e.g. p53
signaling, G1/S and G2/M checkpoint regulation), DNA damage response (e.g. ATM
signaling, role of BRCA1 in DNA damage response), and purine/pyrimidine metabolism.
Most signicantly dierentially expressed genes in these pathways were upregulated, for
example DNA-PK, BRCA1, and CDC25A. Some downregulated genes were detected as
well, such as CDKN1A, which has an inhibitory role on cell cycle progression, and genes
downstream of TP53 (e.g. THBS1 and SERPINE1, encoding TSP1 and PAI-1, respec-
tively). Interestingly, as shown by unsupervised clustering on expression levels of genes
of these pathways, osteosarcoma pretreatment biopsies can have proles more similar to
those of osteosarcoma cell lines, or more similar to proles of the control cells. The rst
is associated with poor, while the latter is associated with good metastasis-free survival.
Expression proles can also be of an intermediate type, with intermediate metastasis-free
survival (Additional Figure 6.1, Figure 6.3). This suggests that deregulated genomic sta-
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Figure 6.10: Unsupervised clustering depicting dierential phosphorylation of peptides of the
PI3K/Akt pathway by cell lysates treated with dierent concentrations of MK-2206 for dierent
time intervals, as compared with untreated cells. Blue: logFC < 0, orange: logFC > 0. Dierent
treatment options are shown in dierent shades of gray (from light to dark gray: 1µM 5, 30, 180,
and 960 minutes, and 10µM 180 minutes of treatment with MK-2206. Light green: 143B, dark
green: U-2 OS.
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transcription factor analysis showed that MYC is the most signicantly activated (z-score
of 6.294), and TP53 the most signicantly inactivated (z-score of -7.660) transcription
factor. Other highly predicted activated transcription factors are e.g. E2F1/2/3, whereas
CDKN2A and RB1 were detected as inactivated. These dierent genes are known to be
aected in osteosarcoma (7, 9, 29). The role of these genes in cell cycle progression further
conrms the importance of these pathways in osteosarcoma.
As kinome-wide screens have previously led to the detection of specic targets for
treatment in other sarcoma types (13, 14), we performed kinome proling of osteosarcoma
cell lysates. Since the pathways that were shown to be signicantly aected on mRNA
expression mostly contained Ser/Thr kinases, we selected a Ser/Thr peptide microarray
the Ser/Thr PamChip R©. Pathway analysis on kinome proling data showed that 50% of
the pathways that were signicant on gene expression data were also signicantly enriched
in dierential phosphorylation signals (Figure 6.6). All signicant peptides were higher
phosphorylated in osteosarcoma cell lines, except for a peptide present in the gene CREB1.
Since most of these peptides showed higher phosphorylation, we expect these pathways
to be highly active, demonstrating higher cell cycling of the tumor cells, and deregulated
responses to DNA damage.
We next determined the most signicantly aected pathways in the kinome data from
the entire IPA canonical pathways database, and detected deregulation of the PI3K/Akt
and AMPK signaling pathways. Molecules downstream of Akt showed higher phospho-
rylation (Figure 6.7), while downstream of AMPK, lower levels of phosphorylation were
detected. Akt and AMPK act antagonistically to regulate mTOR signaling through in-
hibitory and activating phosphorylation of TSC2, respectively (18). The Akt pathway is
one of the most commonly aected pathways in cancer, with active PI3K/Akt signaling
leading to excessive cell growth and proliferation (30, 31). Inhibition of this pathway by
targeting mTOR with agents such as rapamycin is eective in some cancer types (32).
In a recent phase II trial in bone and soft tissue sarcomas, inhibition of mTOR with
ridaforolimus resulted in better progression-free survival (12). Inhibiting mTOR can,
however, also activate a strong negative feedback loop from S6K1 to enhance Akt sig-
naling (30, 32). It may, therefore, be more eective to inhibit Akt itself. Inhibition of
Akt was recently tested in a panel of xenografts of dierent pediatric cancers, and was
most eective in osteosarcoma, with signicant dierences in event-free survival in 6/6
xenografts (20). In addition, AMPK activators suppress growth of cell lines of various
tumor types (33).
We treated osteosarcoma cell lines with the allosteric Akt inhibitor MK-2206 (Selleck
Chemicals LLC, Houston, TX). Inhibition of proliferation was dose-dependent in U-2 OS
(IC50 = 2.5µM), but not in 143B (Figure 6.8). Important to note is that active Akt
signaling can be detected by kinome proling in this cell line, but this does not neces-
sarily imply that this pathway can also be fully inhibited, for example in the case that
downstream actors in the same pathway cause a survival benet for the cell line. As 143B
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is derived from the HOS cell line with a KRAS oncogenic transformation, we determined
inhibitory eects of MK-2206 on HOS as well. HOS responded to MK-2206 in a similar
manner as U-2 OS (IC50 = 2.6µM). This suggests that constitutive Ras/Raf/ERK signal-
ing causes insensitivity to inhibition of the Akt pathway to MK-2206. Kinome proling
of cells treated with MK-2206 resulted in dierent phosphorylation patterns in 143B and
U-2 OS of peptides of molecules in the PI3K/Akt pathway (Figure 6.10). Dierences be-
tween these cell lines were found in BAD Ser-99, of which phosphorylation was inhibited
after treatment with MK-2206 in the responsive cell line U-2 OS, but stimulated in 143B,
and in BAD Ser-118, where an opposite pattern was detected. BAD Ser-99 is the major
site of Akt phosphorylation, while Ser-118 is the major site of PKA phosphorylation (34).
Opposite patterns were also detected for TP53 Thr-18 and CDKN1A Thr-145/Ser-146,
of which CDKN1A Thr-145 can also be directly phosphorylated by Akt. These results
suggest that activity of other kinases may be aected by inhibition of Akt using MK-2206,
or by MK-2206 itself. This depends on the cellular context, as we otherwise would not
have expected to detect any dierences in a paired analysis for the dierent conditions in
each cell type.
An important nding of our studies is that the PI3K/Akt and AMPK signaling path-
ways were detected with kinome proling, while mRNA expression proling did not result
in the identication of these pathways. This suggests that in osteosarcoma, these pathways
are regulated by phosphorylation rather than by transcriptional activity. Gene expression
and protein synthesis imply a long time commitment of a cell to potential activation of
its synthesized proteins. Phosphorylation, on the other hand, provides a very rapid way
to mobilize extra catalytic power for a short time, and allows ne-tuning of the activation
of a pathway to the needs of a cell. This dierence in time scale emphasizes the impor-
tance of applying dierent platforms for the analysis of a complex tumor as high-grade
osteosarcoma.
Conclusions
In summary, this study shows that genomic stability pathways are deregulated on both
mRNA and kinome levels, with most signicantly aected genes being upregulated and/or
phosphorylated. Akt was detected as most probably overactive in osteosarcoma, as down-
stream peptides were hyperphosphorylated as compared with MSCs. Akt inhibitor MK-
2206 could inhibit 2/3 osteosarcoma cell lines. Based on these results, we conclude that
Akt inhibitors and other drugs inhibiting the PI3K/Akt/mTOR pathway could have an
eect on survival of osteosarcoma tumor cells.
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Additional Figure 6.1: Unsupervised hierarchical clustering of osteosarcoma cell line data
(black bars), control cultures (MSC: dark gray bars, osteoblast: light gray bars), and data from
osteosarcoma biopsies (blue bars) on mRNA expression levels of all DE genes present in the 17
signicantly aected pathways as determined by IPA. The dierent clusters selected for Kaplan-
Meier analysis are shown in the upper dendrogram in dierent shades of blue, corresponding to
the legend of Figure 6.3. Red: upregulation, green: downregulation.
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Chapter 7
Identication of osteosarcoma driver
genes by integrative analysis of copy
number and gene expression data
This chapter is based on the publication: Kuijjer ML, Rydbeck H, Kresse SH, Buddingh
EP, Lid AB, Roelofs H, Bürger H, Myklebost O, Hogendoorn PCW, Meza-Zepeda LA,
Cleton-Jansen AM. Genes Chromosomes Cancer. 2012 Jul;51(7):696-706
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Abstract
High-grade osteosarcoma is a tumor with a complex genomic prole, occurring primarily in
adolescents with a second peak at middle age. The extensive genomic alterations obscure
the identication of genes driving tumorigenesis during osteosarcoma development. To
identify such driver genes, we integrated DNA copy number proles (Aymetrix SNP 6.0)
of 32 diagnostic biopsies with 84 expression proles (Illumina Human-6 v2.0) of high-
grade osteosarcoma as compared with its putative progenitor cells, i.e. mesenchymal
stem cells (n = 12) or osteoblasts (n = 3). In addition, we performed paired analyses
between copy number and expression proles of a subset of 29 patients for which both
DNA and mRNA proles were available. Integrative analyses were performed in Nexus
Copy Number software and statistical language R. Paired analyses were performed on
all probes detecting signicantly dierentially expressed genes in corresponding LIMMA
analyses. For both nonpaired and paired analyses, copy number aberration frequency was
set to > 35%. Nonpaired and paired integrative analyses resulted in 45 and 101 genes,
respectively, which were present in both analyses using dierent control sets. Paired
analyses detected > 90% of all genes found with the corresponding nonpaired analyses.
Remarkably, approximately twice as many genes as found in the corresponding nonpaired
analyses were detected. Aected genes were intersected with dierentially expressed genes
in osteosarcoma cell lines, resulting in 31 new osteosarcoma driver genes. Cell division
related genes, such as MCM4 and LATS2, were overrepresented and genomic instability
was predictive for metastasis-free survival, suggesting that deregulation of the cell cycle
is a driver of osteosarcomagenesis.
Introduction
High-grade osteosarcoma is an aggressive primary bone tumor, which mostly occurs dur-
ing adolescence, with a second peak at middle age, at the metaphysis of long bones. The
tumor is characterized by aberrant production of osteoid matrix and by very complex
karyotypes (1, 2). Since the introduction of DNA microarray technology, recurrent DNA
copy number changes in human osteosarcoma tumor tissues have been identied by com-
parative genomic hybridization (CGH) and high-density single nucleotide polymorphisms
(SNP) microarray analysis. There is a general consensus about gain of chromosome arms
6p, 8q, and 17p, but many additional regions are reported as well (37). The eects of
copy number alterations may be reected by changes in expression of genes in the af-
fected chromosomal regions. There are various publications on human osteosarcoma gene
expression, but few show robust bioinformatics (as described by Kuijjer et al. (8)). Of-
ten, small sample sizes and heterogeneity within groups result in only a small number of
signicant genes, on which usually no correction for multiple testing is applied. Another
problem when studying osteosarcoma gene expression data is the lack of an osteosarcoma
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benign precursor lesion and its debated cell of originalthough it becomes clearer that
the mesenchymal stem cell or its derivative is the progenitor of osteosarcoma (9, 10).
The disease seems to develop suddenly as a full-blown tumor, rendering it dicult to
detect early drivers of osteosarcomagenesis. We have previously determined dierential
expression related to specic clinical parameters (8, 11). In addition, we have compared
osteosarcoma with osteoblastomaa benign tumor which develops at the same site as
osteosarcoma, but which does not progress into the latter. This comparison of human os-
teosarcoma with a control tissue showed that cell cycle regulation is the most signicantly
altered pathway in osteosarcoma (12).
There are advantages of integrating copy number and expression data when aiming to
identify driver genes. First, copy number data analysis of tumors with complex genomic
proles may return numerous bystander or hitch-hiker genes, as copy number alterations
may occur not only because they are advantageous for the tumor but also as a result of
general genomic instability. Regions of copy number alteration may therefore encompass
no driver gene at all, or may include additional genes. Also, some genes with altered
copy numbers may not be expressed in the tumor due to tissue-specic expression. These
aspects hamper the identication of drivers of tumorigenesis, especially when the number
of recurrent genes in such tumors is high. Second, at the mRNA level, drivers aect
downstream genes and switch on feedback mechanisms, again rendering it dicult to
determine the real osteosarcoma drivers in a pool of dierentially expressed genes (13).
Integration of DNA copy number and gene expression data lters out at least part of such
bystanders and of genes that act downstream of drivers of tumorigenesis, because most of
these genes have altered copy numbers, but no change in expression, or vice versa, while
drivers are both amplied and upregulated, or deleted and downregulated. Particularly
osteosarcoma is genetically extremely unstable and therefore genomic data analysis of
this tumor type would benet from an approach that distinguishes driver genes from the
numerous more random genetic events.
Nonpaired integrative analysis may be performed by determining recurrent regions
of copy number alterations which have higher than expected numbers of dierentially
expressed genes. Paired integrative analysis is a more powerful method, because the re-
lationship between copy number alterations and gene expression can be inferred in each
specic sample, instead of being based on averaged quantities. A statistically correct
method for paired integrative analysis of these dierent data types has not yet been de-
ned. Paired integrative analysis is usually performed by selecting genes based on the
correlation between gene expression and copy number levels, such as is performed by the
recently published methods DR-Integrator (14) and Regularized dual Canonical Correla-
tion Analysis (15). However, gains and losses may not necessarily directly translate to the
same quantity of change in expression levels (13), and important genes may be overlooked
this way. A method where paired integrative analysis is detected for specic chromosomal
regions with altered genomic and transcriptional status does exist (16), but this method
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is not optimal for tumors such as osteosarcoma with highly unstable genomes, since copy
number values are normalized to the mean copy number over each array, and this mean
value may be altered in such tumors. Two methods, PARADIGM and CNAmet, combine
dierent types of data on a gene-based level. In PARADIGM, integration of dierent
data types is used to detect patient-specic pathway activities (17). CNAmet returns
genes that show dierential expression between samples with and without methylation
and/or copy number alteration (18). This elegant approach may however hamper the
identication of genes that are regulated by other frequently altered genes, such as TP53
and MDM2 in osteosarcoma.
Aiming to identify osteosarcoma driver genes, we performed both nonpaired and paired
integrative analyses on high-grade osteosarcoma prechemotherapy biopsy data. We com-
bined results from analyses as compared with dierent control setsmesenchymal stem
cells (MSCs) and osteoblasts, so that we did not exclude one of these proposed progenitors
as the cell of origin of osteosarcoma. We show that the paired integrative analysis returns
more aected genes than the nonpaired integrative analysis. There is an overrepresenta-
tion of genes involved in genomic stability in osteosarcoma samples. The identied genes
may be important drivers in osteosarcomagenesis.
Materials and methods
Ethics statement
All biological material was handled in a coded fashion. Ethical guidelines of the individual
European partner institutions were followed and samples and clinical data were handled
in a coded fashion and stored in the EuroBoNeT biobank.
Patient material and cell lines
Genome-wide expression proling was performed on pretreatment diagnostic biopsies of
84 resectable high-grade osteosarcoma patients from the EuroBoNeT consortium (www.
eurobonet.eu). Clinicopathological details of these samples can be found in Table 7.1.
Human bone-marrow-derived MSCs were obtained from ve osteosarcoma patients and
seven healthy donors. Osteoblasts (n = 3) were derived from MSCs on osteogenic dif-
ferentiation. MSCs and osteoblasts were characterized and handled as described (12).
Copy number analysis was performed on 32 pretreatment diagnostic biopsies, of which 29
overlapped with the 84 samples used for expression analysis.
Copy number microarray data analysis
Aymetrix Genome-Wide Human SNP 6.0 arrays (Aymetrix, Santa Clara, CA) were
used for SNP data analysis. Genomic DNA preparation, labeling, hybridization, and
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Category Patient characteristics Number of biopsies (%)
Institution LUMC, Netherlands 36 (42.9)
IOR, Italy 12 (14.3)
LOH, Sweden 3 (3.6)
Radiumhospitalet, Norway 1 (1.2)
WWUM, Germany 32 (38.1)
Location primary tumor Femur 40 (47.6)
Tibia/Fibula 28 (33.3)
Humerus 11 (13.1)
Axial skeleton 1 (1.2)
Unknown/other 4 (4.8)




Minor subtype 11 (13.1)
Unknown 1 (1.2)
Huvos grade 1 or 2 38 (45.2)
3 or 4 33 (39.3)
Unknown/NA 14 (16.7)
Metastasis at diagnosis Yes 14 (16.7)
No 69 (82.1)
Unknown 1 (1.2)
Sex Male 54 (64.3)
Female 29 (34.5)
Unknown 1 (1.2)
Age < 20 years 64 (76.2)
>= 20 years 19 (22.6)
Unknown 1 (1.2)
Table 7.1: Clinicopathological details.
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scanning were performed as described by Kresse et al. (7). Microarray data preprocess-
ing was performed as described previously (19). Hybridization quality was estimated
by the genotype call rate using the Birdseed genotype calling algorithm in Genotyping
Console (version 4.0, Aymetrix). Samples of poor quality were excluded from further
analyses. We performed copy number analysis in Nexus software version 5 (Biodiscovery,
El Segundo, CA) using CNCHP log ratio les generated by Genotyping Console using
27 controls as a baseline, which is a subset of the reference set of 29 samples which was
used by Pansuriya et al. (19). We rejected two samples based on results from the qual-
ity control analysis in Genotyping Console. Circular Binary Segmentation (CBS)-based
SNPRank Segmentation was used to identify aberrant genomic regions. To be included as
frequently aberrant, a copy number alteration was called when detected in at least 35%
of all cases. Correlation of copy number alterations with clinical data was performed in
Nexus software, with correction for multiple testing.
Genome-wide gene expression microarray data analysis
Osteosarcoma tissue handling, RNA isolation, synthesis of cDNA, cRNA amplication,
hybridization of cRNA onto the Illumina Human-6 v2.0 Expression BeadChips (Illumina,
San Diego, CA), and microarray data processing and quality control in the statistical lan-
guage R version 2.10 (20) were performed as described previously (11). High correlations
between these microarray data and corresponding qPCR results have been demonstrated
previously (11). Unsupervised hierarchical cluster analysis was performed using R package
pvclust with default settings (21).
Data deposition
MIAME-compliant copy number and gene expression data have been deposited in the
GEO database (www.ncbi.nlm.nih.gov/geo/, superseries accession number GSE33383).
Detection of signicantly dierentially expressed genes
We performed a LIMMA analysis (22) in order to determine dierential expression be-
tween high-grade osteosarcoma samples (n = 84) and control tissuesMSCs (n = 12)
and osteoblasts (n = 3). Also, gene expression dierences between MSCs and osteoblasts
were determined. We used a Benjamini and Hochberg False Discovery Rate (FDR) of
0.05 as cut-o for signicance.
Nonpaired integrative analysis
Nonpaired integrative analysis was performed by importing lists of dierentially expressed
genes into the Copy Number module of Nexus software version 5. Based on the length of
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the gene list, Nexus software performs a Fisher's exact test in order to determine whether
the number of dierentially expressed genes in a specic region with a signicant copy
number alteration is larger than expected by chance. Genes present in such regions of
copy number alteration with FDR-adjusted p-values (Q-bounds in Nexus software) < 0.05
were returned from this integrative analysis. We did not apply any restrictions on the
size of copy number aberrations. A few small altered regions that did not encompass
an entire gene were detected, but these regions did not return genes upon integration
with expression data. Nexus software only reports genes which are both gained and
overexpressed, or both deleted and downregulated.
Paired integrative analysis
For the paired integrative analysis, copy number data of all autosomal overlapping genes
between the copy number and gene expression data were exported from Nexus software,
and converted into a binary matrix containing all genes with a gain (1) and no gain (0),
and a similar binary matrix for losses. As in the nonpaired integrative analysis, we did
not apply any restrictions on the size of copy number alterations. Gene expression data
of each probe for each sample were normalized against average gene expression values of
the corresponding probes over all control samples (either expression data from 12 MSCs
or from three osteoblasts)this was performed by subtracting the average expression of
the control samples from the expression levels of the sample of interest, since these are
log-transformed expression values. For both analyses, only genes that were signicantly
dierentially expressed between the 84 osteosarcoma samples and the specic control set
were analyzed, in order to make sure that all genes returned from the integrative analysis
were signicantly dierentially expressed. Subsequently, genes that overlapped between
the copy number binary matrices and that matched the fold change of expression (upreg-
ulation for genes with gains, and downregulation for genes with losses) were returned as
two-way contingency tables using scripts in R. Genes that were altered in two types of data
were further ltered by applying the sample recurrence criterion of 35%. This generated
lists of recurrent two-way altered genes. The odds ratios for having both copy number
and expression changes were calculated for dierent combinations, for instance gain and
upregulation. We used Bonferroni corrected Chi-square or Fisher's exact p-values < 0.05
to determine signicance.
Gene set enrichment
GO term enrichment was tested using Bioconductor package topGO (23). Lists of signi-
cantly aected genes were compared with all genes eligible for the analysis. GO terms with
Fisher's exact p-values < 0.0001, as calculated by the weight01 algorithm from topGO,
were dened signicant.
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Genomic instability scores and survival analysis
We calculated genomic instability scores for 83 (out of the 84) osteosarcoma biopsies
(for one sample no follow-up data were available) and all controls, as well as for two
normal bone samples (obtained from cancer patients at the Norwegian Radium Hospital),
20 osteosarcoma xenografts (Kresse et al., unpublished data, and Kuijjer et al. (8)), 19
osteosarcoma cell lines (24), and the HeLa cervical cancer cell line. For calculation of
the genomic instability scores, we refer to the article by Carter et al. (25). In short, this
method calculates per sample per probe the expression of that particular probe minus the
mean expression of that probe over all samples. For each sample, the sum of these values
for all probes present in the genomic instability signature is calculated. This value is then
compared between all samples and thus gives a relative measure of genomic instability.
We used 24 genes of the CIN25 signature, because for one gene no probe was present
on the Illumina v2.0 BeadChip. For genes with multiple probes, we used the probe that
showed the highest variation in expression levels. We determined metastasis-free survival
using the Kaplan-Meier method and performed a Logrank test for trend using GraphPad
Software (La Jolla, CA, www.graphpad.com).
Results
Recurrent chromosomal regions with copy number aberrations in
high-grade osteosarcoma
Thirty two high-grade osteosarcoma prechemotherapy biopsies were hybridized to Af-
fymetrix SNP 6.0 arrays in order to determine recurrent copy number alterations. In
total, 67 regions with recurrent alterations were detected, of which 35 regions had copy
number gain, and 32 copy number loss (see Supporting Information Table 1 (available
online (26))). Recurrent gains were present on chromosome arms 1p, 1q, 4p, 5p, 6p, and
8q, and losses on chromosome arms 1p, 1q, 2q, 3q, 6q, 7q, 8p, 10p, 10q, 12p, 13q, 15q,
16p, and 16q. A genome-wide frequency plot of copy number alterations is shown in
Figure 7.1. No signicant correlation was detected for specic regions with copy number
alterations and clinical information (tested clinical parameters are shown in Table 7.1).
Comparison of osteoblasts and MSCs
Unsupervised hierarchical cluster analysis resulted in separate clusters for biopsies and
cell lines. Within the cell line cluster, osteosarcoma cell lines formed one subcluster,
whereas MSCs and osteoblasts formed a second subcluster (Supporting Information Figure
1 (available online (26))). This indicates that the control cell lines are more similar
to one another than to osteosarcoma cells. On the basis of hierarchical clustering of
gene expression data, we cannot determine the cell of origin of osteosarcoma. A total
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Figure 7.1: Genome-wide frequency plot of copy number alterations on chromosomes 122 in
32 high-grade osteosarcoma prechemotherapy biopsies. Left of the chromosomes: loss, right:
gain.
of 1, 382 genes were dierentially expressed between osteoblasts and MSCs. GO term
enrichment resulted in seven signicant GO terms, which are represented in Supporting
Information Figure 2 (available online (26)). In summary, GO term enrichment showed
dierences in cellular structure, proliferation, and apoptosis. Genes showing signicant
dierences between both control cell types, however, can nonetheless be dierentially
expressed between osteosarcoma samples and both control cell types, thus can still be
important drivers of osteosarcomagenesis. We therefore set out to select genes that showed
dierential expression in osteosarcoma as compared with both MSCs and osteoblasts.
Gene expression signature of high-grade osteosarcoma
We detected 12, 542 and 2, 939 probes encoding for genes that were signicantly dif-
ferentially expressed between the 84 osteosarcoma biopsies and MSCs and osteoblasts,
respectively. MA plots, showing log-intensity ratios and log-intensity averages for both
analyses, are depicted in Supporting Information Figure 3 (available online (26)). A total
of 1, 679 probes overlapped between both analyses, of which 1, 639 were either up- or
downregulated in both. GO term analysis on the genes represented by these 1, 639 probes
showed an enrichment of apoptosis and signal transduction genes. Antigen processing and
presentation, as well as angiogenesis were also overrepresented (Supporting Information
Figure 4 (available online (26))).
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Paired integrative analysis is more sensitive than nonpaired inte-
grative analysis
Nonpaired integrative analysis was performed on data from 32 samples hybridized on SNP
arrays and from 84 samples hybridized on gene expression arrays, whereas paired analysis
was performed on a subset of 29 samples for which both SNP and expression data were
available. In total, 16, 105 autosomal genes were represented both on SNP and on gene
expression arrays. Nonpaired integrative analysis resulted in 253 signicantly aected
genes in osteosarcoma biopsies versus mesenchymal stem cells, whereas 71 genes were de-
tected when osteoblasts were used as a control. A total of 45 genes were identied in both
analyses versus MSCs and versus osteoblasts (Figure 7.2). Of these 45 genes, 23 were also
Figure 7.2: Venn diagram with numbers of
aected genes in both nonpaired and paired
analyses, and in osteosarcoma biopsies ver-
sus MSCs and versus osteoblasts. NP: non-
paired integrative analysis, P: paired inte-
grative analysis, OB: analysis of osteosar-
coma biopsies versus osteoblasts, MSC: anal-
ysis of osteosarcoma samples versus mes-
enchymal stem cells.
detected in expression analyses of a panel of 19 osteosarcoma cell lines (24) versus MSCs
and osteoblasts (Supporting Information Figure 5A (available online (26))). For the paired
integrative analyses, we determined whether the number of genes with gain combined with
overexpression and with loss combined with downregulation was higher than expected per
sample, based on the numbers of copy number alterations and gene expression changes in
the whole genome. This was true for most samples, as depicted in Figure 7.3, in which the
odds ratios and signicance of data dependencies are shown. Paired integrative analysis
resulted in 445 and 138 genes when compared with MSCs and osteoblasts, respectively.
A total of 101 genes overlapped between these dierent analyses (Figure 7.2), and of this
set, 31 genes were also detected in the cell line expression data (Supporting Information
Figure 5B (available online (26)), Table 7.2). Hence, paired analyses detected > 90% of all
genes found with corresponding nonpaired analyses. In addition, approximately twice as
many genes as found in the corresponding nonpaired analyses were detected (Figure 7.2,
Supporting Information Figure 6 (available online (26))). Note that in the paired analysis
fewer samples are included. Thus, paired analysis gives more robust results despite the
lower sample size. Changing the threshold of FDR-adjusted p-values in the nonpaired
integrative analysis from 0.05 to 0.15 (data not shown) did not alter this ratio.
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A B
Figure 7.3: Dependence of gene copy number and gene expression data. The heatmaps depict
odds ratios for the numbers of genes per sample which show gain and overexpression (overGain),
gain and underexpression (underGain), loss and overexpression (overLoss), and loss and under-
expression (underLoss). Chi-square tests, or, in case a group contained < 10 genes, Fisher's
exact tests, were performed in order to evaluate whether the number of genes reported from the
integrative analysis was higher than expected by chance. ∗ Bonferroni-corrected p-values < 0.05.
A, Osteosarcoma biopsies versus MSCs, B, versus osteoblasts.
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Symbol Cytoband CNA CNA freq (%) logFC
CLCC1 1p13.3 Gain 41.4 1.24
MCM4 8q11.21 Gain 37.9 1.35
AKR1C3 10p15.1 Loss 37.9 -1.94
AKR1C4 10p15.1 Loss 37.9 -1.34
ARHGAP22 10q11.22 Loss 37.9 -0.45
PGBD3 10q11.23 Loss 41.4 -0.82
ARID5B 10q21.2 Loss 48.3 -2.33
REEP3 10q21.3 Loss 48.3 -0.51
HERC4 10q21.3 Loss 51.7 -1.31
PBLD 10q21.3 Loss 48.3 -0.29
RUFY2 10q21.3 Loss 48.3 -0.20
KIAA1279 10q22.1 Loss 43.1 -0.57
SRGN 10q22.1 Loss 43.1 -2.26
AIFM2 10q22.1 Loss 44.8 -0.52
CHST3 10q22.1 Loss 48.3 -1.17
FAS 10q23.31 Loss 44.8 -0.42
PCGF5 10q23.32 Loss 37.9 -0.34
PPP1R3C 10q23.32 Loss 37.9 -2.89
AVPI1 10q24.2 Loss 37.9 -2.35
BLOC1S2 10q24.31 Loss 37.9 -0.51
CASC2 10q26.11 Loss 44.8 -0.18
FAM45A 10q26.11 Loss 39.7 -0.78
ERCC6 13q11.23 Loss 41.4 -0.52
WASF3 13q12.13 Loss 44.8 -2.43
C13orf33 13q12.3 Loss 48.3 -2.26
LHFP 13q14.11 Loss 48.3 -1.89
WBP4 13q14.11 Loss 55.2 -0.93
TSC22D1 13q14.11 Loss 58.6 -1.39
RCBTB1 13q14.2 Loss 58.6 -0.25
LATS2 13q21.11 Loss 44.8 -0.96
DCUN1D3 16p12.3 Loss 37.9 -1.39
Table 7.2: Candidate osteosarcoma driver genes. All frequencies and fold changes are mean
values of both integrative analysesosteosarcoma biopsies versus MSCs and osteosarcoma biop-
sies versus osteoblasts. For genes for which more than one probe was present on the array, the
probe with the highest fold change was used. Cytoband: UCSC cytogenetic band, CNA: copy
number aberration, CNA freq: copy number aberration frequency (for n = 29), logFC: log fold
change in biopsies (negative means downregulation, positive means upregulation).
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Genomic instability genes play a role in osteosarcoma progression
We calculated genome instability scores using the method of Carter et al. (25), which
compares levels of gene expression of a previously dened genomic instability signature
between samples in a dataset, for all osteosarcoma biopsies and dierent control tissues
and cell lines (Figure 7.4A). The osteosarcoma biopsies showed highly variable scores,
A B C
Figure 7.4: Genomic instability scores and metastasis-free survival. A, Genomic instability
scores for high-grade osteosarcoma biopsies, normal bone, osteosarcoma xenografts and cell lines,
the HeLa cell line, and mesenchymal stem cells (MSC) and osteoblasts (OB), as calculated by the
method of Carter et al. (25). B, Metastasis-free survival Kaplan-Meier curves for four quartiles of
genomic instability scores. C, Metastasis-free survival Kaplan-Meier curves for the total amount
of genes with copy number gains and losses, using a cut-o based on the median amount of genes
per sample showing copy number aberration.
whereas genomic instability scores for the controls, normal bone, MSCs, and osteoblasts
were relatively low. High instability scores were detected for osteosarcoma xenografts, cell
lines, and the HeLa cell line, in increasing order. This signature predicted for metastasis-
free survival in osteosarcoma samples as well (Figure 7.4B), with high scores correlating
with shorter metastasis-free survival (Logrank test for trend p-value = 0.0112). As ex-
pected, the total number of genes with copy number gains or losses, which is a direct
measure of genomic instability from the SNP data, was predictive for progression as well
(Logrank test p-value = 0.018, Figure 7.4C).
Candidate osteosarcoma driver genes
The 31 genes returned by the paired integrative analysis on clinical samples that also
were dierentially expressed in osteosarcoma cell lines are shown in Table 2, together
with their chromosomal locations, aberration frequencies, and log fold changes. A total
of 22/31 genes have been described to play a role in cancer. Interestingly, one third of
these 22 genes have a role in cell cycle regulation, matching the importance of cell cycle
and replication in osteosarcomagenesis as was found both using the genomic instability
scores of the expression data and the overall chromosomal instability as detected in the
copy number data (Figure 7.4).
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Discussion
In this study, we report copy number and gene expression alterations in high-grade os-
teosarcoma prechemotherapy biopsies, and then integrate these data in order to detect
osteosarcoma driver genes. Copy number analyses, which were obtained with high-den-
sity SNP microarrays, showed very high genomic instability in the osteosarcoma biopsies.
The pattern of aberrations is in line with previous studies using aCGH and SNP arrays,
which show recurrent gains in chromosome arms 1p, 6p, and 8q, and losses in chromosome
10. The previously reported recurrent amplication on chromosome arm 17p (36) is not
listed, because we used a very strict cut-o for aberration frequency (35%). Aberration
frequencies of 17% (4) and 26% (6) were previously found on chromosome arm 17p, and
a distinct amplication in 17p with an aberration frequency of 21% can be seen in Figure
1. We chose such a high cut-o for recurrent aberrations in order to enrich for selected
genetic events and exclude the numerous haphazard alterations that can be attributed
to the high genomic instability of high-grade osteosarcoma. In addition, we previously
determined that this cut-o, as compared with cut-os of 15% and 50%, showed the most
consistent results in subsequent network and pathway analyses on osteosarcoma cell line
SNP data (data not shown). For genome-wide gene expression analyses, both MSCs and
osteoblasts were used as control cells, and we only considered overlapping genes between
both comparisons, in order to make sure the aected genes were dierentially regulated in
osteosarcoma when compared with its putative progenitor cells. This analysis identied a
large number (n = 1, 639) of probes encoding for dierentially expressed genes. Many of
these genes encode tissue type-specic proteins, as is shown in the GO term enrichment
analysis, and appear as upregulated in osteosarcoma biopsies because the in vitro grown
control cells, MSCs and osteoblasts, lack surrounding stroma and are nurtured under other
conditions. Antigen processing and presentation as well as angiogenesis pathways were
expected to be upregulated, as macrophages and other inltrating cells are present in os-
teosarcoma tissue (11), and as angiogenesis plays a role in osteosarcoma progression (27).
Nevertheless, most stroma-derived gene expression is ltered out by integration with copy
number data, as this expression is not a result of underlying copy number changes. In
addition to stroma-related gene sets, GO term analysis showed enrichment in apoptosis
and signal transduction genes, which are probably altered in the osteosarcoma tumor cells
and not in the stroma. Because genes with concordant changes in copy number and gene
expression are likely to be enriched in drivers of tumorigenesis, we performed integrative
analyses on both types of data.
We found a remarkable increase in signicant dierential genes in paired compared
with nonpaired analysis, i.e. 101 versus 45. In general, paired integrative analysis was
advantageous over nonpaired integrative analysis, identifying roughly twice as many genes,
also when dierent aberration frequency cut-os or less stringent cut-os for signicance
were used in the nonpaired analysis. Nonpaired analysis as performed in Nexus software
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compares the number of dierentially expressed genes in a region of copy number aber-
ration with the expected number of dierentially expressed genes, which is based on the
total number of dierentially expressed genes over the whole genome. This method may
be too rigorous, because an altered copy number region may encompass tissue-specic
genes, which may not be expressed in the particular tumor tissue. These genes then have
altered copy number, but no dierence in expression. If an altered copy number region
contains a relatively large number of such genes plus only a few candidate drivers, the
entire region will be removed from the output of the analysis, which increases the amount
of false negatives. Moreover, in the cancer gene expression prole, a large number of
genes downstream of drivers, i.e. directly or indirectly regulated by drivers, or present in
feedback loops will be dierentially expressed. This increases the total number of dier-
entially expressed genes, which again lowers the chance that a specic altered region is
returned from the nonpaired integrative analysis as signicantly aected. Furthermore,
a single dierentially expressed gene in a certain region of copy number alteration may
still exert its driving function, and this driving function usually does not depend on the
proportion of dierentially expressed genes in the same region. Because of this, and be-
cause our method of paired integrative analysis is gene-based and not region-based, we
did not perform a correction based on the total number of dierentially expressed genes
when compared with the aected copy number regions in the paired analysis in R, and
this may be an additional reason why more genes are returned from the paired analysis.
However, in all samples, except for one (L3438), the number of genes showing both copy
number alteration and dierential expression was higher than expected when compared
with the numbers of copy number alterations and dierentially expressed genes over the
whole genome. This was signicant for the vast number of samples (28/29, 23/29, 27/29,
and 23/29, for combinations gain and overexpression, loss and underexpression in biopsies
versus MSCs, and gain and overexpression, loss and underexpression in biopsies versus
osteoblasts, respectively, as shown in Figure 7.3).
Genomic instability scores showed that the instability in osteosarcoma tissues ranges
from a level comparable to that of the controls, to the high instability levels of repeatedly
passaged tumors in xenografts and osteosarcoma cell lines. We demonstrated both on
copy number data, as well as by applying a genomic instability gene signature to genome-
wide gene expression data, that high genomic instability in osteosarcoma is correlated
with poor metastasis-free survival. This suggests that genes playing a role in genomic
instability may be potent drivers of osteosarcoma progression, as has been reported for
various other tumor types (25). Paired integrative analysis conrmed this result, as one
third of the genes with a possible role in tumorigenesis had a function connected to the
cell cycle. Of these genes, MCM4 showed gain and overexpression and was only detected
by the paired integrative analysis. MCM4 is part of the minichromosome maintenance
complex, which functions as a replication helicase, with a role in maintaining genomic
stability (28). This gene has been reported overexpressed in various tumor types (2931).
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Genes that were detected in both nonpaired and paired analyses were all deleted and
underexpressed. AVPI1, or arginine vasopressin-induced 1, may be involved in cell cy-
cling (32). ERCC6 is involved in transcription-coupled nucleotide excision repair, which
is a critical survival pathway protecting against cancer (33). RCBTB1, a candidate tu-
mor suppressor, was recently shown to have growth inhibitory activity in osteosarcoma
cells by regulating pathways of DNA damage/repair and apoptosis (34). LATS2, or large
tumor suppressor homolog 2, plays a critical role in centrosome duplication, maintenance
of mitotic delity, and genomic instability (35). Positive feedback between the p53 and
Lats2 tumor suppressors prevents tetraploidization (36), which could be an initiating step
in osteosarcomagenesis, leading to genomic instability (37, 38). Also, a role of Lats2 in
quenching of the increased genomic instability of H-Ras-induced transformation has been
identied (36). DCUN1D3 encodes for a UVC-responsive protein involved in cell cycle
progression and cell growth (39). Additional candidate genes with no direct role in cell
cycle regulation include for example genes with a role in apoptosis (AIFM2, BLOC1S2,
FAS) and metabolism (AKR1C3 and -4). Some previously reported genes with a driver
role in osteosarcoma were not identied, mainly because our high cut-o for recurrence.
For example, CDKN2A, MDM2, and E2F2 had recurrence frequencies of 28%, 17%, and
34%, respectively (in the dataset of 29 samples). CDKN2A and MDM2 were not sig-
nicantly dierentially expressed, but E2F2 was consistently signicantly overexpressed
with log fold changes > 1.50 in all analyses (biopsies and cell lines as compared with
dierent controls). TP53 and RB1 aberrations were present in > 35% of all samples (38%
and 69%, respectively). TP53 was signicantly downregulated in biopsies as compared
with both controls, but not in the osteosarcoma cell line dataset. RB1 showed signi-
cant downregulation when compared with MSCs, but not with osteoblasts, indicating a
dierence between these controls in RB1 signaling. We set our cut-o for recurrence to
35% and only selected genes present both in osteosarcoma biopsies as well as in cell lines
as compared with two dierent control sets, in order to select for the most important
osteosarcoma drivers. Using this method, we were able to detect previously unreported
driver genes.
In summary, we have shown that an individual gene-based paired integrative analysis
of copy number and gene expression data performs better than a region-based nonpaired
analysis. Several osteosarcoma candidate driver genes, especially genes playing a role in
cell cycle progression, have been identied. Additional research, particularly functional
studies, should reveal whether these genes are early or late drivers in osteosarcomagenesis.
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Chapter 8
Frequent loss of heterozygosity and
amplication in high-grade
osteosarcoma: analysis of recurrent
tumor suppressor genes
This chapter is based on the manuscript: Kuijjer ML, Liebelt F, Rydbeck H, Myklebost
O, Meza-Zepeda LA, Szuhai K, Hogendoorn PCW, Cleton-Jansen AM. In preparation
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Abstract
High-grade osteosarcoma is an aggressive primary bone tumor, with a peak incidence at
adolescence. Osteosarcoma karyotypes are heterogeneous, and characterized by a high
degree of genomic instability, rendering it dicult to detect recurrent driver genes in
this tumor type. By performing Aymetrix SNP 6.0 microarray data analysis of 29
prechemotherapy biopsies, we observed that loss of heterozygosity (LOH) often cooccurs
with copy number gains. We performed paired integrative analysis with genome-wide
expression data in order to determine which genes show dierential expression in regions
of LOH and gain, and integrated data from biopsies with data from 12 cell lines, which
resulted in the identication of 29 recurrent genes with LOH, gain, and overexpression. We
validated LOH of candidate tumor suppressor genes by Sanger sequencing and screened
for mutations in candidate genes, as osteosarcoma cells may have selected for LOH and
amplication of mutated tumor suppressors. We did not identify recurrent mutations,
suggesting that these genes do not have a tumor driving function. Fluorescence in situ
hybridization (FISH) analysis of candidate gene XRCC6BP1 showed that this gene was
present on homogeneous staining regions (HSRs) in 1/2 cell lines. As we detected a large
number of recurrent candidate oncogenes by paired integrative analysis of LOH, gain, and
overexpression, it may be valuable to determine whether these candidate oncogenes are
present on HSRs in osteosarcoma.
Background
High-grade osteosarcoma is the most frequent primary malignant bone tumor, aecting
roughly ve persons in a population of one million each year (1). The tumor is highly
aggressive, leading to distant metastases in approximately 45% of all patients. Since the
introduction of neoadjuvant chemotherapy in the 1970s, survival proles have reached a
plateau. In order to identify specic targets for therapy it is important to screen for recur-
rent driver genes in osteosarcoma. High-grade osteosarcoma karyotypes are characterized
by a high level of genomic instability, often harboring numerous numerical and structural
changes, and high degree of aneuploidy (2). This results in many frequently aected genes
in osteosarcoma, which may not all be important drivers, and thus renders it dicult to
determine which genes are true drivers of osteosarcomagenesis. Integration of genomic
and transcriptomic data will lter out most bystander and tissue-specic genes, and can
thereby result in a more specic list of candidate recurrent drivers. We previously de-
tected novel osteosarcoma driver genes by integrating high-throughput copy number and
gene expression data (3). Zygosity status can also be retrieved from SNP microarray data,
which we describe in the present study.
Loss of heterozygosity (LOH) and allelic imbalance have been studied in osteosarcoma
to quite some extent, and several recurrent regions have been described in detail (48).
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Smida et al. reported that the amount of LOH negatively correlated with survival (9).
This may be a readout of general genomic instability of the tumor, as for multiple human
cancers (10), including osteosarcoma (3), it has been shown that genomic instability is
predictive for survival, but LOH of specic regions may play an important role in tumori-
genesis of osteosarcoma. Loss of heterozygosity caused by the loss of one allele may cause
downregulation of the transcript, which may especially be relevant for tumorigenesis when
an aected tumor suppressor gene shows haploinsuciency (11). In osteosarcoma, TP53,
RB1, and PTEN are frequently deleted (2), and these genes could drive tumorigenesis by
haploinsuciency, although one study found that the LOH state of RB1 is not associated
with prognosis (12). CDKN2A, another tumor suppressor often aected in osteosarcoma,
also shows hemizygous losses which may have a role in tumorigenesis, although small
homozygous deletions in this gene are also seen (13). LSAMP is frequently focally deleted
in osteosarcoma, and may have a role as haploinsucient tumor suppressor (68). Copy
neutral LOH (CN-LOH), which is LOH without change in copy number, may play a role
in tumorigenesis as well, as is for example shown in hematological malignancies (14). In
a study of osteosarcoma samples on Aymetrix 10 K 2.0 SNP arrays, it was reported
that 28% of LOH events result from CN-LOH (6). Regions of LOH accompanied by gains
have not yet been discussed in high-grade osteosarcoma, but have been described in other
cancer types, e.g. in lung cancer (15) and triple-negative breast cancer (16). Tumor cells
could in theory select for a region of amplied LOH in case a mutated tumor suppressor
with a gain-of-function or partial dominant negative function is aected, with deletion of
the wild-type gene and amplication and overexpression of the mutated gene. Another
advantage for the tumor of stretches of LOH accompanied by gains is that tumor sup-
pressors with inactivating mutations and oncogenes can have tumor-promoting activities
at the same time (17).
In the present study, we analyzed high-throughput SNP data of osteosarcoma pre-
treatment biopsies, and detected that LOH is often accompanied by copy number gains.
By paired integrative analysis of LOH, copy number gain, and gene expression of os-
teosarcoma biopsy and cell line data, we identied 29 candidate driver genes, exhibiting
both LOH and copy number gains. Gene set enrichment on genes in regions of LOH
accompanied by gains and overexpression of the transcript returned pathways important
in tumorigenesis and genomic instability. We validated a selection of candidate tumor
suppressor genes by Sanger sequencing and Fluorescence In Situ Hybridization (FISH).
Mutation analysis of a selection of candidate tumor suppressors did not reveal any recur-




SNP microarray data analysis
Previously published Aymetrix Genome-Wide Human SNP 6.0 arrays were used for SNP
microarray data analysis of high-grade osteosarcoma pretreatment biopsies (GEO acces-
sion number GSE33383) and of high-grade osteosarcoma cell lines (GEO accession number
GSE36003). Microarray data preprocessing was performed as described in Pansuriya et
al. (18). We previously described quality control and detection of aberrant regions (3).
We used recommended settings for detection of LOH and allelic imbalance in Aymetrix
SNP 6.0 dataa minimum LOH length of 500 kb, a homozygous frequency threshold
of 95%, a homozygous value threshold of 0.8, and a heterozygous imbalance threshold
of 0.4. High gain, gain, and losses were dened using log2 ratio cut-os of 0.6, 0.2, and
-0.2, respectively, which are slightly more conservative cut-os than recommended by the
software (0.6, 0.18, and -0.18 for Aymetrix SNP 6.0 data). We selected 29 patients for
which gene expression microarray data were available, so that we could perform a paired
integrative analysis. Of the 19 cell lines, 12 passed our quality control (143B, HAL, HOS,
IOR/MOS, IOR/OS10, IOR/OS15, IOR/SARG, KPD, MG-63, MNNG-HOS, OSA, and
SAOS-2). For all cell lines, expression data was available. Aberration frequency cut-os
of 5% (at least 2 samples out of 29) and of 15% (at least 2 samples out of 12) were used
to detect recurrent regions in biopsies and in cell lines, respectively.
Genome-wide gene expression microarray data analysis
Genome-wide gene expression Illumina Human-6 v2.0 microarray data were previously
published (GEO accession number GSE33383 for biopsies, GSE42351 for osteosarcoma
cell lines). Microarray data processing and quality control in the statistical language R
version 2.14 (19) were performed as described previously (20). Mesenchymal stem cells
(MSCs, n = 12) and osteoblasts (n = 3) were used as control samples, as described by
Kuijjer et al. (3) (GEO accession number GSE33383).
Paired integrative analyses
A detailed description of the paired integrative analysis can be found in Kuijjer et al. (3).
For this study, we generated dierent binary les, including all genes that showed both
LOH and copy number loss (1) or not (0), and LOH and copy number gain (1) or not (0).
Gene expression data were normalized against average gene expression of the correspond-
ing probes over all control samples (MSCs or osteoblasts). Dierent from our previous
study, we included all genesnot only the subset of genes with signicant dierential ex-
pression. Genes were determined to be aected when frequencies of recurrent aberrations
were higher than 5% and log fold changes > 1. Finally, only overlapping genes between
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analyses with both control samples were considered of interest.
GO term enrichment
Gene set enrichment was performed using Bioconductor package topGO (21). Lists of
signicantly aected genes were compared with all genes eligible for the analysis. GO
terms with Fisher's exact p-values < 0.001, as calculated by the weight01 algorithm from
topGO, were dened signicant.
Other statistical analyses
Comparisons between the number of genes with both LOH and loss, and with both LOH
and gain were performed using Pearson's chi-square test. All p-values were below 0.001.
Primer design
Primers for PCR amplications were designed with a universal M13 tail in order to be
able to use one set of universal primers for all sequencing reactions (M13 tail forward
5'-TGTAAAACGACGGCCAGT-3' and reverse 3'-CAGGAAACAGCTATGACC-5'). In
order to rst validate the LOH detected with the SNP arrays, we selected Aymetrix SNP
probes for XRCC6BP1, RASD1, and LLGL1 according to the population frequencies of
the specic SNPs. Population frequency data from Aymetrix validation studies (www.
Affymetrix.com) were assessed in order to select probes with frequencies close to an even
distribution (50%/50%). We determined the number of SNPs to be evaluated for each
gene by minimizing the chance of false positive homozygosity to less than 5%. Primers
were designed up- and downstream of the SNPs using Primer 3 (www.Primer3.com) and
the UCSC genome browser (www.genome.ucsc.edu). Primer sequences can be found
in Additional Table 8.1. For mutation analysis primers were designed for the exons of
XRCCBP1, PLEKHO1, and TCC19 using Primer 3 (www.Primer3.com) and the UCSC
genome browser (www.genome.ucsc.edu) (Additional Table 8.2).
Sanger sequencing
The procedure for PCR amplication is described in Rozeman et al. (22). The following
PCR protocol was used: 5min at 95◦C, 3 cycles of 10sec at 95◦C and 10sec of 60◦C, fol-
lowed by 10sec of 72◦C. Sequencing was performed at Macrogen (Macrogen Europe, Am-
sterdam, the Netherlands), Baseclear (Leiden, the Netherlands), and the Leiden Genome
Technology Center (Leiden, the Netherlands). Sequences were analyzed with the Mutation
Surveyor software, Softgenics (State College, PA) and Chromas software (Technelysium
Pty Ltd, Helensvale, Australia).
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Fluorescent in situ hybridization (FISH)
Metaphase preparations of osteosarcoma cell lines KPD and SAOS-2 and of a control cell
line were obtained using colcemid as in Pajor et al. (23). The BAC probe for XRCC6BP1
(BAC/Fosmid ID RP1160O7) was ordered from the BacPac Resource Centre at Chil-
dren's Hospital Oakland Research Institute (Oakland, CA) and was labeled with biotin-
16-2'-deoxyuridine-5'-triphosphate (Bio-16-dUTP) using a Nick translation method. The
centromere probe for chromosome 12 (23) was labeled with digoxigenin-11-dUTP. For
immunodetection, the following antibodies were used: streptavidin-Texas Red (1 : 100),
mouse-anti-digoxin (1 : 1, 000), goat-anti-streptavidin-bio (1 : 100), rabbit-anti-mouse-
FITC (1 : 1, 000), and goat-anti-rabbit-FITC (1 : 100). FISH was scored by counting red
and green probes in 50 metaphase and 50 interphase nuclei per cell line.
Results
LOH and allelic imbalance in osteosarcoma biopsies
We set out to determine recurrent LOH in high-grade osteosarcoma. From SNP data anal-
ysis, we could demonstrate that LOH and allelic imbalance was detected less frequently
than CN gains and losses (Figure 8.1). Recurrent LOH (frequency > 5%) was detected
Figure 8.1: This gure shows the distribution of frequencies of LOH (blue) and allelic imbalance
(purple) on a background of frequencies of copy number gains (green) and losses (red) for the 29
osteosarcoma biopsies.
for 9.4% of all analyzed genes. The highest percentage of recurrent LOH detected in
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this dataset was 35%. Recurrent allelic imbalance was seen in 0.14% (23 genes), while
recurrent total allelic loss was detected in 0.16% (25 genes, including TP53 and RB1) of
all analyzed genes, with highest recurrent frequencies of 7% and 55%, respectively.
LOH is often accompanied by copy number gains
On average, 0.05% of all genes show LOH and loss of DNA. A chi-square test demonstrated
that LOH and loss occurred less frequent than expected (log odds −1.55, p-value <
0.0001). Also copy neutral LOH occurred less frequent than expected (log odds −1.75,
p-value < 0.0001). Based on a comparison of the allelic ratio overview of the genome
with CN gains and losses, LOH appears to often cooccur with gain at the other allele
(Figure 8.1). On average, 1.10% of all genes show LOH and gain at the other allele in
the same sample. Chi-square test veried that LOH accompanied by copy number gains
indeed occurred more frequently than expected (log odds 2.44, p-value < 0.0001).
Integration of LOH, gain, and dierential expression
In order to identify genes present in regions of LOH and gain (LOH-gain) which also
were dierentially expressed and hence may have a tumor driving function, we performed
paired integrative analyses of LOH-gain and expression in the dataset of osteosarcoma
pretreatment biopsies. Paired integrative analysis of these biopsies as compared with
MSCs resulted in 148 up- and 17 downregulated genes in combination with LOH-gain,
while the analysis where osteoblasts were used as a control resulted in 135 up- and 9 down-
regulated genes in combination with LOH-gain. Of these aected genes, 114 upregulated
and 5 downregulated genes overlapped between both analyses.
The same approach was taken for the analysis of high-grade osteosarcoma cell line data.
This analysis returned 137 up- and 44 downregulated genes in combination with LOH-gain
in osteosarcoma compared with MSCs, and 134 up- and 35 genes when compared with
osteoblasts. In total, 97 upregulated genes and 20 downregulated genes overlapped. Of
the 119 genes being over- and underexpressed together with LOH-gain in osteosarcoma
biopsies as compared with MSCs and osteoblasts, 29 showed recurrent LOH-gain in com-
bination with signicant dierential overexpression in both analyses of osteosarcoma cell
lines (Figure 8.2A). No genes showing LOH and CN gain together with downregulation
overlapped (Figure 8.2B).
Involvement of cell cycle pathways
GO term enrichment was performed on the 29 aected genes obtained with the analysis
of biopsies and cell lines. This resulted in three signicant GO termsS-phase of mi-
totic cell cycle (GO:0000084), double-strand break repair via non-homologous end-joining













































Figure 8.2: Depicted are the numbers of returned genes from the paired integrative analysis on
LOH with gain and A, upregulation or B, downregulation, as compared with MSCs or osteoblasts
(OB), in both osteosarcoma biopsies and cell lines.
such as CDK4, MCM4, and XRCC6BP1 (Table 8.1). Literature review (www.genecards.
org) indicated that 17/29 genes may have an oncogenic role and 2/29 a tumor suppressive
role.
GO ID Term Ann Sign Exp weight01 Genes aected
0000084 S phase of mitotic cell cycle 114 4 0.26 0.00013 CDK4, MCM4,
PSMB4, PSMD4
0006303 double-strand break repair
via NHEJ
10 2 0.02 0.00023 PRKDC,
XRCC6BP1
0000216 M/G1 transition of mitotic
cell cycle
67 3 0.16 0.00049 MCM4, PSMB4,
PSMD4
Table 8.1: GO terms signicantly enriched for genes with LOH-gain and overexpression. GO
ID: GO-term ID, Term: GO term, Ann: number of annotated genes, Sig: number of signicant
genes, Exp: number of genes expected to be signicant, weight01: p-value obtained with weight01
algorithm, NHEJ: non-homologous end-joining.
Validation by Sanger sequencing
Tumor suppressor genes which are present in a region of LOH and gain may be partic-
ularly interesting, because a tumor cell could select for a mutant allele with a partial
dominant negative or altered function. We therefore set out to identify mutations in tu-
mor suppressor genes present in these regions of LOH and gain. Yet, false positive regions
of LOH may be returned from SNP data analysis in regions of high CN amplication as
a technical artifact. Hence, we validated regions of LOH and gain by Sanger sequencing.
For validation, we selected the candidate tumor suppressor gene XRCC6BP1. In addition,
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we chose to validate the gene LLGL1, which showed LOH and gain in the SNP data of cell
line IOR/OS15 and allelic imbalance and gain in cell line IOR/SARG. We also validated
RASD1, which showed recurrent LOH and gain, but downregulation when compared with
osteoblasts. We validated LOH in the cell lines which showed LOH and gain in the par-
ticular genes in the SNP data analysis. The selected genes harbored homozygous as well
as heterozygous SNPs when analyzed on normal blood donor DNA. Sequencing of the
selected SNPs in and around XRCC6BP1 in the cell lines KPD and SAOS-2, and of the
SNPs in and around RASD1 in cell lines 143B, HOS, and IOR/OS15 and the diagnostic
biopsy L2613 revealed only homozygous SNPs. For LLGL1, we detected homozygosity
in cell line IOR/OS15, but heterozygosity in cell line IOR/SARG, which was detected
as allelic imbalance in SNP microarray data analysis. The probabilities for obtaining
false positive results in the Sanger sequencing validation were 0.001, 0.037, and 0.019
for XRCC6BP1, RASD1, and LLGL1, respectively. These ndings therefore conrm the
detection of homozygosity by the SNP microarray data analysis.
Nature of the amplication
The copy number state of the XRCC6BP1 locus in the aected cell lines was analyzed by
FISH (Figure 8.3). For KPD, 42/50 metaphase cells had four copies of chromosome 12, of
which two were negative for the XRCC6BP1 probe. In addition, these cells showed more
than ten homogeneous staining regions (HSR) for XRCC6BP1. 8/50 cells had only two
copies of chromosome 12, of which one harbored XRCC6BP1, and showed 510 HSRs per
cell. In 50/50 SAOS-2 metaphases, in contrast, we detected two copies of chromosome 12
harboring the XRCC6BP1 locus, and two additional chromosomes without a chromosome
12 centromere, but with signals for XRCC6BP1. These results do not prove homozygosity
of the locus, but do illustrate the dierent levels of amplication in the dierent cell lines.
These amplications identied with FISH corresponded to results from the SNP data
analysis, as we detected a high gain in KPD and a normal gain in SAOS-2.
Mutation analysis of selected genes
We performed Sanger sequencing for the entire coding region of XRCC6BP1, one of the
two candidate tumor suppressor genes with recurrent LOH-gain and overexpression, but
did not identify any mutation in this gene, indicating that the wild-type allele is amplied
in the osteosarcoma cell lines KPD and SAOS-2, which harbor the region of LOH and
gain. We therefore expanded our list of candidate genes with tumor suppressor genes
showing upregulation when compared with MSCs only (2/11 genes may have a tumor
suppressive function), and when compared with osteoblasts only (3/5 genes may have a
tumor suppressive function). The coding region of PLEKHO1, which showed overexpres-
sion only when compared with osteoblasts, was sequenced and analyzed for mutations in





Figure 8.3: FISH depicting A, a control
metaphase cell, B, a metaphase cell of KPD
with arrows indicating examples of HSRs,
and C, a metaphase cell of SAOS-2 with ar-
rows indicating XRCC6BP1 alleles not lo-
cated on chromosome 12. Green: probe for
the centromere of chromosome 12, red: BAC
probe for XRCC6BP1.
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could be identied, but we were not able to sequence the rst exon of this gene. Mutation
analysis of TTC19, which showed overexpression compared to MSCs, revealed a point
mutation in exon 7 in the cell line IOR/OS10, but no mutations in the other aected cell
lines (143B, HOS, IOR/OS15, IOR/SARG) and in two additionally analyzed diagnostic
biopsies showing LOH and gain (L3437, L3469) were detected, indicating that the mu-
tation in TTC19 is not recurrent in osteosarcoma. The mutation, R274G, however, was
predicted to be possibly damaging with a score of 0.752 (sensitivity of 0.85, specicity of
0.92) by PolyPhen-2 (24).
Discussion
By analysis of high-grade osteosarcoma high-throughput genomic data, we demonstrated
that, in osteosarcoma, recurrent LOH happens less frequently than copy number aberra-
tions such as gains and losses. Interestingly, we found that LOH was more often accom-
panied by copy number gains than expected by chance. Tumor suppressor genes showing
overexpression in recurrent regions of gain and LOH may be drivers if these genes har-
bor mutations leading to a gain-of-function or partial dominant negative function. We
thus screened for mutations in candidate tumor suppressor genes in these regions. Of
the 29 genes that were recurrently aected in all comparisons, two may have a possible
tumor suppressive roleXRCC6BP1 and PRKDC. We performed mutation analysis for
XRCC6BP1, or XRCC6 binding protein 1 / Ku70 binding protein 3, which is involved
in non-homologous end-joining (NHEJ) of DNA double strand breaks (25). XRCC6BP1
has been reported to be amplied and overexpressed in an alternatively spliced isoform
in human gliomas, which may interfere with the normal function of the DNA-PK com-
plex (26). In regions of LOH-gain in osteosarcoma cell lines, XRCC6BP1 did not harbor
any recurrent mutations. We did not screen for mutations in PRKDC, or DNA-PK cat-
alytic subunit, a Ser/Thr kinase which also plays a role in NHEJ (27), because of its
size (over 13kb). We did analyze two additional genes, PLEKHO1 and TTC19, which
showed recurrent LOH and gain, but which were overexpressed only in comparison with
osteoblasts, or only in comparison with MSCs, respectively. No mutations in PLEKHO1
(pleckstrin homology domain containing, family O member 1), a gene with a role in regu-
lation of the actin cytoskeleton (28) with an inhibitory eect on PI3K/Akt signaling (29),
were detected, but we were unable to sequence exon 1 of this gene. We did detect a mu-
tation in TTC19 (tetratricopeptide repeat domain 19), of which the protein is reported
to be involved in oxidative phosphorylation in mitochondria (30), and which may play a
role in cytokinesis as well (31). The mutation detected results in a arginine to glycine
substitution at codon 274 of the TTC19 protein and was predicted as possibly damag-
ing. However, the mutation was only found in 1/6 samples analyzed, and is therefore not
recurrent. A shortcoming of these mutation analyses is that only exons were sequenced,
and mutations in e.g. intronic regions may also aect the protein function, for example
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by aecting alternative splicing. We thus cannot exclude that these genes harbor any
recurrent mutations.
A weakness of this study is that we did not have paired control samples available for
the SNP microarray data analysis. Using paired control samples helps in avoiding the
false-positive regions of LOH which are detected when comparing tumor samples with an
independent set of controls, because of patient-specic inherited segments of homozygos-
ity (32). A second limitation in the analysis of these data is that high-grade osteosarcoma
is extremely genomically unstable. Copy number aberrations that are returned by data
analysis are relative changes against the background copy number state of the samples,
and therefore true copy number states are not uncovered (33). Regions of copy number
gain could, e.g. in a tetraploid background, consequently represent even higher gains
than what is expected based on assumption of a near-diploid background. In the case of
an unbalanced gain, the detection of the other allele may be low, which can lead to the
detection of a false-positive region of LOH. Because of these considerations, we validated
a selection of genes in regions of recurrent LOH-gain by Sanger sequencing. All regions
we tested were indeed detected as homozygous for the all SNPs. However, in a highly
amplied region, Sanger sequencing may also not be sensitive enough to detect the se-
quence of an allele of which only one copy is present. We therefore cannot conclude that
these regions are actually homozygous, although for regions of low amplication this is
probably the case.
FISH analysis of XRCC6BP1 revealed four copies of chromosome 12 in both cell lines,
of which two harbored the XRCC6BP1 locus and two not. In addition, cell line KPD
showed numerous homozygous staining regions. These results could be an indication of
LOH and amplication of the other allele with intrachromosomal HSRs, but allele-specic
FISH should be performed to clarify whether these are true cases of LOH. Nevertheless,
FISH validated the copy number states that were detected by SNP microarray data anal-
ysis, as the gain detected in SAOS-2 was represented by four copies of the gene, and
the high gain detected in KPD was represented by > 10 copies of the XRCC6BP1 locus
in FISH, thereby conrming the detection algorithm for copy number gain we used was
appropriate for these samples. Chromothripsis, or chromosome scattering, is reported
to be present in bone tumors with a frequency of at least 25% (34). In chromothripsis,
part of the genome generally oscillates between two states, with the higher copy number
state retaining heterozygosity and the lower copy number state showing LOH. The regions
of LOH-gain we detected in the osteosarcoma SNP data could represent chromothripsis,
since it would be possible that small oscillating regions were not detected due to the den-
sity of the probes targeting SNPs on the microarray and the detection algorithm. Such
regions may be returned as larger regions of CN gain harboring LOH. A characteristic
of chromothripsis is the presence of double minutessmall circular extra-chromosomal
DNA fragments, which may be highly amplied in the tumor cell, and which frequently
harbor oncogenes in cancer cells (35). The HSRs which were detected in cell line KPD
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may represent chromosomal integration of double minutes, especially considering 17/29
genes detected by our analysis are possible oncogenes. It would thus be interesting to
characterize whether the regions that we detected are recurrent HSRs or double minutes,
and what the function of these oncogenes is in tumorigenesis of osteosarcoma.
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Concluding remarks and future
perspectives
166 Chapter 9
High-grade osteosarcoma is a primary bone tumor with complex genetic alterations, for
which targeted therapy is lacking. The aim of this thesis was to use high-throughput
molecular data analysis of high-grade osteosarcoma specimens and model systems, in order
to learn more on osteosarcomagenesis and to nd possible ways to inhibit this process.
Chapter 1 and Chapter 2 give an introduction and literature review on microarray
data analysis of high-grade osteosarcoma.
In Chapter 3 we provide a rationale for the use of model systems for osteosarcoma.
It describes dierential expression for the clinical parameters sex, tumor location (femur,
humerus, bula/tibia), response to preoperative chemotherapy (poor responders, or Hu-
vos grade 12, versus good responders, or Huvos grade 34), and histological subtype
(osteoblastic, chondroblastic, broblastic osteosarcoma). Importantly, as we describe in a
previous study performed by our group (1), no signicantly dierentially expressed genes
were detected between poor and good responders to preoperative chemotherapy, even
though a substantial amount of tumor samples was analyzed (see also Chapter 2). Several
publications do report dierences between poor and good responders, but used relatively
small sample sizes, and did not apply correction for multiple testing. An analysis of gene
expression proles of the three described histological subtypes showed that these diered
signicantly. Sets of broblastic- and of chondroblastic osteosarcoma-specic genes were
determined, and were enriched in genes with a role in cellular growth and proliferation
and in the chondroid extracellular matrix, respectively. Using nearest shrunken centroids
classication, an expression signature consisting of 24 probes that could predict for his-
tological subtype was generated. This prole was validated on an independent dataset
of osteosarcoma and control samples. Interestingly, this prediction prole was able to
classify histological subtypes of the primary tumor from which the tested osteosarcoma
xenografts and cell lines were derived, even though such material often lacks extracellular
matrix. This implicates that the mRNA expression proles of these model systems are
representative for the primary tumor, and favor the use of osteosarcoma xenografts and
cell lines in studying osteosarcoma biology. This is of particular importance given the
rarity of this tumor as well as the diculties to obtain adequate tissue.
Targets for treatment of high-grade osteosarcoma
Dierent comparative analyses of the various types of data that were available led to
the discovery of a number of particular ways to target this tumor. In Chapter 4, we
compared patients who developed metastases within ve years with patients who did
not develop metastases within this time frame. The list of signicantly dierentially ex-
pressed genes was enriched in macrophage-associated genes expressed by inltrating cells
(approximately 50% of all genes), which were all overexpressed in patients who did not
develop metastases. Tumor-associated macrophages (TAM) of both the M1- (antitumor)
and M2 (protumor)-type were quantied with IHC in additional cohorts. The total count
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of M1- and M2-type macrophages was signicantly correlated with a better overall sur-
vival. This is in contrast with most epithelial tumor types, which often show a correlation
between (M2-type) inltrating macrophages and poor survival. However, mesenchymal
tumor cells may not need the guidance of the inltrate to metastasize, and tumor-associ-
ated macrophages may have a more antitumorigenic role in osteosarcoma (2). Moreover,
macrophages are plastic cells, and it could be that M2-type macrophages polarize towards
M1-type macrophages after chemotherapy due to the release of danger signals by the dy-
ing tumor cells. The results of Chapter 4 provide a rationale for adjuvant treatment
of high-grade osteosarcoma patients with macrophage-activating and recruiting agents,
such as liposomal muramyl tripeptide phosphatidylethanolamine (L-MTP-PE). This drug
has been previously shown to increase overall survival in canine and in human osteosar-
coma (2, 3), although interpretation of the results obtained from the latter study has been
dicult, due to the 2x2 factorial design; standard adjuvant chemotherapy treatment plus
L-MTP-PE and/or ifosfamide. This study showed that two additional drugs did not show
signicant interaction (p-value = 0.101) and therefore the treatment arms were pooled.
A signicant dierence was then found for overall survival, but not for event-free survival
(EFS). In an unpooled analysis, EFS for patients treated with L-MTP-PE and ifosfamide
was signicantly improved when compared with patients treated with ifosfamide alone,
but EFS arms of patients with only the standard adjuvant chemotherapy and patients
who received L-MTP-PE without ifosfamide were not signicantly dierent (3). Further
testing of this drug in osteosarcoma is therefore necessary, and this will, in the near future,
be initiated in a phase II study in patients with metastatic and/or relapsed osteosarcoma.
In addition to dierences between high-grade osteosarcoma tumors with dierent clin-
ical features, we studied common gene expression changes between sets of tumors and
control samples. In Chapter 5, mRNA expression in osteosarcoma cell lines was com-
pared with expression in osteosarcoma progenitors. Global pathway analyses pointed to
dierences in mRNA expression of the IGF1R pathway. Specically genes negatively
regulating this pathway upstream the IGF1 receptor showed downregulation in osteosar-
coma, of the highest degree (i.e. the highest negative fold changes in the dataset). We
therefore hypothesized that this pathway can be inhibited at the receptor level, and that
this may inhibit growth of these tumors. Osteosarcoma cell lines were treated with a
dual kinase inhibitor OSI-906, which inhibits both the insulin receptor (IR) and IGF1R,
as IR can take over downstream signaling in case IGF1R is blocked, thereby inducing
resistance to single IGF1R targeting (4, 5). Inhibition with OSI-906 resulted in an inhibi-
tion of proliferation of 3/4 osteosarcoma cells, and may therefore be a promising drug for
treatment in addition to adjuvant chemotherapy. Other pathways with a role in bone de-
velopment, namely canonical Wnt signaling (6) and TGFβ/BMP signaling (7), have been
reported to play a role in osteosarcomagenesis. Because of the role of IGF1R signaling
in bone development and growth, it is not surprising that this pathway is deregulated in
osteosarcoma. Notably, in a recent caseparent study, two SNPs in the growth hormone
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(GH)/IGF1 pathway (in IGF2R and IGFALS) were signicantly associated with osteosar-
coma incidence (8). Interestingly, one of the very few genes which were overexpressed in
patients developing metastases within 5 years (Chapter 4) was the growth hormone recep-
tor (GHR), which was also frequently amplied (in 34% of all samples). IGF1 synthesis is
largely dependent on growth hormone signaling (9), and an association between osteosar-
coma and height/growth has been reported. The specic roles of the GH/IGF1 axis in
osteosarcoma tumor growth and metastasis remain to be elucidated. The osteosarcoma
cell line panel shows a variable expression of GHR, and includes four cell lines with high
expression of GHR. These cell lines could be utilized to further experimentally examine
this pathway in osteosarcoma.
Chapter 6 described Ser/Thr kinome proling analysis of two osteosarcoma cell lines
using a peptide microarray. Although it is not yet possible to directly infer what kinase
caused dierential phosphorylation of the identied peptides, by pathway analysis we
detected hyperphosphorylation directly downstream of Akt, pointing to active PI3K/Akt
signaling. We treated osteosarcoma cells with MK-2206, an Akt inhibitor, which inhibited
proliferation of 2 out of 3 cell lines. Inhibition of the PI3K/Akt signaling pathway may
therefore also be a possible target for treatment of these tumors.
The eects of IGF1R and Akt inhibitors on osteosarcoma cell proliferation should be
studied further, in order to determine why these cells stop proliferating after treatment
(this may for example be ascribed to induction of apoptosis). In addition, the drugs need
to be tested in combination with chemotherapy, in order to check for synergy and also in
order to rule out toxicity of a combined treatment, as targeted treatment using a single
drug against these signal transduction pathways will probably not be able eliminate all
osteosarcoma tumor cells, and patients may develop resistance to targeted treatment. In
addition, if targeted treatments will be used to treat osteosarcoma patients, the genomic
and mutational status of associated pathway players should be determined, because pa-
tients with downstream aberrations may be insensitive to treatment, as was shown in
Chapter 6 for the 143B cell line, which is insensitive to Akt inhibitor MK-2206, most
probably due to its oncogenic transformation of KRAS.
Integrative analysis and genomic instability
A main nding of this thesis regards genomic instability, which appears to be aected
in all data types studiedthe genome, transcriptome, and kinome. In Chapter 6, an
integrative analysis shows that pathways with a role in genomic stability are enriched for
overexpressed genes, as well as for hyperphosphorylation of peptides, implying that not
only gene expression, but also kinase activity is deregulated in these pathways.
In addition to complementing two dierent data types as was performed in Chapter 6,
integrative analysis can also be performed by applying intersections of both data types.
This is useful in the analysis of copy number and gene expression data, because dierently
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from kinase activity and transcript expression, the inuence of DNA copy number of a
specic gene on the mRNA expression levels of that particular gene is more direct than
the inuence of kinase activity on gene expression, since kinases usually act quite far
upstream of transcription factors in a specic pathway. Dierent methods for performing
integrative analyses on gene expression and copy number data exist, as is described in
Chapter 7 of this thesis. We tested the performance of two of such methodsa non-
paired and a paired analysison the high-grade osteosarcoma dataset. In the nonpaired
analysis, genes showing signicant dierential expression as compared with the control
samples were returned when present in recurrent regions with copy number alterations
that contained a higher number of signicantly dierentially expressed than expected by
chance. For the paired analysis, a new approach was developed in statistical language
R. This method determined cooccurrence of copy number changes and signicant dier-
ential expression. A comparison of both methods on osteosarcoma data illustrated that
the paired analysis returned more genes with biological relevance over a larger number
of regions, even though fewer samples were used for this analysis, since complete RNA
expressionDNA copy number pairs were available for 29/32 cases. By using a conserva-
tive approach and by combining the results of dierent paired analyses, we identied 31
candidate osteosarcoma drivers with high frequency of occurrence and signicant dier-
ences in expression. While most of these genes were not yet reported in osteosarcoma,
more than two-thirds of the genes have been described to play a role in cancer. A large
number of our candidate genes had a role in cell cycle regulation, stressing the possible role
of genomic instability in driving osteosarcoma progression. This was further evaluated by
calculating genomic instability scores, which showed that higher genomic instability corre-
lated with poorer metastasis-free survival. In addition, a negative correlation between the
total amount of copy number aberrations and metastasis-free survival was detected. We
determined correlation with metastasis-free survival, and not overall survival, because of
the limited follow-up available. Metastasis-free survival, however, highly correlates with
overall survival, as only a small percentage of patients with resectable metastases survive.
Some issues can be raised with regard to the selection of the method we applied to
identify candidate driver genes. For determining recurrent copy number aberrations, we
used a cut-o for frequency. This will result in the detection of mostly broad events
(e.g. the amplication of an entire chromosome arm). Focal events may be detected as
well, but this method of analysis does not directly pinpoint specic targets (alterations
with selective benets) of recurrent copy number aberrations. Focal events are most
often determined by the identication of the minimal common region of overlap of a copy
number aberration, but this approach is prone to misidentication of the driver gene,
especially when the recurrence frequency of the driver event is low (10), which is one of
the reasons why we did not take this approach. Even though broad events do have a
higher prevalence in most cancer types (low-level aberrations aecting a chromosome arm
or an entire chromosome), determining focal alterations may have great power to identify
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important genes in cancer (11). Importantly to note is also that both types of events
may have dierent biological consequences. A method exist which can distinguish broad
and focal events from each other and from background (i.e. passenger) events (GISTIC,
Beroukhim et al. (12)). It would be therefore interesting to perform this method to the
osteosarcoma data set, in order to also identify signicant recurrent focal aberrations.
Results obtained with this analysis could return less frequently occurring aberrations,
which are specically selected for in a subset of the tumors. Using our integrative method,
which does not lter out passenger copy number alterations statistically (as is done in
GISTIC), but which integrates copy number with expression data, we were able to identify
those signicantly dierentially expressed genes of which a large part (at least 35%) of
all tumors could be explained by an underlying copy number aberration. This approach
gives us more information on osteosarcomagenesis in general (i.e. genes are aected in
a high percentage of osteosarcoma samples). In addition to our list of new candidate
osteosarcoma drivers, determining signicant focal copy number events could provide us
with some additional possible targets for treatment of a subset of osteosarcoma patients.
Candidate drivers need to be validated in an experimental setting. For the detected
amplied and overexpressed genes this can be done by shRNA studies, but the eects of
deleted tumor suppressors are more challenging to validate, especially because aecting a
single gene will probably not be sucient to stop tumor growth in cells with large amounts
of aberrations. Because the majority of osteosarcomas do not have a known benign or less
malignant precursor lesion, it is dicult to study tumor evolution, and to discriminate
between early and late events in tumorigenesis of osteosarcoma. The detection of early
drivers is importantit will reveal the rst steps a normal cell takes in order to become
tumorigenic, and these ndings may be used in for example diagnostics. Genomic instabil-
ity appears to play a major role in osteosarcoma, and in at least 25% (13), but probably
in total approximately 50% of all high-grade osteosarcomas, this can be explained by
chromothripsis. However, how chromothripsis exactly occurs, and what happens in the
other half of osteosarcomas is yet unknown. By using the right model systems, these
mechanisms can be studied. This is for example ongoing in studies which make use of the
injection of dierent passages of transformed MSCs in mice and zebrash (14, 15) upon
which their tumorigenicity can be assessed. Furthermore, conditional transgenic mouse
models are useful tools to follow osteosarcomagenesis from the normal cell to the fully
malignant tumor.
Finally, in Chapter 8, loss-of-heterozygosity (LOH) calls were integrated with copy
number calls and expression. This approach identied a high cooccurrence of LOH and
copy number gains. Such regions may harbor mutated tumor suppressor genes. Because
the detected LOH may have been a technical artifact, we validated the LOH of a subset
of tumor suppressors by Sanger sequencing and uorescence in situ hybridization (FISH).
Sanger sequencing may not be sensitive enough to pick up LOH in regions of high am-
plication, but using FISH we conrmed regions of low level gains. In these regions,
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the LOH which was detected with both the SNP microarray and Sanger sequencing was
probably not an artifact. Mutation analysis of a subset of genes did, however, not de-
tect any recurrent mutations. In order to improve the accuracy of mapping regions of
LOH in osteosarcoma, an analysis which includes paired tumorcontrol samples should
be performed.
FISH analysis detected homozygous staining regions (HSRs) in samples with high level
gains. Oncogenes may be present in HSRs, and could be associated with chromothripsis.
It will therefore be of interest to perform FISH on these regions of high amplication,
to validate whether these oncogenes are indeed highly amplied. Targeting a specic
oncogene that is highly amplied could be benecial in osteosarcoma, as the tumor may be
addicted to such an oncogene. In osteosarcoma, screening with high-throughput methods
for such events may detect possible patient-specic treatment options.
Summary
In summary, by high-throughput data analysis of pretreatment biopsies of a relatively
large, homogeneous cohort of osteosarcoma patients, which was collected as a collabo-
rative eort by EuroBoNeT, we discovered a protective role of macrophages against the
development of metastases. In addition, the IR/IGF1R and PI3K/Akt signaling path-
ways were discovered as potential targets for treatment. By integrative genomic analyses,
the genomic complexity of this tumor was conrmed, and a correlation of genomic com-
plexity with metastasis-free survival was identied. A conservative integrative approach
to lter out passenger genes from driving events resulted in a list of mostly new, highly
frequent candidate drivers in osteosarcoma. Most convincingly, genes playing a role in
the maintenance of genomic stability have a considerable driving role in osteosarcomage-
nesis, as these pathways were aected in all three data types studied (mRNA expression,
copy number data, and the kinome screen). Figure 9.1 summarizes the results obtained
from these studies. This thesis provides the rst steps in unraveling the genomic and
transcriptomic landscape of this highly genomically unstable tumor. The research of os-
teosarcoma genomics at an even higher resolution (Next Generation Sequencing) will,
together with the proposed future studies discussed in this chapter, help to better under-
stand this highly genomically unstable tumor, and will provide indispensable knowledge
on cancer evolution, diagnostics, prognostics, and targeted therapies.
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Het hooggradig osteosarcoom is een maligne primaire bottumor, welke met name bij ado-
lescenten en jonge volwassenen voorkomt op de plaats waar tijdens de pubertijd snelle
botgroei plaatsvindt. Het is een zeer agressieve tumor, welke in 45% van de patiënten
uitzaait, meestal naar de longen. De 5-jaars overleving van osteosarcoom patiënten is
ongeveer 6070%. Behandeling van het hooggradig osteosarcoom bestaat uit chemothe-
rapie en operatieve verwijdering van de tumor. Een gerichte behandeling tegen speciek
osteosarcoom cellen, zoals dit bijvoorbeeld bestaat in de vorm van tamoxifen tegen oes-
trogeenreceptor-positieve borsttumoren, bestaat niet. Osteosarcoom tumor cellen hebben
vele en complexe afwijkingen in het DNA. In dit proefschrift is zogenaamde high-through-
put moleculaire data analyse gebruikt, om genoomwijd het osteosarcoom op verschillende
niveaus, zoals DNA en mRNA, te kunnen bestuderen, met als doel meer over deze tu-
mor te weten te komen en eventuele gerichte behandelingen tegen het osteosarcoom te
kunnen identiceren. In de inleidende hoofdstukken van dit proefschrift, hoofdstuk 1
en hoofdstuk 2, worden de verschillende microarray techniekenSNP-, genexpressie- en
kinoomproleringbesproken die gebruikt zijn in dit proefschrift, en wordt in een litera-
tuuronderzoek een samenvatting gegeven van de tot nu toe gepubliceerde studies waarin
dit soort technieken gebruikt zijn om het osteosarcoom te bestuderen.
Hoofdstuk 3 betreft mRNA expressie data analyse van pre-operatieve osteosarcoom
biopten en modellen van het osteosarcoom, zoals cellijnen en diermodellen. Dit hoofdstuk
beschrijft dierentiële expressie tussen osteosarcoom biopten van verschillende groepen
patiënten, bijvoorbeeld geslacht, de locatie van de primaire tumor in het lichaam van
de patiënt, de reactie op de pre-operatieve chemotherapie en het histologische subtype
van de tumor. Een opmerkelijke bevinding is dat er geen verschil in expressie bestaat
tussen biopten van patiënten met een goede of slechte reactie op pre-operatieve chemo-
therapie. In tegenstelling tot een aantal publicaties waarin wel verschillen in genexpressie
beschreven worden, is in onze studie gecorrigeerd voor herhaaldelijk testeneen statis-
tische methode die toegepast moet worden als meerdere hypotheses worden getest, zoals
het geval is bij het analyseren van microarray data. De meest voorkomende histologische
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subtypes van het conventionele osteosarcoomosteoblastisch, chondroblastisch en bro-
blastisch osteosarcoomvertoonden onderling verschillende genexpressieproelen. Het
expressieproel van het broblastaire osteosarcoom was verrijkt met genen die een rol
spelen bij groei en proliferatie, terwijl het proel speciek voor het chondroblastaire os-
teosarcoom verrijkt was met genen die een rol spelen bij de chondroïde extracellulaire
matrix van deze tumorcellen. Met behulp van een classicatiemethode werd een proel
van 24 probes (die met bepaalde genen corresponderen) ontwikkeld, welke het histolo-
gische subtype van de pre-operatieve biopten kon bepalen. Dit proel werd vervolgens
toegepast op genexpressie data verkregen uit osteosarcoomcellen en diermodellen en kon
de histologische subtypes van de originele tumor waaruit deze modellen waren ontstaan
correct classiceren. Deze modellen hebben minder of geen extracellulaire matrix, de ei-
genschap waarop de verschillende histologische subtypes van het osteosarcoom van elkaar
onderscheiden worden. Dit impliceert dat genexpressieproelen van deze osteosarcoom-
modellen nog steeds representatief zijn voor de primaire tumor waaruit deze ontwikkeld
zijn, en is daarom een beweegreden om deze modellen te gebruiken in onderzoek naar het
osteosarcoom indien er niet genoeg primair materiaal beschikbaar is.
Gerichte therapieën tegen het hooggradig osteosarcoom
Met behulp van verschillende analyses van verscheidene datasets zijn een aantal specieke
manieren ontdekt om deze tumor te bestrijden. In hoofdstuk 4 zijn genexpressiepro-
elen van twee groepen patiënten met elkaar vergelekenpatiënten welke binnen 5 jaar
uitzaaiingen ontwikkelden en patiënten bij wie in een periode van 5 jaar geen uitzaaiingen
gevonden werden. De lijst van genen die signicant verschilden in expressie was verrijkt
met macrofaag-geassocieerde genen, welke door tumor inltrerende cellen tot expressie
gebracht werden. Deze genen vertoonden allen overexpressie in de patiëntgroep zonder
metastasen. Het totale aantal tumor-geassocieerde macrofagen van type M1 (anti-tumor)
en type M2 (pro-tumor) associeerde in aanvullende cohorten met een betere prognose. De
resultaten van hoofdstuk 4 verschaen een reden om osteosarcoompatiënten naast chemo-
therapie tevens met macrofaag-activerende/aantrekkende middelen te behandelen. Een
voorbeeld hiervan is het medicijn liposomal muramyl tripeptide phosphatidylethanola-
mine (L-MTP-PE), wat in een fase III trial de prognose van patiënten met osteosarcoom
kon verbeteren.
Naast het testen van verschillen in genexpressie tussen groepen van hooggradig osteo-
sarcoom biopten met verschillende klinische karakteristieken, is genexpressie van het os-
teosarcoom ook vergeleken met controles. In hoofdstuk 5 zijn verschillen in genexpressie
bepaald tussen osteosarcoomcellijnen en voorlopercellen van het osteosarcoom. Een glo-
bale pathway analyse wees op verschillen in de IGF1R signaaltransductieroute, welke een
rol speelt bij botgroei. Negatieve regulatoren van de IGF1 receptor waren sterk downgere-
guleerd in de osteosarcoomcellen, wat zou kunnen duiden op een verhoogde activiteit van
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deze signaalstransductieroute. Deze route werd daarom vervolgens in osteosarcoomcellen
geïnhibeerd met kinaseremmer OSI-906, welke niet alleen IGF1R, maar ook de insuline
receptor kan remmen, wat noodzakelijk is om resistentie tegen remming van IGF1R tegen
te gaan. Inhibitie met OSI-906 resulteerde in verlaagde proliferatie in drie van de vier ge-
teste osteosarcoomcellijnen. OSI-906 zou derhalve een veelbelovend geneesmiddel kunnen
zijn voor de behandeling van het osteosarcoom, naast de gebruikelijke chemotherapie.
In hoofdstuk 6 wordt Serine/Threonine kinoomprolering van twee osteosarcoom-
cellijnen beschreven. Voor deze studie is een peptide microarray gebruikt, welke peptides
bevat die gefosforyleerd kunnen worden door kinases die aanwezig zijn in de cellysaten.
Met behulp van een pathway analyse werd ontdekt dat de PI3K/Akt signaaltransductie-
route verrijkt was met hyperfosforylering van moleculen direct downstream van Akt. Deze
signaaltransductieroute speelt een rol bij celdeling en celgroei en kan geremd worden met
verschillende medicijnen. Osteosarcoomcellijnen werden behandeld met de Akt remmer
MK-2206, welke proliferatie van twee van de drie geteste cellen kon remmen. Inhibitie
van de PI3K/Akt signaaltransductieroute is dan ook een mogelijke manier om deze tumor
gericht te kunnen behandelen.
Genomische instabiliteit
Een tweede bevinding van dit proefschrift betreft genomische instabiliteit, welke zijn stem-
pel drukt op verschillende niveausDNA, mRNA en kinaseactiviteitin de tumorcel. De
geïntegreerde analyse beschreven in hoofdstuk 6, toegepast op signaaltransductieroutes
van verschillende types data, laat zien dat signaaltransductieroutes die een rol spelen in
het behouden van genomische stabiliteit verrijkt zijn in zowel overexpressie van genen als
hyperfosforylering van peptiden. Geïntegreerde analyse kan ook uitgevoerd worden op
genniveau, door naar genen te kijken die aangedaan zijn in de te bestuderen data types.
Deze methode kan gebruikt worden bij het combineren van DNA en genexpressie data,
omdat de hoeveelheid DNA een directe invloed heeft op de expressie van het betreende
gen. In hoofdstuk 7 worden twee methoden voor geïntegreerde analyse besprokende
gepaarde en de ongepaarde geïntegreerde analyseen toegepast op data van osteosarcoom
biopten en cellijnen. In de ongepaarde analyse zijn alle genen meegenomen die signi-
cant dierentiële expressie vertonen ten opzichte van de controle celculturen. Signicant
dierentieel tot expressie komende genen die zich bevinden in gebieden met genomische
veranderingen, welke een hoger aantal van zulke genen bevatten dan verwacht, zijn hier
kandidaatgenen. In de gepaarde analyse wordt van alle genen die signicant dierentieel
tot expressie komen bepaald of deze in hetzelfde weefsel of in dezelfde cellijn tevens in een
gebied van amplicatie of deletie liggen. Dit zijn vervolgens kandidaat kanker-drijvende
genen. Met gepaarde analyse werden meer kandidaatgenen gedetecteerd in de bestudeerde
osteosarcoomdataset dan met de ongepaarde analyse. Een conservatieve aanpak waarin
alleen kandidaatgenen meegenomen werden die zowel in biopten als cellijnen, en vergele-
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ken met verschillende controle celculturen gevonden waren, resulteerde in een lijst van 31
osteosarcoom kandidaatgenen, welke in minstens 35% van alle osteosarcomen aangedaan
waren. Het overgrote deel van deze kandidaatgenen was voorheen nog niet ontdekt in
osteosarcoma, en meer dan twee derde van de genen speelt een mogelijke rol in kanker.
Een groot aantal van deze kandidaatgenen is belangrijk voor reguleren van bijvoorbeeld
de celcyclus, wat aangeeft dat het verlies van genomische stabiliteit een rol speelt in het
osteosarcoom. Deze bevinding werd verder geëvalueerd door het berekenen van bepaalde
genomische instabiliteit scores, waaruit bleek dat hogere genomische instabiliteit gecorre-
leerd was met slechtere prognose. Tevens werd een negatieve correlatie tussen het totale
aantal DNA kopieveranderingen en prognose waargenomen.
Tenslotte is in hoofdstuk 8 loss-of-heterozygosity (LOH) data geïntegreerd met DNA
kopie en genexpressie data. LOH gaat veelal gepaard met DNA amplicatie. Zulke ge-
bieden zouden tumor suppressor genen kunnen bevatten, welke door bijvoorbeeld een
dominant negatieve mutatie voordeel kunnen hebben van de amplicatie. Door hoge
amplicatie kan echter vals positieve LOH gedetecteerd worden, vandaar dat LOH voor
een aantal tumor suppressor genen gevalideerd werd met behulp van Sanger sequencing
en uorescence in situ hybridization (FISH). Sanger sequencing detecteerde geen hete-
rozygositeit in deze genen, maar deze methode is wellicht óók niet sensitief genoeg om
heterozygositeit te kunnen detecteren in het geval van een hoge amplicatie van één al-
lel. Met behulp van FISH werden zowel hoge amplicatie als lage amplicatieniveaus in
verschillende samples weergegeven, welke overeenkwamen met de SNP data. LOH in lage
amplicatieniveaus zijn waarschijnlijk geen artifact, en tumor suppressorgenen die in deze
gebieden liggen zouden interessante mutatie kunnen bevatten. Mutatieanalyse van een
aantal tumor suppressorgenen wees echter niet op mutaties in deze genen. Zogenaamde
homozygous staining regions (HSRs) werden met behulp van de FISH techniek gedetec-
teerd in osteosarcoomcellen met hoge amplicatieniveaus. Deze hoog geampliceerde ge-
bieden zijn wellicht geassocieerd met chromothripsis (het uiteenvallen van chromosomen)
en bevatten mogelijk oncogenen waartegen gerichte, tumor-specieke therapieën gebruikt
zouden kunnen worden.
Conclusie
In dit proefschrift is `high-throughput' data analyse beschreven van een relatief grote
microarray dataset bestaande uit osteosarcoom pre-operatieve biopten, cellijnen en xeno-
transplantaten, welke beschikbaar werd gesteld door het FP6 netwerk EuroBoNeT. Met
behulp van data analyse is gevonden dat macrofaag-activerende middelen en IGF1R en
Akt remmers mogelijke adjuvante therapieën kunnen zijn in de behandeling van het osteo-
sarcoom. Geïntegreerde genomische analyses wezen op de genomische complexiteit van
deze tumor, en de rol van genomische instabiliteit ten opzichte van agressiviteit van het os-
teosarcoom. Een conservatieve benadering om zogenaamde passagiergenen weg te lteren,
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zodat genen die een belangrijke rol spelen bij tumorgenese gedetecteerd kunnen worden
resulteerde in een lijst van 31 kandidaatgenen die frequent in het hooggradig osteosarcoom
aangedaan zijn op DNA en expressieniveau, waaronder meerdere genen die een rol spelen
bij het behouden van genomische stabiliteit. Met dit proefschrift zijn de eerste stappen
voor het in kaart brengen van het genoom- en transcriptoomlandschap van het hooggradig
osteosarcoom in gang gezet. Deze informatie is onmisbaar voor het begrijpen van deze
zeer genomisch instabiele tumor en voor het ontwikkelen van diagnostische/prognostische
methoden en nieuwe therapieën.
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